var title_f15_40_16000="Carcinoid flush";
var content_f15_40_16000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinoid flush",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked facial flushing in a patient with the carcinoid syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen E Goldfinger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16000=[""].join("\n");
var outline_f15_40_16000=null;
var title_f15_40_16001="Glycogen acanthosis Light";
var content_f15_40_16001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glycogen acanthosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a biopsy specimen from the upper and mid esophagus revealed glycogen filled squamous cells, known as glycogenic acanthosis, a benign condition with no clinical significance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16001=[""].join("\n");
var outline_f15_40_16001=null;
var title_f15_40_16002="Patient information: Fluid in the belly (ascites) (The Basics)";
var content_f15_40_16002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16989\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Fluid in the belly (ascites) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/fluid-in-the-belly-ascites-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7956410\">",
"      <span class=\"h1\">",
"       What is fluid in the belly?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Fluid in the belly&rdquo; happens when fluid collects in the space between the organs in the belly and the belly wall (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ). The word doctors use for fluid in the belly is &ldquo;ascites.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956427\">",
"      <span class=\"h1\">",
"       What causes fluid in the belly?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common cause of fluid in the belly is a liver condition called &ldquo;cirrhosis.&rdquo; Cirrhosis is a disease that scars the liver. The liver is a big organ in the upper right side of the belly. Cirrhosis is usually caused by heavy alcohol use or certain liver infections.",
"     </p>",
"     <p>",
"      Other causes of fluid in the belly are not as common, but can include heart problems, cancer, and certain infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956442\">",
"      <span class=\"h1\">",
"       What symptoms does fluid in the belly cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fluid in the belly can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A big belly, which can lead to belly pain &ndash; The belly usually gets bigger over a short period of time.",
"       </li>",
"       <li>",
"        Weight gain",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling full after eating only a small amount of food",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, the fluid in the belly can get infected. This can cause worse belly pain, fever, and sometimes confusion. If you have fluid in your belly and then get any of these symptoms, see your doctor right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956457\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To look for fluid in your belly, your doctor will do an imaging test such as an ultrasound or CT scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      Many people also have a procedure called &ldquo;paracentesis.&rdquo; For this procedure, your doctor will put a needle into your belly and into the collection of fluid. (He or she will numb the area of skin where the needle goes in.) Your doctor will remove a sample of fluid and send it to a lab for tests. These tests can show what&rsquo;s causing the fluid to collect and if the fluid is infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956472\">",
"      <span class=\"h1\">",
"       How is fluid in the belly treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends partly on what&rsquo;s causing the fluid to collect and how severe your condition is.",
"     </p>",
"     <p>",
"      If you have cirrhosis, your treatment will probably involve:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Following a low-salt (also called &ldquo;low-sodium&rdquo;) diet &ndash; This can help reduce the amount of fluid in your belly.",
"       </li>",
"       <li>",
"        Taking a medicine called a &ldquo;diuretic&rdquo; &ndash; Diuretics make people urinate much more than usual.",
"       </li>",
"       <li>",
"        Stopping your alcohol use (if you drink alcohol)",
"       </li>",
"       <li>",
"        Avoiding medicines called &ldquo;NSAIDs&rdquo; that can harm the liver &ndash; NSAIDs are a group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"       <li>",
"        Checking your weight every day &ndash; Following your weight will help your doctor monitor your condition.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment also depends on your symptoms. If you have severe symptoms, symptoms that don&rsquo;t get better with treatment, or symptoms that come back after treatment, you might need to have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Paracentesis to remove a large amount of fluid",
"       </li>",
"       <li>",
"        A procedure called &ldquo;TIPS&rdquo; in which a doctor puts a device in your liver that reduces fluid build-up",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Both of these treatments can help improve your symptoms so you feel better.",
"     </p>",
"     <p>",
"      If you have severe liver disease, your doctor will talk with you about the possibility of having a liver transplant. A liver transplant is surgery in which a doctor replaces a diseased liver with a healthy liver.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956487\">",
"      <span class=\"h1\">",
"       How can I prevent more fluid from collecting in my belly?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help prevent more fluid from collecting by following all of your doctor&rsquo;s instructions about treatment.",
"     </p>",
"     <p>",
"      Let your doctor or nurse know if you are having trouble following the treatment plan. For example, if you are having trouble following a low-salt diet, your doctor or nurse can recommend a dietitian (food expert) to help you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7956502\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/40/16002?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16989 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16002=[""].join("\n");
var outline_f15_40_16002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956410\">",
"      What is fluid in the belly?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956427\">",
"      What causes fluid in the belly?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956442\">",
"      What symptoms does fluid in the belly cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956457\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956472\">",
"      How is fluid in the belly treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956487\">",
"      How can I prevent more fluid from collecting in my belly?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7956502\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_40_16003="Plantar verrucae";
var content_f15_40_16003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Plantar verrucae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note disruption of the skin lines on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16003=[""].join("\n");
var outline_f15_40_16003=null;
var title_f15_40_16004="Mitral valve prolapse with patient squatting";
var content_f15_40_16004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1278px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/80360/mvpsquat_conv.mp4?title=Mitral+valve+prolapse+with+patient+squatting\" style=\"width:566px;height:296px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Mitral valve prolapse as heard with the patient squatting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram and phonocardiogram of mitral valve prolapse as heard at the apex. S1 (mitral and tricuspid valve closure) is followed by a mid systolic click resulting from the prolapsing mitral valve after which there is a systolic murmur of mitral regurgitation. With squatting there is an increase in systemic vascular resistance or afterload and an increase in left ventricular pressure and volume. As a result, there is a delay in mitral valve closure and the prolapse (and click) are delayed, occurring late in systole. Consequently, the mitral regurgitation murmur is late and shortened.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16004=[""].join("\n");
var outline_f15_40_16004=null;
var title_f15_40_16005="Shoulder active internal rotation exercise";
var content_f15_40_16005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86071/Sh_activ_intern_rotat_video.mp4?title=Shoulder+active+internal+rotation+exercise\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Shoulder active internal rotation exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Active internal rotation is among the exercises used to strengthen the subscapularis muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16005=[""].join("\n");
var outline_f15_40_16005=null;
var title_f15_40_16006="Condyloma acuminatum1";
var content_f15_40_16006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perianal condyloma acuminatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 513px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIBAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD17Eu2RH3GPAYAenrUQ2omC2SvTPcVMVCsxdyR6jkVG4Bbcqqv4dfxrzj2SncKC21MZPOR61Vu+dvDbnGAxPGf6VdmKICAwOBzx29qyrtpNrKyZTqT6D2rJ6GkRpckmPGM8ZI4pkmwSMoO7jr6U4MNwbYq49D0p+xWDYOQRSGQKcsdnzED1/WrNugZ8O7szcnacVRjUozFAN54PoatZBZTGSrAfMtITLWeCDg54yRzUchJyjZPYA9KbvBfIzjGee9OLAu3OCO3WjoQJKqEMU+XAHPbOKrxMTuVjzinNIQMAcdOlMcbU8xRkqMN+NIZII90ZbIyvGPX61RY5YjgHp8verLyKE27SuSNxas5yd52nCkkjjt25pgiFpVVxld2T90dxWPq6o2Z4sFY8E7uBWtGqll3AYKkHPtVe7ZDbTROUSMoMACmmB5v4mWO7t5VkQZYk5DZGa4rw7PGsVyGOGhkwgHfnmvRtRW3+y3W5WwFzwuBivM4Y0i1W4RWAeQBxGwwQa7aOsWjCr7s0zr45h56yBRg+laSlkwEU4brk1hWu7y1XlSoxk9614ZdyQ8MGHynPrWcjpRppJtIBUsB6c5qa0HmvJKR32gfSq0T/fxxjvVq0AWNcnAOWrIC6XxHvY8L0p9m58rac78c1VkywjxnHpV+3HPcHHQ96zbESpGCQZM4pJcNOsK53ZyxHpSPLgEj5jnAApsGRNGNh3HqT3oWoGiADEVPQdMUwxMNpI4/pVhc7jlTj+VLO3yALyB0qZDjLUqlCHXsTnmnwZBwMDnnI5pATwT64ppmCtxwSc1JsbtlhUABJPXFXYMswxwD1xWLaz/dLHrxx6VqW7jJOTgdjRczaLj7lCDryPyq5Cd5JAG3tWe84CdNw9qkhfYq7DlMf8CFUSXnBMgJ4UelL5oBODiqjTggjDrj2oSdQhBHH0p3A0EkB2g8A1DO4DFh90ckGq0uow20MjSsQE5ziuS1vXpNT3Q2oMdueCxPLf4U1Zk2behd1XxHLLJLDZAZ+7uHQVhbGZ/NlYvIepNECLGuxe3U1MibsjnFDRtGFkLbrvY9vStKL5ARjrgcVVgTMiLjg8E1eiUEyDOADjHr/hQU0Pt413EYya1bM7GaNgRg9xVS1jVZVz1BFXzhdQXdna/Q+poSZLHcJIVcAc4FK6FUdk52jJq/qdsI7eKQt84z0FVo2B7feGDVNWdmY3vqhbeM+bjHBAIq+EJXPde3tVWzYMsbAcxttYe1aIXa7LkDn9DVJEslj+YRyIfmBx+FQq7JcOG9c0lnJ5ZeMnhT0NNvci4bAHzDcCKZFtS1IuwFx8wPQDmonl+QOynp0PFWRJGLcK2VYHk5xVeXBVA/+99abGitJsmlbauC+MADPHr9Kzbgobnb9844BPH1rQV2VQFU7znIqpcxjPmYAY85HGBWctTWOhnMpIfdzzg46/Wnw42Lz8w607kAlgpz+FQBmAIKHOQcdPpUovcUqUdgVKjOQD6etKYS0u1WyPugjrU6sxfoN205zzmpoRGowSC/BPFNpENkbiSFWVlDkdOxqJJPMZ32uAOuOasTHfLhQc7cY7VD5axwbQxyepz71BI2YlmCq+0HG3cOlRXHneWoQ5BX5/U1NIfmIGXXjI71EzsrbdwJI2k+ntTApF5HcmVwoHJ/+vSPOJpWIjCoRx2qyYi6bpCrFuOnT3qrc4hB3HaSvHtzRZjKcsYkkUHIUgjj1rOmhkVCgGVY4yeCBWrHIqyDe2QCShzkc1DPIHlRewOCQOopoDidbiK3E8SrhOOCeCK8x8VJ9n121lKlWK7D6Y7V7H4ggV/NK4ypAHcE5ryjx1AVdEK7tuGGD0PXFdtB62OfEL3bl6zuW+zgZyoI49a1Ucyn7zdyBniuZ024DJEXzzxj0NblhJ8mzHOePzomjenNNGvBMxjww5x+dXrScNGm4Oy92xwDWQH3NIN2Tjb+tW7a4WNnjySR90HnNYuJcjZgdJZAVy2PvfnWisvyKWPzHj8KwLZxJK0kbZIHzL0zWorebwuQq/eIPf8Au1k0SWIlPn7gOMfKP61MzkN/dxxUcbEOhO4rjHHpRPt2yM+VwB+AzUNDNWKVmAPO4cH6Ukzb8hOo6kdvassSPJKi5KQtznuw9fpWjnCAhcYHahgNBKgq3I60iiMsQx4NSKQIyGGc+vaq6ujTrGrqrE8FjwKRomWw4iwCM4FaNs425/iNY7yZk4XjOM1ctJQWwc7cdfepaB6mwLhdmDjAHYUKMxliTjPy4ql5gTg8j1xT5LzEexdqqOrdx7ULQmxNLPKF2GTAI5OOayL+7KjJlcADruxmlubsxREkjB5ya56a4e8m3tkKPug1aVyoq7HT3lzckLM7mHdwM/zqaMbenSo0U5xge9TEbQAe9aWNeVIsQqXOAetWkjKsAoHHc1VhOOnBFaUChiGz1pMG7bFmxRS248lfmx9KntRlndcYYlsVBZgpMZB0HBzVu0XDzoSMoeAO4oSM2yaAAHLnkfnV+/Qz6cZY2xNCd6gjk1nRuizLhuepGK0YpgCd24KetOJL7li1vzeW0LNjCjHTiqjDbIVGQwPHPWqUTmxvHhwTE53oCe1XLiTeiuACyd/alczejJUm8q4DtwGGGHvWkJAAsmcg8NXPmQSOMn5W7+4q3azkoynqODQTJGpPLtKzLgrjDDHSnuySwqecg9azlnyMMfY02GYxMUcj1HvVXFY33gIYZdVz1yM4qD95sOWVmyRn1HrT1YrC2+UyKTkr3FJ5iBiVI6VTBFDLrOwwTu4XFQyyEAKN3TbzVy45TBBUfqKqzEtANqkp25zWTNEUJQQSFfC7s8+lNkG51G44HA96kwNjs5yeh74FRhk8ssvLH0/hpIouRMvlZbqMjA9KZEysOoGRzVbeSGBwA3NOtl+fLHJYemAKbJY8s27KjPZjntUBZw2D9098daldgCCCBnrUMfzylcsB3PapJGzrtYSKfmIweah3hlQMOc9u59asHBcLglc9Pb0qvfSxwlVVA7fwilcY+WTy4wi/PIp+gAqlNCXZvNZpHwABjgVPEryOQ2dznJPYU6NEeJmBJIGSwPSqWoFZ4URFVj09O/vVNo1dgzdVxg+wNWppWV/mA246nsPU1ExBDNEVcKQePT0pgY3iARmGUxY3vgL8vGc4rzT4hWwR3VVDOEzkd8da9G1qTLpDGm/5jJx1T2rivFySzWTh4z5iZKunzE5HcV0UtGZ1VeDPP9NuDNaKVAEi4JHY810NlNlCY87gAenFclYK8UjKWxyQDXS2km0RyAYLcEjvXTNHPhp3VmbkbearoW+96DpV0EKIdvGOOOorP00ZUHPzE+vWtKX5kZXUow5Arnlc7dy1t8s+aoO5sKCfX3ratlMSDd6Dge/c1gx3YaWJWByCNwx3rejmUo75zzzWMkIsySCKME54PNIirJHJkkqecHuar3zqYBt4ywJ5B4+tOgLbS5PI646UrAaMCq5WXOcqARUkknzhIxuc9Bnj8aqWzDyn/vhiPw6ikgYghgflJzu7g1LAnaCVsGSQnPVVGBUq26IoYr7fWlhyQepRD1Pc0uQTwOv41NikxqYORn8zTo5GReOOetNk25ygH0IxTYDyd3Qc0rFplprklNqg8c/hUCygxPMxxGDhc1FeSbEEgAC9OPSud1q+kM0dtbyYErFivXC1UYtivfRF+7uWv7kiLIt0P5mpRDtBPNO0u1by+Fwq1ZeKTY2FbA5rSxqpKOhEhXOcE+1JI2W6cCj7PdMSI4mzj71K9hfxqG8onb3Bzge9BPOr7k8M646c1bhnGQozjtWPHN8xVxh+hBq5GxAGwY4zipY7G/YzLL+7lOwngH37U52MFwDIu1h8jFTmsyB2kUEDL9x61Z83zoTG6/Nnj60XM3uaEhQbXUEbuSPSr9qY5ItzufMDY2+orPsWEkKA5LrwVJ6VNNtPKgIy/rQnbUl66Bq4WRXKMS0X3GptlObq2DRsudvzLT7aWOVSuRkcEVlzn7DeFx/qpeM+hpN2dxWurFh2VeM/KevtUYuykmGPPQN6iobyQIPOX7jcH2NZ886sCHbBHIPapEdEl3tZSTj+tLcXkcg2E89Qc1yQ1MqSkn5mo5NRU48w89mFF2hqJ7MoEe8uQT6DvSssRf8AcghMZAz3qMwRFWK53MPl2nAH4UF/JcLIyo44AxgGtzIjcoybWBkDcHt+VUZQcEL8q87R0q7I4kThoxz97PSqFzOInL7uAMDHrWbLiU5W8mJuzMcAAcmqyD5DzyBwR1qW4mUYLMAT3znioA5PEYDZ5BI5xUGqRIoz83bHepEBZQFznGCcdKQY+Xdk8gtxTvM+Z1z8q+nXFUtSWNkXaeTkAVXddzLjIRepFWJXdlGxME9c96rgyDDbuD1FJk2AxsFQs+I39OoqssTLMOM8cN3+tXpTIvllSDgcYHrTYiqK2OeeGPPap2C5XYGNNyg5zxUFzCrRkseAu5e1WiSVHzDf0x0FZ8rhmMYbJ2547HPemgK01uY8BTkMuCM5zzVQTHc0BQiRc7ccEj1NXVuFYnCbT0wWwc1FcxxToolGAeS3901SKMWaVX1VSqMh2YbPHf1rE8XKm1ihYYPbvWuqSNeuqOd6rtLHqR2NY3iCEFXDOXkAzvxkD8K1ixSWh5pMQjajCY0VX2NjHIcHIcenGQadZz8AMfoKZqyOdViO0Ksv7ssf4Tj/ABqpbs6Om9RuVscDvXfujzYtwlY6KzmAdVLEL0OT2rVillC+U+XRTlR2xXNoSjYByRxWtZ3k0QDbVK4x9B6msZRO2MjdtsCRD0O7IatO3kXzFQkjJ+YY7VzsUjZRkPToCa2IZXVjnG9lHJ7VhJGjNpw00TqG/dsNoyORTdOuGEbCRScfKSORn1qjbuVkb52I7elTWsjJI5YAb+TioAuG4VGuCrBlCYZh69qt2qZsoigzkA/SublgkWdntpTtlwSD0rY0+Vok2yAjceueKl2sO5pKRzliOOcetSpMvmshUY2qCehBqAEEARkO2c4HaiHCkbhls5Y1IXJ3J85j/CBgEmmyRlUDt8qHp701yCpAPy+p6UksjSSDghQuMdsikK5Vv7hIYCxzheoNct4dDX99cXQUvufYnsParfjK+Fvpb4ZfMf5cCui8GXdlZ+FrOa0tniu44yZXcgiRj0xW6Vo3ZPPrZGhZOqx+VJbuz5G3Bx+dbdjBNnzJwGkI2heqqPYVBotuXzNMd0knLE10Crx8vFKKvqxTl0RSNu4JcNhj1qsY5re4E0bDd/ED0IrZCjbzUM0YZTWqSMzB1/Sba8ga705THcR5Zxj73f8AOudtrx5iPOYlgAvPHFdkl29jMsi8jPKnoR0rmvF+nrZ3TXtmM2spBwP4T3rOpDqjalUt7rGySGOQPFgheoFTNK0waaEKHUfMmfvCsW3uyyEjgdPrUyzBXLbiD7Vg7m1jYFwqBZot8kOOWXqD7irVrqm0q4Cl16Z/iFc6tw8OTEfl/iXsaqtdN8zIep49qNRWudRc3izSGePhwfmUdMe1TrdwXlssUxwnselcSdTZDwSpqi2rSQyEqx2nmlr0DlOvuAYiyNzF0DGse7fyGK5Lxdj6VWHiGMx/fGO4JrLutdj3GO3R5W7IozQosGWbq8Vgfm3CsG81Ngwig3Sk/wAKjNbNloF5qYEtzm1hPJReprbsvDUEA/dpgnHPerTS3Ee4TGOM52hZOhz6VDfLG8Y2k+aOhzx+FWrjY4yV5BySe9RMyrEUCIWYY65xWjMEZ8cSSKrIoGfmxj86jmjwo2jIP4UB3BeJCAo5U4yMelVWhY5RpH6/3qyZqiK5RdwL7cZOcjI+tZcpVPmHAP8AB6CtW4TYCXyRjPTp9aoBS8ZmYgrnCL149allont5PNDbnyeMcYxTpG2kbVywPB6VWOCGYYDA5x6D2p8MweRgyn5cdaqJLLIXcNp443daJQig+WQSOgNPIibIA5XqTxkUybA+6cE0mSUl8xXZnTcCeAvIp8i4XbGAynjAwMetWCcRoq5Azn6+9RNHkjC5xnrzzUgVXLZIAIkAx836VmxxOl1JtwxY/Mex/wDrVbvC7TIkY3hfnLA9vb1qOOQeaQWB44xx06g+9MDMe3aWYosakk5J/wDrUMkpCRxTAqrZLAfyFWpVZ3PJG4Hp1+lU554LUJ5jbQB90dTTW5Rlag3kXom279oO49M81lahLE9w65wijJyMBiTWhqEuAz3QwkxG3d29MCsq8QyhmK4UjCsRyMelbRFZnD+LUJM5WM7BhwMdCKwEOyUyuvuMetdjqWbszh8fdCEjv71yEshU7RIrY/dkAnjHSu2DurHBWjadyxbSxqyFnAA4K4Oa1oZmhlZo2GRyo7H2NYEHKy/MAUG7FaNrHJ8rSKyIRgSN0J9KGiqU9NToYlhu0eWyAix963zkqe+31FWoL3f5QlwZFO3OeSPf6VzcEpVsK5EjZDc4/KrdtIQVMhwRwTWconRGWljqo7kRoM/MvbBqcurRKQCCOdvc+tY9pMqlS0YYHj0/GtCJl4Ky5ySNrDDfnWLjYu5oqY2YCH7mdw+mKBBKrsscmcDgHpVVPNt7j5lbJAIz0Iq59ojM/mK2OQAD+vNZtCuSWsr27qJRtyOSOQa0o5UlUn7jk/dPce1UftEbDaRuOTjBqNow0W7cyOD8qj0qbDubIIkCGLO1j8y+lNPyqzE8FuCemKz455RwHPPG3PIqtPfoqOkZdwAQBjqaaWpEjiPHt95t+0aHCRgqK9Q8JaeG8F2HH7x4BKR9a8O8R3Dz3s7ckE17x8Pb9L7w5pkQHAtgu7t6EVvVh+7OeNS0zotLAEKHpWqkgIGATWDbzLFLJGTwhwMVcN1gZGMY65rKOxu9S+7jBOcVVlnAyeQvTk1nTX6hTg846nms661JdpJbIFVcEi3qF2MHaR9TXM6lqDNaSWpbOeUYnv6VBqmrxjKKS754VOtZEiyyJK10ywYXKp3aqvcfL1IbK+2GRXxkHGW7GrQvsMCpDe3rWCISXcsSA3apGZI1A3rn61Dib8xt/wBpnjg1BJesQTHkE9jWM96F/iqOO4mupNtvE8rngkdBS5BXNJ7sjO8ZHc5qnJciRwkUJlk7Bea1dM8KXV2Q15JsXPKIf613eh+GreABIYgDxzjJqG0g5jhdL8L3t+6m6It4z1VfvY9DXa6V4bsrCELFCqv03dTXS/YRCqhU+bPLDtViCABgMZJPHvUNu4m7lG0sQcZXAHbFWktPMBIAHGBxWrbxbBKy91PWmWu1JE3DJKnAxweKaRNzp54l2fxE+zc1nSWrxKTG53Hgjd3PbmrrXBClUxknBPqKqPIzuADgLknBrYiNylcxSIV2HcYu2eg7/WomclwW44PPr71bupSYz5bYXPT1rLMrLIYUBZz27YrKRoiG4zKwjV3KZ3N2GPeq0saghUBVVJAA6D2rRKiRSThX9BxWbc/x+XjI6+1QaRYyE4IDAEnuTzSTKyP5gPKt17H61XLuvoXJ7DoKs/aI1gJ4fnoRwTQgkTQXRcEw/OO5zwM1KzbkwygY5yDVG2zH+7XhQ2cj1PetFcBASAecH1NBDId21mAb5cdfWmI7s4VM8kmll3HKqMDoD2pBGqRsWYLgZ57n1oEVp1CyMFlJccmsu8tJGG9GxcDkHPDfhWsihQDICQRkkd6r3CoNyL8jDDg+ntTsIyJHkn3bixU43IvGKqwyQG8YSDyo8gYZf0rQuFExQgNgA7yOP0qnDEq3MmwuFHIVjnNMtFK9iN5dGYKXjjG3OMDPoKyZ5dm6OaPywAQDnOK33uFKtgMoBwAehrlNa3XG9YmIfnI29a1hqGpz+pLK0+wINjOdrE/ePf8ACuLuLWSO7kZ1+Rn9cc49K7mPE9lEp/1o4OT+tc7r9vGt5CxcKWJVmxkGuqmzjrwuuYyEdlHzLyflarcM6xxZOX4xtzjHvUd7CqLE0bBgRtbDZw1Z0bkSmNeQR96tDm5uVnpOm+Hra5tI2kuJEaVf9YMcd6xr+3ezna2lkMkYz5b+nNUbHXJLaHypAXGOG3YqW6vhcJExYMOQfUVmk76nYpxa90nW6MZxuzntVuO4lLoBhcsOOuKxyRtyOQDnIHNSwXTLKuRnbycjmhxDmOhiedmIDHcvIwcc1dt7gPxJxJn+PnmsFLklo2GTvPeronQt5fBUHJ46ms3HUakmdPEUKbsbm9RxU0MmY8SjPv6Vz8MrKuFb5cEbWNWob1fLEZRy2MHHas3EdzWWSOQMqr/wLPNY9/MLa0k4wy5Yc9amMykDy1IYc/NWB4inYWUoZOGOQRVwhqTORw+oSM8zEtkk5Nei/CLxXFaxSaNey+Wxbdbu3Q+q15ddOdx9aqbzu6kMOhBxiupwUo2PO57SufTeoXY3NNbjc2fmBNZi64uTvk/A8V4dB4t1e1QRpdNLGvAEnzY/GpYPFd28u67hjmXrgfLmuf6tJHZHFQ2Z69ea6rkRwfM5PAHNSJYXdwu/UJTbwFNy4IJPtXnun+M44IyFsSje2DViTxrcSriOBgPdql0WjZV4PZnarFb2ifusZ7luT+dZt7dxE4cKfxrkv7Y1K9YCMAZ9BmtSw0K+vHU3khCnnApODW7NYyT2Eu9QiDnYcH0Wm21te37Dyoiqf327fhXW6b4Zt7UDEYZu5Irft7NY1+5+VZuokXa5yuleE0OJLwmR89DwK67TtJgtkAhj289quQRBWHHWtFI8KpBArJzbE1YW3tlxwuMd617RVjGAvbFQQY29uTVlXw3oKS7kslcIT6GiMYZeMY4pAoyCSDxU4ZWYAgZ/pTsIkz+4cA/wmooWzFuA5I4xUqqfnAPykEfpWfZynAU9BwTT6gtjrWj3MSSMDAC+lVbhVUnaN24YPHSq0cojVmbO1j1z1pvnGaIRkOobgHuT7CtWw5bMrXFxucqBnnB4xiqc0bowKMyuR+dWo0EOSyhn54Y07zGkGMR+VjqRyPxrFloqCRmws+4PgkleDVBwRuC9jn6CtWRSAu4bV9T0qjOg5+Ybs8+9SUii+C5DLwOSaRR++DsS2eAMDGakkUCT5iGQDp3NMidShV8ZVsg+1C0GywzBFbavPQ49KfDI5iQbeTxkcnPrUNuf3m5lBXGAD0+pp7S+WoKk4B4Kjr7ZqiGSPukjwOMevWoZFYwts5OMAGpHlEnRcENyvU5pcs0RUgY6nNHUkiYkgkAdAcDsaplGKzOSoCtuyec47CrG9S3LDbuznNZ8kpup/LBPknAbPBPtQNFO7eVpG3EsW7Djis/dsvE3kouMA9DW5q0ZESmIFjvHHSsLVHklnQGNd4BXI6ZHagaDVFQWcqklAw7dveuVuLeRomKKzxqMfKcM+R3rUuDNANkzk5PzDGVAqjczpb28zbsn+EA/ePbFaxDY5SOKVYTISwZSQQP5fhTL22TUIkSI4crgEjow6H8a0SpEC/MyyMvzZGfmqKKKSOUxkKRgHcv4Z4rpjIzlC6scrfxwzacJoAUnDbZEzkZ6H6VnpF1ViA2PvV0+v6fbLLBdRB080kTLGOPYkVhiLPmSKAypjPbI9a1R584O4QLG8RD5WVOgPRqejsu3Cheoz3NOkLQKk0aq4GQNw4bIpmlSx/2haCdv3OckntQyk7aG01rfx/ZpPsxxKOEByTj1FQzNJbyEXMDxMf4WBFdho99AuqM4ImTgDmn/ABBu7G80wMoRJVOAFOTn0zWfM27HTKFldM4e2uWJeMDKvyMdiKt/aUCKsZbzB29azrBEa7gjM4j3thiOcZrc+zJpGsyxvIskbRqQ3XKnrVtIxjJ31JrJ/MA24Y9w3UGrEbtG2QwyTzWjoMcOqSuZJIYoSSFUDB9qm1Tw9GrjyGCsyk8jOayZ1cul0Yj3wO4YJk/LNY+s3xeFk/Iikv4JrWZ1kKEjqSxGfpXN6lO7hgsg68oDWsYnHVqNblC7bEjEA/jVUbpOR60FmkZ8gnA4GK1NNh/cJI6jYcke+K3Wi1OW12VI7RsZI4q3HZk4G3p7VrW/k7gH9fSta0jgYnOM54zWbmbRop7mJY6a0r4UYNdHp+goBvfk8dakhjjjkJTHPWtqMAwLsGcDdXPOb6HXSpRLulaXBHghQoxwPWt/T7dAcHIyeMVk6dcERk/3xjNasdwDNDtc4K4/GuWTbOyKNooFBVcNnnNW2gMlsHXAKHOB6VjCT97wcYHOK17eYGBwScMmMVANW2GjKqwKgZ5zVhZ8Kg9qz3kIhVmzlcBvpUbzYyBnA6VImjdguPkbB6Grgl3Jn3rnLK4/eFWOATg1oWlwNuw8kHFNEtG3FJkfSrO5TJgj5sA5rJjkBUEnH0qwZNpDHHPBPpTJZoFypGDwetUChjupwDxndTzIHhaTPCYOPWq9xJkxTKcBvlagSNKCVQ4CkEj+OtFUZFWR3Rt2T1yR9ao2lrvQlEC4P3m71ce3kMR2kBiOSTWhrNq+gsyll2goQ5+Yk/pUDxyFc8bf4UU9B7U4I4O1ypyMZApssJ2lgw2e5qWQmQDLYIGdvWoLhBwwUK68sQ2KnIyAQ4bkcKf6VQuX8uVlBUv1H+NZs0RSnm2sRtZj1LY5rOmlLTp5YDjG3jjOfWprlSWd2fc5/h7UwRt5K8Ecg8DikWXoYgV/fbmK4AUfdqznOEAAQDoKptkN8uQx6DGSalRYxHud9zqO7YzVXMrDXZMqRkSdCFNOeYlNpxgHnHWnSWyyJmLauRjpUZjOzIBJPYc0ydChebvN3knaDxT1dWkQkYZjkt2zUd2FkAGT83UYqoyTRhCr5RMqcj7ufShlmhdMw2/dOT3rPmi8tY8jDA53evPNSzCIQgh28xemTz+VRzSPIQdg3HOBnAUdyfr6UJ3JMbX5NqySBAEJ6E/eHtXIRWzNcF2+XOcAnO2uxu4y826VvMlRfvFeB7AVz17lRu2HcDwccfl6VpEuKMm6b978m1j0IDfe+nvUAf8A0qNwBnoVHVRV1Ih5xLhAGOcgYxWdeoYrqKQ4VG6dip7D6VtDVkz0Rn65O+ny7wokRhiRSeoJ65rOAUFPKRf3g2bQc5Oa09aIuIlLofNjwQF6Maw9P1COPXLRgVwh+YEYA4x0roW2h58naevU3L3R7iz0ZRJE5YoWDDoq+tcnOBw+35ducdq9b8Q6paf8I3cxLcq0kyAZwCTz0HtXld7KFQQhQW9u31pw2FVilqVLDVbq2nHkztGPTsTnvWneRu0kTS3nmSOclACdvqawfKYS5UDnqSP1ra8Fa1BoviRJ71BLE6NCc9t2OatrS6MIzu7M39U0mzi0uK4jysiAEFT949apLdLe2jrfFluFRjGQfbivS7Kw0HVI2hj2oGUkFzuGT6CuN1Owh0ySSy1O2Plp/q51zgj61lGVzqnT10Oe8J+JjpmoKmoDdE7cMf4TXtsM0Or2UE29VYdEVs5HrXz5rFrCs2yBw/JI55/GtDwxrt/YERxT/L/CG7UThfWIqNa3uTOr+KNlHBDFIrnzN+0Y6EelcBZ2s/lyN5DHDY8zsM16RqUEerabHJcyguo3kk9D7VjrPCoaMwqYuhZcgMfU1UJNImrT5p3ORtTHAs6TINxyVNdp4W0u1l06KVwN8agg54z159aztasdOk0Oe4Rtl6si7Bnt3zWl4Dut3hlgGCyo7KT6jNFRvkujOEbS5TatdFindp5kQs5JIxgflSXXhuFt3lblIHUVq2cwMC4OcjjNXVfIztHTFYqT6naqdkefz281hMEuOUPAI7irdvNsJAZ9jdMnpW7rFot2hjbaoI4Y9j2rlrY7ZngmIWRDtPocelNq4RfK7HT2VyDDt/hFaSSndGwHK8Yrl4XKSfK3Fa1pdBnXB+ccjPeueUTojI34bsb0LfeXt6j0qzDdmKZoS2D1U/0rKZI5tsqZAzhl6banNtLLEvlk+cmNnv7Vm43LurG1HKsiPG3yhxjP8qzopirFJMh0O0io7S5Lr8ygMp+YelP1KPEsNxyUf5WPoexqeUyci5bz/OVJ5BznFXBdbX+Uhgec1hNOPPXOQCvQdiKmVyqpz83UU2hXOltbnc2D0xxWsmdmG6HBBrlbB90iOcqTW9HNtXZu7EjvxRcGX4Cpyp78YqSNPNt3hxtK9M+orOE7eWcAfKR061aeco4lCjB4bjv60JiO0RA+cSAE9z/KoWXanLqATgk9KjidI02rhh6k02VVduFbJ52nv71oFhsrF3zHkxnvjaPwqCeJXJ3nPop5AFWthZ5FV0+Ubj2AFMdI1ZjtyT+GeOtSxooXJKqQFYleOB2rOMbElRj5uc1qXTFI+D25weKyy6Y35y2eSOwrJmsdiCZYyG6cdSBUAPIwOPXPFSXExKMc/MfUVUjuFYsGbGO/pQUTuQZQQ3ze3FNuAIyvI96rPO6sC2ST/FinRz5O5mcMe5XrTRFi3K7BFVWJD8k9unenNMQiAZ3N6d+KqSyiCVIjyD8w5qbzN0qYUq4yVOOppiZnzW0znLNwT90N0FFvuQSwsQxGGG7kYrQLKG2BuPQD1qhMqpLG4PBOx2+tJgJcR+XJ56YI6sCPeluBuUtnauce9WbraEKOMDuB6VztxfMNwVGcZ++OnFOwlqTXLIFJAyDyf8a5TUbp45irwsVc/IRyxHr9K3ZpHmt2MaMOPlPU+9crqlyftIBUsY/kUdyepNawKQRbJyxYkbVyq1a1TTGuNMVsJmRNyspyQfeq1g8ARkbcrP2bjP0q0mqT29uYBavNCg+V1PIHvWidgkr6HLyFWjEU0TIynKsema5/VNPW2u4JVwfN+U+nXg11j20632+4iaOKXJA6jmqWs6bDcQ+WhkjYNliBxx0xW8Za2OOcLowmZrdCI490iMQWJyCPQVQkjeRioYeYwyeegNLdNPBOyGRUPXMnFUILiJbuIN94SiSR88EDpWyicc5XdmaV1pFyxiEYH7z5QvTGKpxaW8TSs6/cPIbnFdrJcR3unq8DMJojujK87vXNVmuLK/nRb0/ZZvus69/TINLmNXRj0MAXNxZGPY0ioRwc4Dc16PB4k0nxDoEVlqUsEEkKY+fgn8a4u80q6hfNtJHcxAbsg5BHsKx1ilsr2Oa6tcx7twXFTZSEpyg9TRvLXS5tQlFnKQgwqvjIY960rDwt50pjM9qmV3Kzv/hnmsO4a0uDJKB5bM2QoHzc1HFJc2OJop54sOBuH8IPeqtpoS2r6o6OJbuK5Nvc7fIUkFwchvwrbGiaO1o8LK/nkAqyynef+A9Kd4fsdOvpXWebzzIN2/ONxx19q3LDQtPhnVPtvkOMkTDDDI4HXmsnbodCpOWrPIfGOjXuiXMUd1K0iSLuB549j71Y8D6gI3uLJyF8z94mfUda6X4nadc3Bikkuop1XjcGy2fevNFeS1uQ0ZxIjZBxWySlGxyzXs53PYdPvAoaNiAOxrVhut64x83pXn2n6st7bJKgxIOHX+61bNtqZP3mKsOCT3rmcLM9GnNSR1EkwPDEfQ1zetWylzNHwzclqla9DDcHXj361Wnvwy4I4IwRnrVIU0raENrcbwBuGfu1e8xoSChGRXMzMY7hjCp2HkD0q3bX/ADsCBzyO9JwIjUOw026EhYqwxJwQT3rYtbw8IcBlIBB9q8+W+8lxIDwTyPT3rpLPUUnCSY3P0OO49axnCyNlNPQ6O+QSKby2GHC/vUHcf3hUEd0lzYNEz8snyjPfsaqQ3hglXceJOR7Uy7t/s14jQvm1mO5G/unuDWaWow+0m4tl4BePk49R1qxHegJGxILZ5PrWPM7W1wshAEUpyMHofpUMlwIVwXGM5jJ/rTsSditwuAVc7T0we9aNvdiSJSWAkj7e1cHa6iAGVycHkD0qyuqFGXB3kdPpWcoFXO/W6ABfjpg/wCNTw38bIEJzkYPPWuFGtKuGJ2qw4B/h9qjk1dEG4Esh5yD0NSk0Ox77b2xxkF4weevANSbdj5O4gDJIIOabI0iMHBVVIzgmp4pGLblCn3JxWwm2UywAB2Ec4JxTGKhMNg85qe5k3Zy4JbrxUJ5TaVGF5JNSxozL8yO6x5KK2ef9mqjonlsApCjoF7mrzxmZzubODjBqN0KnkcfXr9KzkaJ9DGuI2MXzPj1Vf61nbgkjbdpbHIz94elbd1g/eLYB6CsO8CLciXAOOpxg4qS1qTRlSAc9qexAQhuFAxjrVe2kjBI+YKxyO4AqcFFc5+6eKsl6FJn2zLufp9zNaNqXkkDty2CKx5l8yUAc4yVJ7YrVTeY1OBHGRyQTnHtQJ2JdgL7UPAI3GiaLgRhh8oJz/KlQqi5QFY8ce9QXkyQs23dLKRhUXuaCCrfThYVhVibiXoufz/Cs3y1DqlyQwAJwtSW1o7XlxJdE5AwsfZfbNS3e1mbyNoCA727j2FNIaM2TEcqmJ1AHyspbAbPpWRPbxGQPuHmMCdw/h5xitvUYYzarEqhmYcEms2YrEmMYXGcAcVa0GjGuoJJYyFYrgfLtGcUWF7MDJb7SXADSHb0571N9vEU6rBHI+7hmx8op2najFD4lZZyBA6BXB788/WtI6lWuXfLuGsvLVuM5AIzke1c87CJX8xMHeVJJ6V3GqQwT2MU8b7VbCx/3iAOCa5AIJ9SkjkwEUl/941cdWZzWlznNZsoJ4y3+tnbAXuK43XNPmtgspjKq4wxHQV6pe2yXVvHi2VXDH94OOB7+tct4j0tU0yaQLLIQduOTzW8J8uhwV6d7s53wlKwlKRXAinT7qN0cd67KKKL7bHBrVmqi5AMbseD75rzKHfDMrjKkHrjGK7GXU0vNKSB5Q06f6pH+8D6A+lXJdjOlOy1Owu/Dot2/wCJVewlTgpC/UNnkfSq1w80NvIt8itNGxIdh8pXvj1rnNN1C7tN37p2kTDPnr616bO1jr2gwzQk+X5DZUHO1yP61m1Y6o8skZnh3StLu9NjM9vA7y5kywHX+lb9r4RsLi2Zj5jxchl3A8H2NeY6N4hfS3WzkhHmKflzyDjtW9/wkb7/ADVkuIuPwJ9Kn3kCUGtx+u+ALq1MraNvWVOkYfAbPt24rn/7G16PdHLdi1nX5tkh5I9q76L4hFbZfNjgUkYdpOP1pbPVP+Ek1WOaNIZLWNfLWSMjG7qevSjnfUSpq9rnkmvLrFrGRdvvHQ4Oc++a5Z2Jdi5+Y17P8T0sbbS5DGQZyv8Aqx/e78dhXA6bosF9pMt2zIsoXJHQVtB6HLWp+9ZMwtK85bgyQMUI4JHf2rcFzLwxjGfr1q3pelLHZx/umbuSB1zWhFaW4kKHaSD+dTKaNKVJpbmOLy4H3YkXP40vmao4+TAUeiV1Vlp9vJKpCqB7101lp1uq42KeKylVUTSVKXc8imi1BjmSWTGfypg+0xHPBr2Obw9auhbaATyRVQeFLa4cAKoAHTFT9ZWzRH1e+tzy1LuQDEkZwauWWpNA48p/l7g12OreFYopFSI/Me/pWdD4Pkm5HzDOP/r1XtIMuNKp0IotZR4gGcHBzg9q0rfWopIPIuCrREcHP3T61GngeRywDDgA01PBEmMmTAzgGs3KBsvaLcW5uiVCyFW44dTWfNcqquBJ8hHQ8811+meA4WbM0jsgPIB61snwpp8IAS3X61m6kEPlbPKxdFiBEXOOOAamV7qRhthkYj2r1ODw9aIxYQJ7cVr6do0MbZESenTqKTrLoilTtqeSQWmrXKfu7VivrWpaeFNXuCBO/lgjODya9cjsIoyzbFCouSPU+lTw2+9yONx65Hb0rN1X0K5TqlkeU/PuUkcg1KMC0MeVWQHgjjj+VI7O5VnBAHQGmzukh8w8YP8ADwa0Bh5ICfNIWXqWA6VSmjDbnWRmPp0qRmB3MjP5JIBz1B7VDJuUs2xwo9KljRBHLKqHzGAyc7sdu1MuZAhKE9RwAKmPMcasCpX+8P0NV7jyVI3OBj16VEi0V5htUKBnI5/wrM1C3Tb+65DHAUnoKv3FzCGO2ReuCACRWReXY2gBWO053AdPeoLKiuqqrgZMZwfp3qxNMrKPs5LMO/RapEpuAT5oRw3YEnuajd8MIYnBT+HHBHrxVxQ+W5btfM81zgP2wODWnBIAflZ946q3b2xWfabQdq56ZOfWpy4LAoArfxMOpHpQZyRY89o0ePZufp/k1FbqVUyZVnYZBzgA/WpJJN0aCLC7+CP9mqqOwjCMBtUlcAdutNK5mytdtI8hyvDHG0Hk/T0FNvNsduI1wGbg/ianmURkyyMVdh8uO3tWfdy54lZiRgqPbdVDWoy7NuqPEnJ+6rburGsyZjMxgRWEhHKkdAPSrt84MW/oeSF6YI6VhfbJobuGaE7mK7ACepAprUq3YlvrV7OUGYgAcbRxtpLyO1S0LzxJIzAhfUNjgk1nahPeXN4HuywHYA5J71Z03cbe+t5ixUoHAKb+PTPatUrDW5JZeI4f7IW1vTtmhGCpTOcdMEUthZieylmlLi4kG5UGOB2FVLRiVdY3j2yDDqRkEVoWVwba0WCJWEijBIBYfn64qlpqTUd2VJEZbNHjyUjwMdgc81X1gpbBdx5fDe2fWtO1guH01/s4zNOu0Bjwue/NYmp2l7ugt71o3BHyiPgmluzCdjzfxT5P26QorKpPygripokS4t7f7Mp3NgMhPUjuK2tc0aK4tp5MuZUGVLHp7VyVjcYVFLFWUcHsR2rsVpI86S5ZWZ0Qu7me9j3r5V0oKkKOGA7YrqfDepW8QuIIpfLMy4aJvlIPtXDySG42yLJ+8UYJBwavXElzBDEb7ypon+VX7qR2JqJK5tTqcjubPiTThcSJ5HlpcR/OxJGW9BWdDq2oxyG1xDGuMgSj5c9OKuxX6zNbstvbJKgC5ZuCPQgdfrWnHGdS1iNWltI8xgGFEyPxz0ND03B3lK66mXGzzQOLxEZVyCFQAfXNYtj9vt7gx6bNcQxSMQxj5Bx+lei6haQaHDvuIIZMnsmSCeBz6VsWsVmiWlpG0SyzNkogwVXHPt1qVU0NFRbep5+giTba3rZW5dVkmkGSBnnmqWr2Y02/axhZmtJXzCwH3lJr1TxF4fXWVkgmWPMUP7o7AAvTk4615Hr9wYdXgS4Gx4HWM4+7nvj2qoy5iJx5dT0XQpjp9oDGAxYAbW6H3NTT6Ol8zzzIGmkO5mQBRn6CsmK8X7PHGT0rqNHk3qA5z6YrmludaStdHJ3dpNpMgY7pIc547VqRXha3V426YODity/t47hWUgsDkYripQ1lqcturYjxuAPNKULq4077nYWN0bgc4yTWlFMiO2wYzxk1yOmXRVm+bGK2Yp9ydeck1zSTTNlBEd2TJKScbm45/nWjZlViURquegPpWPeMzyqVALhgdp+lWpp2hghlj4jLAOpHK0O7NHE1lVVlCDILD5iOuKtLAjRyHaBuGRj0FY8V2PtkLD7hIXOf51qQ3A2MhPIz+PNTqQy/alQnAxk8U9lQE5HPeq0MoAKgg9CMelWRg454qbCJfKHkggc9qntXWONnf6VFK/yIvXHoagkZtqjoNx/KkNamlPOiwhRy5O4mmy3Gy2BX7zHGfSs6J9qvvAb5f1zUk7g2ybsl1bpRsVypHfSkKW43AfdIWqstwVBwvbvzTrrEDbs8E9DVOOdLmR/lyo4CsMEn2rqZkl1HrKSuImXa/LgiiO5DsAGYInHTq1ODQsm3JEg4wfT0phi2Rgjp2GeTUtCGXQEiYWTD5zkntVKWFUUhmQAevJqaYkqNiHnjGec1Qe3fzFZsgnqv+NQ2XEq3cybwqZbcQTtHasueECdcYAycj1+lbVzDlySwJHBzwKzrlfs4yhbeOcjkVBpFmRNmAOyMFycYYcN+FZ9vIrSkNxIGzjrwfQ1tXYZyHODtHLKOg96yZ7eBZlNqsgnKfvMtkO2Tz7D2rWJqmrGtascAM2O/NX4tikZI9KwrOa4kiEY5K/wjp9au20sijEkeFXr2NDRhNMmMjFpXGFjiXGT71Gmd2HySTnHfFQxyQoHlmf8Ai+VB19qtAtHA0zjbLL0JB+UelMzIJX8y437uFzjNUZcOHTbuO4bSe1TsREioEIc5OScg1VkciRCy4jzkkck+1MpaFK+V1iaJXlZidqqeMVmmFlAZm/dxODk8Zx1x+NbN2z3EuduyMDc3bI9KqzmN2gtY1DSEgImOhpx3ERWmlzahcXF1IxW36R9ugqxdzxW9qEt1WR2BQAnqT1NVr+YW5EAf51bDfN0I/pVV/M+1qJmDRkArgfezV2uK+gkOnqJCWfYAMsuc5NWdOvZBazSSlI9zFfMTocDpV2zdbdr1plXJiAGRnB9qp2NpEYPt8jyRwKT5WAMMc88HjvVqz0JJtMRJbiLzHZQw27mwo3YyD+VUPE+RcwyhcvkqW7DippHiuWKyqMRclgMDI5Bqvrdw1xFLLPuUluIxyBx1qWtSZqyKBgiuId8uAsjEHI7Y4ryvXdPex1GZVUmHduVu1esWQk1C3kUAEphd2OAO1QXemJcxNFOF4U7sgc81rTnyM56tL2iuecaNpM+sx7rLaZUVmcM4QKFGTyfbpV3QdLudXlls5LlhFGocI5JGfpWcs03hrXZ1hCyRoSpVgdrrXVeA9SiuvEFxcKvlKxUnPbnoK3k2ldGFKMXJRZnaYkmjahNbyLkDlBjoO+K25pHURavCFVFKiUZ5xnr71p/ELSPM1dZdMYPIgBbB6r1zx+Vc3aTNsNpdZhV1YDdkgd6zvzK5svceh3+ox/2vocMkH33XbyOQQcjNZcc5lvWmjXBgIDAHODjmo/AOrLYPLZasCkcylIZ2yVZh/D9cVZvLW2m1HUJLW68q4QplNoMbjHPI71la2h0+115kdlo88mouGtFhmKxFHDNjA9frxXjHxKs3TV52O4s4Djd1NdhpF8uia+pu5Vgd4jskiOVJOeo+lY/xCJ1e3iuERj5ICSSseXz0IHYVcNHYwr2km0VtOvxPo9vcBuAV3jvnFddoWobQFzn0xXl3hy88i4l0+ZlCS/dLdAfSum0u82soOQVO3HSnUh1Kw9Tm0Z6YsqyRjHB5rkPE6hLiG4XAC8N71qWF+GVlyM8cVS1xFnsZ1HUAkVCWho9DKS4aKQHnacc10FlOJYt4Hqwrk7C482Dy2AyBjJrTsrryJ8K3D+vSspQNo1NDYMvl37cnaMMM+4robW2jv7aWJwR5oxweh7VzM8aXQQxtl9ozg45q7omokSBGHzA9Pes2rM1butCm0r2sklrcjbIhKtj+YosNWdGEMjHeudrdmFbvimKGYQ6gq5LDZKAOR6EVy1/YGS3Mlo+7YcoR/Kly30MnLqzq4rwFYZVbr8pq39vZSQMEdh61w2k6kXLRSAAv8p/2WFb1pN58JQna479wazlTsCkmdMl8pQNn0yPSpZLoMAU5rlVuirHzSAcYNW4LvK9evWosUjfim2gggEn5SDUjMWRlOcheOKzU2vCrqctn1q9A4YYY+3WkhtnVi9uod0bBpSv8ZH3R7ZrMa8kMo81mLsc44/LHWtScF4yrgDLcc5BqrPbI8pmZW+X+NhlwB2z6V0O5ceVFi0jMjK0a5B5Ks3IP9a1GJTaix4kPtWXbpthBjT5T1KnrVuFsxbmw3HBz0+tMyna+glw0gkZpipGOBnj8KrvI23HzLnlsLzUs7ZCoBleoHcmqU8726gKnmc8ZPIqGJIjl2mMAA7h1HvWXdvukA2huwU5wfxqyb1zIpeFo068jNMYqW8zajLj5Qe2azbNVoZt2ZCZN4ZEY52o3H41i3MQjnV1JJc8g10V2yuu1QH9QRWZJCzy7sAn26CtImkXYjto2iuEVguxh1H8qlup0H7skZOARmqu8QzKFJ4JLnGQOOtPtYUdvMcEIOmepPrVsiWruXba3jkh3sFLZJUE/1qaR1Yjzn2quAB1ApgAcdMr2yOtEfJBBC5IAUAUjJkd7CXLxxlCvZsEH8Krxxx2iMxJaTOeRVy63bj5bAHHGazJxPlo8h067ujUhFW6kLzKjNgycyEdh6Vj6nJNBNHfWzMDA2UXHUd+a2XRUZ3WVWAIBLLgq3df/AK9Z1xiWGMSMSrtwg9+lUnYZVlvIZ7dZlZWLfMTnnp0NQade2k2oojsRJs2xk8qX74NNvNKS5dmiU4T7zD5c+wxU2irZ2mq28Usa+WuCcNjHrg+taxszPqXYIx5/l3Mu+IEttXqT6Gk3zTwuCnl2eWZUVDjP19auarjfILdR8xwH35yAeOapS3Rj042hdH8vOcd880WuXJaXKTzmOya3h3+eTu5Od3pzVm3gTci3DyykoWVkGMyEdD+tT6fp0cVl51ywllnUfux0C9jn1NVFjWCQrlMFTIm1sleen19qproZNXCEtB5oY/u9u7yu7tjiqFv87y7yd2NpP4cVLci4X96gJYDoRjqOn5VajsmEq277UVzvGTx93OKhytqCstGcl4gskm026lkWMOoOM8ZwexrmvBdylpqr+a6xowBy544r0LWrZXi8h2jhjdSSzDO0j0rhPDcdlHr7G6eMIgwm88bie1b0p80Hc5Jx5aicTrxq0ck85u1aOQPt+XIUjHFL4kcS6fYXFrE8kSf62RUyMkdM+la8RsFe/E83m5TzYWRQQCRjFbPhKBX0QW0qDaSVXAyG9jUc1js5XJWOMtrhbiy+yQS7kfG1R1UjoRW7Y6Fp9zDGrSvHfgjMoGAeOc/jVCfRpbDUpJdLaJ1WXiB+D+BqWz1qP7Q6zIsb7iHjYYZT3qm+wRinuZesrNo+rbrnM0cgClnXlMdCKh1LXLG4sZLaV0ZpB8rk4KkVq6hew3lxOyOGhH7vY68MRXNXemLKXlZFQD+EdvammluZTjuo6nGaig+0s0bcbuMDvWlY6iXdTKSJBwxPGferz6RJsDPGFHUD0qjNZgHpuI7VtzxascfLOD5kdRZakVxjJ981pNqQkiOcA9DnvXArcz2pycFfQ1ch1mE4Eiuh7kCs3FnQsQmrM0PO8m9Yp9xjjitGKdWHznJwQK557+0fqkhPY4walt7tGIVC2eoz60OIRqpdTs7WUuqPD0B5Ge9WLecxagTKMbufpXM2V8YGBDFUb06g1uXNwk5jkODlecetYSgddOpdndWTtd2NxbR7WJXKgnk4rFeFdsDQsiSE4btk+hFN0S7eGZCGBXIOGp3iIW/2eae1bDFt2P7re1ZLTQ2nA57W7XbMs8A2M5w2OAG9afpt+RLukGwn5X56H1q3k3kLRyA8r29ax2LgrMQN6ArMo7ir3VmczumdFJKDIJAco/c9jRDI8bY2nAbqT2NZsRYxmNJNyt8yn09qtWl2JF+fPzHBFZSgXGR02nXYZWjY8EfLk1YEx8zqcY7VhoA6J5Y2MOx71oRyFk+6d6cNWLjYu57NMIQpQRkdcZFVJlG4EnGCOO1WWgUXCOzu4IyG6Ckm3h2ZSH9c4Ga6jJMqStJHHNtKnoCQKpXF2rYjWNfPHQnj8cUl1LI7qqqyfNznNTJJGoxKQrE/ex19qgsrpaFFO92XjPLHaT7VMNiqAVwPRTkU542Z2USZU4wP/rVC8e35RyxGc+9TIpBOqMgDKC2eMHNY1whtmd2BaLuB2960H80NhFxn+IGqN5KYvlkJzj5cfxe3NZMpGfJuUOVQvGR94dqyLxxAgABbvirdzHMVKxkoAeQOpqnGkUcjtMcEdXbJOaqLNUU4wiXDuWbpuIq2l4Lg/u1O1AWwRjtVby5bySR1GI88ELzj/GozArKydABh39D6VoNmzBNtMYUl5FGeOQKkSd3Gdy5PCsOgP+NR2CiOL91hGztAHIIqOeKQ/OjKvXfs7++KDB7liVhbhcjfI5yPeqk8ixuHI82RegycZ+lS+YS3mb2DEZc4/lVaXaAHLDY3OVGCf8KBIwdUmkAfy1Leeyr9G71JJGVsgEUhANxJ+82DUjRI0xkOWkLHAboBTrnapkB3bduGYds9BT30QwAa4ZI45RHBg/NGckjHesvVNIKR29xZu6XUJyxY9vT61taC63GkMFUAQghmxnJ/yKpzzmSSRpOFLE4z1GKuN0QPneVLRZ/IbLg7+6jpjisyfTpPtUUPlv5sw3N6EetbNvOWs5N+5dyfKo7k1bsmiE1vKSUAg2q277jDrnNWiHJpFO5dBaxFIggAMbhfbgGq1mhvLp0tyFhjQ7t64J59a0NKP21JZFGYod2DkYeqqXP2eETQx4H8QByxU8EGhvQa7FKeCdCUWORjnKzOc7h/9aiwczTSG4ZN8SEAbup/xq1asZGmnuMIsUeQpbaTk/w+tZ2lK81+0yRK8BY7lK5zxz/OofVCZBcWUt4XiUbpXQ+WCck5/rXk2t2EtpdGOZGD5IYMMYIr2gL5d8zDYHDDBJwENY2teHzrkrzpHHGQ+wbiQGJ6lielb0JcqOevRdTY4PTr8/2fFsnbz4jsZD3HrXbaT4wJsUto4JpZgeAvAB+tcLNp0VnqASQyowJVigDDGeefSuwsha6FqURYgQyRhh5g49ulVUSa0FQnOLs2F62p3Oom7lkns7okFAB8nT9TVnVLCWJrPUJry21GSUbmjQFGib39a1tavrSSKBIHW5vJEZ1j3/Ku4YyMdCKxpozHa7ZH3SocsxqOax0qkpa3EjSDz2naECZyGwOATU0kfmOCWJkz8wYfdqZFEckc55TZlec0skWWVvMQOTkneOKwlNs3hTUVoWLewEzEsx8ofLx3PrVHUNChK/JIhOe3WuhgsI5Io0fMh28BOg/HvVK4eawZ4njLg8IxwCDWUZtPcJR0OKvtCfc2zdxwQaxrnSWgk+Zc5GQDXqGnWi3MqF3CgjdtIOSfX61HrelEr+72yN2GORXRDEtaM454aMjyjy2jyeuR3pUlCYJ4I6V0OpaRPEzFoSo6dc1z1xAUHzdfeuuMlJHFOnKmy7BdI52hxz6mrSXMkLbgzcckf4VzbxnOMYJ6e9W4JZ0TaWLjuD2p8txRqtHc6XqisPvnNa19cI1ozs3zcEkelecxyvE25Qy1rQaqskLwzEjcMA54/GsHRvqj0KeMTVpHXQXOyYcgKxz71FqgxqDTR4xIoLgDgnvXNrqayRgM21xxnNWBqzFFEmSU+7UezaB1YyNOzlVWZUOMg9+lH2gwyiQ52P8AoayZpk+WWFj6n2pxvVkB3cBuo/rScGTzpHVWN/uO1jliOK2UvN37wdSNre1eeR3eANrZIPBB5rRstXCttYdeuTWc6VzSNRH01HcCNSGUjnBGO3sadIylh5YdTn16Uk0wk3NsCxscZ9famQTbpNgyRg49sdRSHYqXRkknV3G4ckEDr7025CupYKpGBwOcfhVxSjplR8wPA61HIm9SueAeABjBpMtFSB2TDR9QcAd/w9adL8xyW+bOeuCTUkkXlrhlyenFMQEcvjBPA6n6VHQoaIm2AtlB6Vm6isXzfOM9d2Ohq+yNJvL8D+6TkVSu7cKCHdF2jj5etQxoxpfn3GNwTxjNZ9xGkZ3MhYAbiMZyfpWg6+WS2P3YGcjqCe2KotJuU73Jc8kdz6ChGiIghEXkruj7v7Duajt41VyWAw35EetT3HmGFvLYKZM/e5OPcVFbxpHF87OxCbVPXmtBva4ttIMkQIzk5YNnAFWI5JZOUh2yg7T3BP40WzKqBFQnjAAIFSTIV+QYLMCKZlLcRlCRqGYmQk5HYYrPvHbCugDDHrir0LYjCru2oMDPQe9VZdkhAB5z1PQUrkmO0pd9jv5ZXoMd/rU11HG1lIZJ3ZuiAjCsx7n1xU0kgiBYgMu7cdo61m332vUW2xAhenTp71URSM3wpfPBrM9g8pjgmj3EueePb3rQvIvIjmklbbt9R+RrJutFnaVJ7NhFLa5zI/8AEf7tQJqF3qCtHdWm4scEbuCa2snqQm3oaa63Z2yqPtCbmTYvzdTSRXUQWKO5k8uRjtwD3Pf8q5260mONf3kSQk9Gxn/9VZN9prtPBJFI/wBrUk7ic4NWku5nNyWqR7hdSWMGjW0OiwMSEKBcZLOeuP51yNxbS2iuDKC5UKydQB1P45NZ2g63aW9qWvvPe6jZsD5ueOq4qS61CLUZhb2Lxxs6sVOcAAdc+5qLXZpC0UFxdAW7xqJC2cBz0x3qeMLbWMUdvH5MgAbczH5896Zo8dwZUaVGZBICZCAQPwpdXUyap5CgqI8BjnOT3pO2xN7lTVQzxWsk7cltyquQCM5/E10CX9qLGForedYhE0OUfJkkPILKen0qt4k0q812S0g0ySKFrJCUd12oyqOg9/51zkGrJ9meCZUS5DneGPKsOlUl2Oii1JcstzmPEIWbVnjZNjqMuPc9BXWaf4Ou7ywS4urhXKoCFY7toHTmuUvzHLfTMnzYO0n149at2F5fxoEgu3jPXbu4xWkr20OVRjztmy2ly6Tdxzuq+WpIGDkE49aQt5szsYshBllc9SfamS3l/doi30zTIp+UgYGantSzM27O1gSOen1rnk2tzrjFWJLe2e6w85+QfdQcACrdnp8bSSHJA6EnvUn2iEW2yOTcyfKBjnFOtribBMMMjKRgkkCsJSZt0NSMMhRInPyjLew9KoXrLdX8izHKwAs2P4jngVPbs6QAnAJblgc/jTbS1Rr53zvhjxvxyX71mtNSGi9p1goh3Sb8sMkbuF9K1raIPaHEYBVtpJHWmx/Imd4YYyCKZFdBQ6DJbdgKTyxqd9yWjJ1nToTCcqPMf7uD1NcFq2glS5cAOOeBxXqphDyCSQAyjgegrl/GM6wW8wYBXYKoNdVGTTsYVIJrU860zRXvJCxXKg847irY8OzbnESlgOAcdq7HwvbRR2MknWRvlB9B3rrbKzhWIIADwOnetJYiV7I5o0UeNXGhXSfwv+Iqtc6VPEpaSM7OmccV7t9giK5eNS3vVDU9Khe0lQxr83P0q4VpdQdKFjxBdNkkxsVifalbSrpeAHGegrtbO3ht3mjdz5iEBSB15rQ8tAcqAT09+etU6zQ44aMkeejT75QR+847AUq2V+q/xn229a9EtolE2zaCfTOa2INPR73EcLu68LGi5JIHpUfWH2L+rJaXPJRHdp9+Ln6EUF5hw0WQO/Ir2XTtGSacTfYvtUMZ/epggZORyR05qvcaLajEfkIGZixGPujsKPbrsNYbsz2komGVlwRxj/CqF1CouUETyIB0foakgvZXH+qeQD5RntUM85Z0MrbH7KOM/WsjRXRZgjwhUPhuuT3qV2RiQ7jpzg1WkgDbS+7HqrEZqSJVjjP3UYfmR6elIbIpowzlI/mHHJ6VSlEqyjOVbt7irczkZZd2T3z1psjS+TyqgDkgNUsaZEiyIsjvcIJVHyqUzn8ulZt1uYkzjgNxg1fYxTbVUMp7kd6o3FrkMWA3dlz0rNlpmVOpAeRJEJI5U8DFY/meW5ZVdC2fmI3AetarKrSYJ3IG5z/SiW3BU5HLc4/z0oRrF2MxZlw4wxPXd0pYZFZHKnCKOh60y5kRDtiGAx2uGHemxlftRZ8ORjgjBUVqW1oW4WDxo4Qqo7sOSabcvLG+6OTJIwF/z61AGaVWhVgYwflZeuPrSSRIGYI7l8Y5OeaDBolukkkZVLHlQx2j17VUnikCEb1KgZOV5/OpbGQRl2uJCFAC8ngfhS3k/mI/lQboxj5i2P0pNEkD4CjdsY4yQM8CssAmRyUIDAqhbp9ABV9pXmLIrAAf3eeKZdFEjBYhAoz9PrSTtoNxMOS7u7qXygBDbR/xEcc09NsUivFHuBGMngZq3aKbiPyzGUjLFi397/61OuSq2rjlT2+lW5DgrGbNBJLcxXN0wf5wyxn7uAc4xTTbw3eqosiqrTOSGPABJ7H2p8Z3ySb2PmjJKD0PTFVL4XDFHiA8yNx8pOQcDpVJ6jt2OikMdiqiEZmtw0cjEAgjnJ9wayg1vLEF+zrbsIvlIPU5znms6O9uJtybZY5D1d8ED2HrSwQ3WoThJZPMBc7hGmDge9aLm6mFRI1ZZwul2yxvnLfNIoP4/lVIIbZXkjkeSNcuWx8x9Bgda2oLaGOaHSNOQSCf5QsjZK99qk0t/pr2SrcMfLu7Z9yZ446FffjioTV2JK5NpmpS/wBm2drdSgTOCxZlwT+JrmfEMNoJZrrCBMEEkfMT610ltb2tzbl98qQn5JEcEgN2A9OKwryGO4FxbMC9lFIFYn74HYAenvVxaTLnG6tE4e148xQAFVu45rTWOOMFjtIKg5HbNVFgVZXCksGcgZ6jBq61sQVQ4+bAHHatJMijGy1Jra7MUcjAK0SqAY35DmtB7eJoreaBidwzJG3WM+g9R71SECeWBj5iR+VaRgkXywjMZOAF/wAa55s6YxV7mkkUZVdvQr1x2qxb25ihZguI3PAHf3qrBFO64klVRjJAUZz9a1IpPLSNZmLBR07VzO5dyFYAuQq7tw6N0qfT7RUWX5BGxc4YGmxyFwSv3M8EjOfpVhH2SsjL8p5zjpU6sGwC3Fum2NkYHpuyOaWHzUui5gEkhG5iPSrkgKxru3FcDnFV7uRkYMpHKFeOoqiWWvthMCIId79Sw4rgPHbytfWwlIOR0/GvQVRRbkM+SCAoxXnfxELC6gYjHynGPrW1H4jGromamjPi3gU52966i2cAjJ47Eda4bT7xVtoXHzKTn6Vvw3YWRSr7TVShqZ0rPQ6wN8vzA1BcjcvU4PtVOK73ICGPAxzRcSSNAQjc9aSVhtHG6qvl67cKi4DMGA7VZjI8wHcBuPNV9czHd287H/YLCiMqDwS23GfeqaLpvoWbVwt0CeAT09Oa7bQJi15qUdpIEuZEZbd2IBznJGa4S3dWl24I+cgVvaPbQSvdz3k8kVvZgPJsGWOeAB+NQkaStY7fwvp1/aavC8iSQW4H74uQAw7jHesIlXuZ3xkGRsD0GTgVb07UtHeaFXfVXAIIEjgislJhHPMPmAEjEA9cZ4pTWmgo3u2z1MTARNKGAiP3j0wfYVUltfMHnNIUReSACSfxpSGWUKkTuAOwxmj5o5ADhMn0zge+asxLMSF++Bj6Cj7JIpMnnH73A4IFQpOm5lDnHpjOf8KSW6ZVUIq7jxjOT/8AWo0GE0rxKfNKtj+JRyPwqsboXAVFAXdwMnH1p8vmEGWSXg/wqufwzVVbGSdw7ShhjgOBhfpWbGTXk6RgfdXYO3esmWaS6fEoKoeQp4LD1P8AhV9gFj2uMEHPsffmqtyGZ93ynHJBGDn/AAqGXEgCBEYgIvGF4yT7e1ULkhCEbAIGcdz71elbzI9o2jPJwOPzqgbcK0jEljjHvmkWmUCgZ/MP3R+lHkBkkMSrt/iccnnPFTMipGckquOn86zpp/Kgbbkl/nCjqfStYmidy3bRkI0Krjg9OOBTlkjSXazKrHqc81TjiJVftJJJHIVsDFWYET7qjC5ye9Nmcya48h0zlUaLBV+uP8azZXyhWVQ14xGRgjIJ61piNAzoIohGHzuH3ifU1SvJRO8UahTJGxOcdaDIptC0WZByC2Co44qPVIo/L8vCqOshznIHT9a0L3aSrZBVtqgelY7HzpvMnPyn5QMZH1qbX1HuQzmRbcFXbazDajdD7H2pjRJctuDsEXvngevFXWEc0ok5EKDKbu59SO1YlwZklad22xvyVI5Iz1xVJXKvYbcXLCdSMrGG2LJt2nn27VafasEZyAc5JHUfSg2Q+UFh5ZYMVPGeajK7BGspVlyVXHUj3qm9i4alaSCP5gTjccjHVffPrS6Pdy29ymy3EsjAlSSQPqcVOkRYAFArkkEe3Y1a8O3dvY6tZyTrGyvgKrruVgDzmmm27EzRcs765s/ENncXEUMcsDbVGAwzjqf6Vd1Y3Gp3XloFLHlt3QD3+tSeJxaxassmnM08CYbeyEBuucA81LEW/tFbq3IglmUFgDwwx3XvSem5FtE0hkNjA9oWEMkVyjkH5gV+UDBx61i3LxJJPbygymRs5AwQQM5z9a3dQu3W1nuDsRQ+wxqASB1JJ64+tc1raqLGVo7ciYxmQPvPygjOMetXHdCs2jjY1/1gJ+ZnJz7ZrScHKMflAwearwFJFEvliOOXH7vOTwOtXJs4CyDLhB8v94YyP51U2FPYRET7MPMYLk5HetW0kE8rOdxUKBz+tZiR/OyuMdPoPpV5H+zxwxZ/eNy528KDWEjdGnG67kxjjovpTLp/MYK2VXd8z9qhEQlkwRkjkEmq7W+ZVUb/AJjk4bgfhWaS6g2dLC6QxqRtGwA7j0FOSUTXDsoQg9GPQ/SsoKW2K8rvGq8qw468Cr7tlUO3cx4Ug4xSJLMcrB2t0YkdRkdc0y+XZJEQfUNTLW0/fK7EtKOgJ4FWfLVPmfO8H72M8/SmMtDCwbg3b8+K4Hx0PtcKzLnbEducdc12fyspXKgbS+MHn6DtWfrlrHc2LwhCQf4R606btK5lUV1Y820e6zBJA7YZPuj1HpW/ZXoeNcthxwRXH6nBPYXTMMrIjcHFS2l9JctvjAjnH3lPf6V6Djzao4I1HTlZnotteK6bcnPfmra3ZVW7gD1rh7PUmAx0b+6e1X01I468kcgVlyo6XUUjQ1xBNp8pU/OvzAehrOtLnzrUurHcF5Hrimz3u6JgG3ZGCPSsfTJyryxg8g5quUhTs7HQR3AMhJOXbBFdd4fdoLi5a6066njnh2MiqQrA+vHNcEHXeuGG05wfQ109l4m1gogOoT4UYI4/DtWTVjfmurHUWT6aWUDQ9SBzj/WEf0rPvwUvN8YYRT5wD2IPTP5VRHijWYirLqE7Jnof4fY1YFyl3p0u8M86N5gIP58VDVxpvqexb9nyyfI/TrjrUBKlmKoWyOWPSmm6DjeiRg55yCQfxqtPerCGDRglzxgYx9KCEiSeNFVTDhnxkAcVCVWILvl8yVgSUXljUIkZeqGPefvE5JH+FStH5a8c55yo/WkUhYy2Q8oAK8hQc4/+vV+NzgkAFm7DuP6VkC4ddwQHg4LehPepkdWCqpKADnqS341DG0TXfy25KMN464GcDvzVOeFGhJIbPqG5/CtCRQluAqnn1AFZrLIEQ4Y8Z96hoaMuSMjIdiO6knBqHc/2eUCTYCc5B5NXL1ZNquwUOrBc/Wspid8m4BgDtJzjrSNCpdSyAurAMCBjPH41TkjSHZ83BYAls5I+tP1Z3KAQRsSOCzdveq63LPLGyAgqBucjco9setaRZadkTeYsDgSsWJGQBzmtCzMuCX2RpyQoH6k1mC2VA0zS4OcjdyD/AIVZcs6ZMbIoHQ8j8SKoUtjQbY4+XPmH+VQzwojI6FQB1x/jS2ZaWIiPAJ4LngZ9qdduI0SFQXlBzgdPxosc73MS/klkxEiHaHBbA5xR5RC/KSAcADHAxV2aKZnIdwuOqdc/jTFiZlKg8nkipb6GiKM5ULOJMqAwIA53Z7fSsq7la4JYhQudu09a1NS2oJGUcqoz2ORWPIoaXz5FYoDuwRjt0FXCyVhSLTwOpgSYBgFyEHQfWlW3+zzKdgIzkDHNQaUsl9NJcSswQAKqg8k1ZaWeJjvAZGJAdjg0SavYqCsVy2+7aTs3HXpiqp2i9shGoZlDYB6AnvWkXhS1WRiyY7Fc960dO0TTdR0VbsyzefKdmI2+5jv9c0otJ6lSehBq+qST6faW8hH7gsFZTySe2K6eDQWXT7FpEDyKoJO3ofrXnGteHdUgJubTVDNJDl49/GMevbNbngLXNU1a2eS/1FYI4gQFCZLHHA59T/KtnHmV0Yczvy2sX/E0LtGAPkjZtm9M4b1B9RXN+IL6VbO5V4Sjuu1d5+4oGMCtvxFrMjOIWVCki7WKrhRj+IehrkdfnleCB2kjlO7cRjpj1opQtoypTtFmZZSEQoAVLKoO4/litVZWeVmwhcIFyT04xmsGGTcm9U5J3HPQVox+c0cjIp8sL+8ORzz0FXJXIg7JF2O5BnKoPvYUvjn3xU0JMsxQuNgO5/6A1TtGdZUlVfnXpkdKv26Ga0mkuCGYnK44zWE9zVNlmCQK0jDc244G3nFXgY1SNmD4HDEqRj0qCxxHCo2MARnpkVZknSSVY0IwT8w6cVl1KJ7W5AnmQA44KkjofarqE5wVx2BI5rNZ0EmBnd1C+lXUkdiGJ7dSaTBFhZGJwODjbnvirIKMgDHJHAXuaoMwyGLH29TRGzSSZJ2pGcs3QfTNITJrX93IzzjDE8nuPYU+4kikPfrnPtUc8sTToqsuwck561XeXzSwyFFBDdzn/EGlR36tIPkBJx7+9ee6nps1pOWAIKnKsK9XnRfk8w5U9eOlU9TsLa4DCQjGPlz6100qziznqUVJHnthrK/LHqcEbJ2YjGTjvWrbRWM6vhWUnlSrnGfSo9S8NSE5gKuuOg5rnpLa7sidrOhBzjHy11e7LY5PehpJXOnOlwmLKs+evL1ibGtrhwT34Oe1Mt9bmibE6Bl74p019bXYJBUN2zwaFGS3B1E9jQjlDAbj1PGPWtK2nZCyscEdfeuXjbbkZLAmug8L/ZHj1S91JHmgsYPNEanbvZjgZ9hSlA1hV1Oh0ue3uJ0jupxbxNkM+3cQMenersE0FtLizuDcQMDu3R7SMHpil0+LTrUaFp1zYxz3WqIZJpCSHhDfdx9P6Vzcd0Le7kiVwwR2UN/ewSKylCx0RqJn0Y6uVO52VDwdo2g1WitsTKZIht6rk5IHrTfPK4kaTaw6ZIOPwqW3mLLvlJYn+7yaxLsPllLbo5VPlkfLtAyagLNGpYKQNucf3qvJtA5jGc8A9aLjAGVjCkcMvdqQJ2M2RRNbrHGuA3JI/hFTpE6jbgFFGcHripIhHtBjHlt3HXNSRyx4If7xHPqaVirkCj5SWXqMKN2adkDAPAx09KFzK/ysRgcE0snzkb/TGfasrAZF/wDNHjHOMgjk1n3EaCMDrIBxxkitebY8kghYnJwCw/Ssx0EMrFpQO4J7Ui4mReW2+Ilm2MB0PU/WqemIrSushCKBkA960dTmBVolOWcfKNvzNn6VUUiP7Oo/hzuGOelUmO+gPCkkqkoMDnOKkWQztsCjykJLc9aWdmRV8nD7hnGeR7mkgCkCIBsDk/WqQ3sXBKFAcjCYwCrY/wD11JEgWAkkEsd5UdfxqnE5MxDFSF6YNXGk8vJUJnuQOR/jVmMihMFjmJzkscjIzj0qNotqqOZJGB6cfjVq5hEksbPxnJwpz27+ppkqCRESLoRjJ/hFQyk9DF1PyIYgso3SNndgZwfSqgiiNsruWkYsQOuCB2HtW3JGomZkQokfBB5JPrVM258hArYJY59ME0r2KWrKFpa4cDcQz5LbeFx7UqWuQskzExAEBc8Z7VZtCS3lFSGjVvbNOuLQCGQDhNuR259aV9bmmxnTQmWGRy/7pgOPU1b8IW5ey1JUlfKODGij1HP61S+S4gSIyRsFJ3HdyKoxapJod+TJvksZAFJX7y4PWtVqKUmkbOq5RGiYnYQGcE8t2OK5jSrSXSvFk8NnIklrNjYrH7mfX6VeS9TUb8SKzmEHaAT6+xrPtLl4fEklyxVbfhCc4xWsU0mmYycXJM6LViI2VtUlZ5ivyqowqAe3fNcL4h1EXGoKiooiBCkrxn/69dXr032oqd25sfeY8CuT1O2MUXylZImffux3x0HtWtPqzCvLRRiJbhXgJUASA59zzitaAoftKI37sL5a54yc8tWZp4KsuVG3HX0960IQoeJVPGd7EjrzUyNaa90vbRGqbBuYgqoPcetNmcLHHCGIYjAUdaA3mbpVBLBSoJ7fSo9imaJUYjHJI5J9qzcdDVvsakit9lADopH8KnLH/Ci2tX8x9r8gAfN2JptzEkrRjYwUk8gYNT2Zlhugr4kSQY3McdKzaG2TREWjGS4JckfePQDoRWgs8TeWSxICj7x7dqo3iqzFSWQDkgjI9hVSylxfIGONilSG6ZHIz7UrXJvYvXUrNKTDw2QoHXr2qWOZYQu1QGU/dbkH86qW0/m3iYGQG3FuwPNP1KYQRYO3Lfd55o5WS5DjfRvICYRlicAYyQKerKbR33CMjnax4NUrG3Rz++LAlfkHXB/pRHADO2Tl0J+VjkZ9aOUlExmAMXyh+4FThTJKryMqHHCkdfaoYFHyySNuYZzk4Aq9EWX94yCTJ6EcfSi1ihsKNH8sQiCEcjGC351FdaFa3eSQPLIxuVcc/jWknlhyzgJgZKlclfcGrVssZDFYmbHJY9cUuZphyI861Xwhgs9sHI3EfdyMfWuUvNElh3ZQ5HtXvCRo25X3fKOAe9U59Khum2sFwR+VaRxEluYzoRkfPzQSwn5CwI9+lbfg6XVxqjDTXhUrETM8+PKWPuXz2rsde8NKQzxxjBPbmsjRbSG3i1Swv5RBDfwCETlTiNgcjd3wa6oVoyOSeHlF3ReaTXE1+b7JqtncX19YLNHKE2hk5wkWehxmuKju9pO44IPfqD3r0CfTbSxvtE1S91SyaLS7OOPy4JN7yyKDwAOg5715rdI73E0m0r5js5X0ySf61rZMyvKJ9YpC10okEAB6ADPT1NWVkMa+Wy4PTpyD7U+SQKFaOJlUDpyTn6VZtJYrlFZAQBjIY45+ledY9RyIoiUcF4iM9cjJNPMiFXP3McYAOfxpJYvMceSXyOpUcCoGtdj5EpIPU+tDRN7kjQu4yhCsP7x7U2AkOC8aLyAex/AVI0rjClAm48HqDUN1HIWHGXHTPWk9EUvMsAo5LAZy2MZqvOoYsDknvioHne3dZgoETnDE/wA6kllidwolO09lrMpIgcNCWIH3+QO9ZV6yhNyIJm6bWGAD7+tXpsOSFkbjqCearzBIAqmLtnOetSWjHitnQb2yXbAyx+6B3HvUMlqwMcaFFPOGck4PritGViVwVKhT055rPuHQfMysMnls9vanEohlhKBiCyyYALZyDn+VPtmx6HJ59KTc5LEqwUnGMdRTSQJQdhHoMVadgLRaNMncGJHRT0otS7uGeEeUDhQTwPempuaYs/yoevHFXLYh22kEBPbrVGUkLJHPF85kQkg/I3GB61UhiLDYrby3ODwTitWXYzYi4YjDMeckelZdypt5ZWUcMOuaGKJUZWyVDZYn5j6VGApXeThc8Ad6uTODAcDgnB4wRUUe0AgcKp4J7Vl1NUUL0Tk/IFVVbIYjLY9cVW1FC6pE0rTF+gBwoH0FaDvJLOmwDGPmY9h9KzJLRVvpJCNzE8bmwAPpTRRS1C1jfaqRqVUcqBzj2pLq3jVULRCWNVGASTn2rUERQ+Y675D/AKsd+nJHtVe9SSCCJo2K9SRj8yPrTv2EziZIWhvIUkRgwysbK23PfmobnULmxlkZIUnH3ZIZON4PofUVs3caXGqFRnAjwpb+91qaKC3ZbZ5Y0YK+x9wyOetdUJJNXOWVNtOxk6bqDXtlsMcMaOCwQclCMd6q6q2zbBcKQ0cfyKPfrmuk12KytNSka3t0SJUGQgwp9MVz3itC+tMzKoY7DsB45GcVvfXQws0tSSxCmNZWUKBiML1zx1qzcsqSRuSVCDoPSooNpxEnKKud3+13onZJJ1Uk8YrJ7nYnyxNGTDeVGrFPkDScY+Y8/wCFLbwrHdgAEOMMM+tROj/LIWy7nLk9j6VZPE8cynBI2moZWlrk0jbfm+bBfgCnT25t0+RjtwTjqR3FVEciVwWyAcE/zqeR2WXazh0H3QfSotoS2PFzJjEqgyN1PY+hpCjCSScyhpMAHAwAM9KcwEq4B5HOe4+lORFRcZJIGWx/nvRYT7iwOlvbzLj59+5ip46VlPI1zdbm3YA4561YuZ/3JjAAcks2OwpsNsl0wlcyKgUYXPBNaKNlcyctSzDPsJ2YYjnnpmpbdnkdRHjeTkk9B9fU1ABGsYWJCFDfMfWrUW1WBYqDu3YHP0qWrFrU00WNmIuGjUnqW/w7UkqBym1sknjP3aQRyT2wZogO5OMEfhUsIA2xysevDYxisWzRIWKMSz4k+dSMAAYx9a1bb92g+8PlIJUAZHpUaxrH9x0Yg889fb3qW0jmunaO3DEFQScfKoz1qErlNk0t1udIkwF4DFsjn0p88Mm/fJGHdeFGeKiazPmkKWIQ8s3Y1rW0Iji3+ZuI65OaQO1jPltIY4CSoMjdx61U03Q9Pd7q41K1S6tkh3MjZyCTgYwa05mEhwTTYre/jvcaeqTO6kOjfcZcdDTho7k8t9DOttJ8P3d7HANBtVEw2oVZzzjjPPSud8S+DbSXTItQ0+0W0bzTBNCjFkBAyCM816nb2N4kBe00q1tJiuGfzAxX1x6VlvdrLYRWkkKIkJOdp+83qT3rV1GiXBN6G9HI6Iwuf3gA+8DxTnijWNfKO1s7skYOfyzisN9U8yeOHZkcGrvmyiYmRF453Ek/hRe5LTW5pwTyJlHcEH+71NSFgEJIbb6jFZpuklYg7Y2I6gdvr2oacogBl81V9B3oEWLmVSxESpJJ/dYkfmaBvjRfP2+YeQV5A9qiWVp8YUFT+P5VXvpfJKMI3Lr95OhFS2UgvCBEzSYKHhlJ4XNIGje2iGBkIM/Wo9QcPbq5LFscKeRt+nrUlmVSEgRtIOuTgYBqEVcpSzSsWEKlnH8TL2pLgKuSZVmbaGZ8EDPcc+lWpLgzSKNqwg8DJ6gf41XuCnmspYAE4x04+tS1YpMzrhyM7nO8dsdqp+XH5YYdB93aRg+9Xrp1jwEAOONw6j/GqIhAbaC7BeSOv1+lNMtO47zcD5gz5BI2noaYsoZ/mB4wOfWnAhWAbOAP4R6015VBVAjKOxxnI96dxbEsYUN1aUnk56VailRfmkjaJW/hzk49KghMTEAcBeMDHWrbtFn5gXJHXONtaEMcGkQKyMFPJ6AkVQ1BTtcSPvDHG4jke9XVeBQFkfJPAA6k1DKsjo27BHQ46ADt9aNyVoZux3iRiASQOM8596c0eEYMcOR09qtQwjzARjfu4HpUUkrD5yBgngY5I9aiSsXcozsQkpi+UiQJ17YHFRQRKXd1BLZwTjIGO1OlkR5woOWkZXAAq1axsgmBGEL7gfwpWKjsQqjLcqwGW2klieeewFZ2pTpDBL5ucKpPI6EnpV+KKSV2m+XO/KiTOAAMVkSadJqN6I5pxKkY3HA2og/qfargtQZjSQypbi4kB3hhLj09vyqrPL9mZ55EUw7g8ig9PQ10eoKsTGLGQRjn0rO0rTk1OdLacboppFTy8cMoPAx9a1joyJ7aGfqt9BdxNJbBzGWVRnknHWsLUZll1KR4t3bAbnB6V1XjmytNP1T7Pp0QgtioHlKMbZAetchENuoSRs+/YvH1NdKfU43dtIv2XKxohAY5AJPX3pv+tZ2IxkHDZ79Kqq5WNRxk/KPpWgsZMagcKmCox196ho3lK+xdjk5PmMcfeJ96nmYyRAtjaP7tUIR5ssm7o3P1PpV9sfZVDcMzVDRV9Lle2YOpLn5B3HXPpV9Y12FxgLnAyeTWZc/6P5bRqDzyOx9amtZ49hHXC5QDoCf50cpHPqbELKn8JIA+8Ko3tykVnK+SWlYLgdcVZlmS0t1aclVPcDO76VzMsxvbgpuPlK5IAGOO1EI6k1J20RcsFaeVp2J+boO+Pers0hk2JASFz85ziqsEr7cW5VEHBfufarUQJjGz5cnBY9veqkwgtCeMqpVFO/kDPYVq2MQbcB5bMpH/AAGq9oloEIaRd4I5k5z+VTWrO80n2f5Gzkqg6fjWTZrEvskHkO6IVPIKlsgn+dEGLhmULvx1UegqsI9jOJJszZwwxnr7+tXre2niIeKQpnggHkisZbGqVh0TnzdkKGQg4baMYH+NWrWF7G4Zo3kJJzszkH61asVkijeBGVY25YY5P1NWwkcAyQ5wO/rUbD0I4hui/dluRlsjHNPj8wARow9we9WLMRtEysyq/TGKduwxJxgcAgVIiiomEZDcc84rY0WFpo7+EyCNpo8IzHGcHpUCRK0fmAgbuvNamlw2rxXEk8ZkWBN3l5wW9/wpx3E3ZFiwtZZTp88cqFIIzFckvzgHuO/Fcq3lySzBAVjDFQDxxng1vRzWTneunR4PzZEprLyUufMVR8rZAIyKHqOCepoQyo5LSQxrK/LLtyVxwOauGx/crPIx8487V4xVeKOTyljjjCrzy3f605JJYpCCxIHBByT9RXR6mNr7Fae2mMbnHynjA6mq6W4ixksOOcvg1qzzyMZABGFznk1G9s7Yac5A71LGtDJnkMXMku7HQqMYx7d6px3c7ygu7Mh67RjI7ZrZntokAGS+ORkdDTo4lVEU4jJ5DEjLVNilIzrW5baULgOOASemakSSZVAZXMB4JCnPXr9Knhtg7M+wSDnqefrTJJJoScK556gZ4qWIe5WQxeS6Mh43DipTEqoNwVsDAA5HHeorfAfzDtjV+uOM+hpZYGlJwzDnO4+voKTGZ1xFm4zGhUKM4HrVWR3XgRO2DjKjgH3rUntxCAJiSpGF2tkH61XxtUbFYFydvHH1xUl3Ku0R48kLKoG5jjB/Ko41KvulGSRjA6c1JLBHGwCEhzy+DnNMjIwM7iqnoexpplExzvxEoGfvfLVjCSbMDJPJbpntR53lwPsQAP1z1+lMiDBWYttVRwBzyatMzkRSwLGxjwVRxj/JqZ3cW6eUoMZAJ5HNQTsTtJGAflQHrzU7n93DBCh8wrt3emOpqrkNFSKe3WZhITHKQMDNFw8Suu4YUcAZ654FMmt1X92uRn155qnA3DpvykOT83pjjn25oKRDEiJdyM+QkYITjt3x681YjuVaF49pRzllBXGR602yiEkcMjKcEHPPU8nNQ3y4ZRuIbLY+hXmky4k32oxQR7W2kfd24J6VjPrMcSSQ3GyNt5O7bgN+NXbmYR6dCccEDJ6HFZd1bOz+SI02YySf504O24FS7uUmYMtxvxgHA4OfSnWl4bHUbI9FL7VboQc0yztkQzwMPnXjb7ZzkVS1lyiLeLx5TqVz9ea2juRJ2VyLxreLNrCRo3mMgDsFPvXO2CCcXcuSu5uCf5VXvbhrkXl7hg7yfKvQqBxW81j5WiWzYO6V95A6An3rp5eVWOGL9pO5VZA7xqi4GOD2xV95GEYIAGBsIHpSWkZdQpI3KSoHtTmC73T5vljxz3JNZNnWvMnsgI4V3AZkPf370k7p9oZFJIhAyB05HWpAQGiQ8KBjHfpWXfOyXNwHz5bL+8PTCjtTirsKr5USRzm9SUW6h9h4GcAjvTrFGgV5HVgAwGFHA9ATVfRlZMeRtDk5ODjcf/1V0kuqh9KntWgCGTaPk5AwetU9NDCm099znvEeolbbemULjaoY52DuRUOnR7LWJJdylhnI5B+tM8UeVNr8UMYcRxRKdm37zkcn9BWrpdsyWyNPtz3/APrU21FEqPNUbL0UMccYA2qOMginoCwKKCB0Ln+lRQfvJggy4JJGO9aG1nbbH+7GPunt7k1zSZ1pWCO1SKMOARGxwWJyxq/bBlb92VDYHOO3rUdpBCkg81wSPyJrU8nywqjbuI4z0qGyiGK1AyTtZs9T1NaVogjjQg5PfNQCcx4aRcY6Hb0qe0Rpl+YFlzkdvyqGBpIAIgybipOAevPvU67er4J7mqNu8saujFdueh/SnxMZZGMgcJgbQCMZ9azKsX42V0KxKMt1Y+lPS1GQOckggmmxuEIYLtHT6VbT94uTg46YPWixLYyKHYhOB8x6CtTRUEclyyRh7hY8xjBPPT+XaqalAMnqR2FasFleQDNvcwozDkiXrVRWpMnoUzqFzGGVrOPee32espSrMxU8E5YY710bwaoMn+0IiT280VygMguGTYAd/L5zmnI1pJPY6KMSIAgbKeoYYGadNGDjaMEd+5+tJGMOu8ELjhDwc1JLbxZXJAY9RnO2tmc5XW4DOdiCQj2+Ue9NdQ+15X3MfmxngU2QeQrmM7hxuGOMZpj7iBEWZEkOcDAqR2LLLGsbhYl3DG7J5NRSp5hCb9rKMMT29qprADKPnJwuBt4GavpHII1Vi209+BmkO1iOSIKFG3cfXpVWeJ433R5VTwcnrVsxyRSkxMMDueap3dwCwymHBxnkCoY0N2bkdWOCR94nAA9MVCXkt/nClh0wMdPWrNwm+FXClyRkNkc49fSs+RLjLYUAZ6M1JjSEvLyQqcRnnvjpVWWfzWV0yFPByRtA+lSTRPKPmUFQMkg81Vji/wBaZASoPygHoagvQdHJsclfkXpuHf2Bp7qzRKgdVC5y2M//AKzUpykCqoy5AbIAyCe1DWwihjBDBupA5FMZB5bgbwQEA9OlMR1zlgcKM9acxKviQO4HPqBVW5k+1SlU+5wGx0xVR3JZoWmy6uGmlyIo1IjHfPrRNIkU4K9GBGc9Pao4GUkRjgKOi9M1DKTFOhlx1ODuyBx6VoQLdJKyZJ8tScYHHFUZ4FmmSCMskbD95j+IDPH41eRXd98q4C/cQ9R9acRFGGeaQFic47sfQfSgNipOxkeMRfLCrBflH54qprEKJC8i5QqpycfdU9/rU09ztlhihQ5OQGPb3qG+Bls5s/OqrwzdPSkaIpOC1sJJSSqpwW+npTI2VLFJGxvdAWakkHl27rI2GwAoboTUYJJZJMYAAUCgZl3xO5pRuMYJXHofXNYfiK4K2ajBCttXfjv/APrrptQUtaTqjAL3yOlcn4klMemlZCS0fPHTsa6KW6OfEO0Wc9BvETbht3uxIPb1NdLpmr/avDUFlJy8LZQnriuZgbzpd29n3qcEfXnFdFpMSvakAFXJxGcV01Diw973LVm4JyBxtP4U6NSXDtgbuST6VI2EbYoCsMRgDv6mmkMJdp5WsGdq2LoEMjwr8wO1lck8ZwcVhajExWdQ24urdPXHSrKyFbuLaSrkjkjPf0qjrDtC8jSkr8x5RPTqa0prUxqyummU/B2oIl1Ityd8cZUk55PqK7N5ft1rHcI7COCTBiVegHK5b3rzKSN5ZbaS2y8ysXk2KAEXPHTua77T7+W+sQssWyMPwyuf3npkdKupoYUGm7Mq2avLK1w43TSbizHnGOgrWt7CR9rsw24+VM4/GqjyrZuScHByo7g+lLE9zc4dsxoo4GMn/CsZa6nVGy0NuDZbwRpA6qsYwx7tntVm0ureJsyZI6fKMlvc+1ZdjCkThpiXUjOM5x9a1reSV5kkQRgA7cdsY4rGRsnckVvNc+WFMZYsCW4xT3SZocrGMq27A5/Gkt7OQlVMQOCM4OB61YEqxFoWDpMFKjHI61AxHmmKKJFMZOOc5rRtGKqqB2TvtIyAPWqMcTMofaGA+9mtFYhGnHUjKfWok7FLsTWozOWcYTdj/wCvWowCIY+GPTOKq6arojq/JLZ/CpBg3LnPJ7etZjbLcdv5gwPbFTlREgHPFETCMdCBjr2qeRkKheOfXvTJISTt4HP86cki5wWUkDGM802NmHJ5HUVqW9zczvshsrV5MZ+4OmfWmlcTdjMIEg5OCDSRbchQV4bpjoK6IJqDA/6JZKcZ6DH1rly8q3DA+WQGOQBxVcthxqXVi4bndtzgvjJB4x+NOVrmVQ4IY44P9aZbqFbcx3vngfw1bhcJJtWHcueSTwK0vczIYYnZW86Qsvft+lLsnB3ABVBxuC5z7U6RJGbcWXjoPSoJLiQEquZMdQvQfjQ0PclC7HCTyKnAOSOBRLcp5TOWKwp/dGcjpVB2d7kSXEg3r91WBwfSrDwMfncbZOACg4/KpYMmuDtO/wDerG/AYnG4ewqJ53VQEUtBkgbl5/D1ph2Rqrs+HAwVPP5elK+JVQvK2wc4PXHsKVhpkExPkeZGygM3YcGooS2FPLKeRkc/SlZRETh1KD7qd8d+KiWZ9rNGVCqdwOfuf/XrNlD2iEmduBJ1Y45+lU2iCZ3op57H9TVqNBJIzSO2TySTgYp7BGAAIwegHb3qRohGCwPHI6npTXKl/vHBqK7QxhmBBDjIX+7VK4je1gZ5Gwz/AHEJ+Y1SRdtCa8uBFDu6nBwKp28D/ZlbzI0ZwXfcefpgVVjSWVwJGHIyR3rThKqwG3Ax0Vsk/jRF6ksrLcSKoMcYKjtuA5qcie5lWRtqbOFQDn3JqcxeZIMJnAyRjp9afjYB8pBBz0rRMllR4GiIJZnkPU57U+NI2dDKgc9Mn+lOac+cRgktyT6n0pZlZUOCAWAJ9RTApTRq7tP8wjT5Tnjiq15+8s9mNpI6r0x1FO1IOlnJt+U8AemKgmLyWy4bYgjydp/Kgdymz+ZKXK+YVxsX6jNLKDI5facgc54OagsTKJpDt5GFXnrwKS4njMj7WI29V9+5zRYdyres6w5CLuYfN32j/GuU8Qsi6bOk64ZotuO/tXTzXMf2dhAjPyCSwwDj+dcb4teURymUqysdwYdhmuiktTmxD91mTZp5QgUq3K8bfpiur0aJpWRoioWLOSTgE47Vzdy/7xApAwgwQO9b+kXKQW/lIQ79TgfxdcV0T11OSho7El/cJHqbiIny4ycd8mnoxeDcDlccnHNVJVRMIAGZiSSfrUaTy3FiiGTbGHI2AALjsfc1k0dN7aEqGSSTziThRtUkcAVi+KZWmuJFhbJkcg98Cr0uqS2qvnB55U9DWGJllut4ZssecDjP19K0granLWlfQ0NLia2gk2CPhQuOuPr71u2W/bGQSsS56/easu1gCxNuBZmOT6D2rQe7ii+SZiVAwFTJNTN3NKSSRammXcdsQfHrzjNaeiXESzOl0pGxd21hw1ZK3JljKWdrIAPlzIMAn+tXIwYZFE8okdTwfw4qLaGyfY24ofPhLRxlZDICyn5cAjt7Vct7cCXKOpkU4YnpzWRbXIaVGuw8Sk43gZXJ9a2YXkDJ5ykBeEIUjevr6cVjNGiNE200s3nWpWbsUBAYAeg7ikjSWWeRVQKy8gONpz+NRbFRApcFTkoQeRWhboZXYzEyAKGPzYOR/Ss9yr2HWzQmH96NrsnGOec96dbookLFTk8YBxj6H0oFsWLSPIm1ThVHcetWIJUY/dOOmRUSRSJ12jYCynK/eA6Gp1iKbW3ZIHU96hKxugMbqBntVmIfughJ4/hqbjJ4WIVCIyAfvA9qfIu6M7TtYjj2oEyiL5VBfHTtinW4MqEE7cDGB2oEVIN4Yk5c/XpW7pLCSK4i3hHlTCs3HfpVO3t441IC4J/HFW7CNTJPLPGXEC5CDjd+NON7kyZpWsJla0njkHlxKY5VLdv61zd1AkVxIQcJk4+meK1dJmSW6e1uYRiU4Vh1Q1n3ys0rJyw3Yx+NaN6XJS1sV2aeJTvUbiMAgZwKmhuAFCFRIGHJMmCD9KXzJ2kEgVFTGM9hVWYkAMjJlTnepGc+9WNO5O5WR90khBXtsNVn3jKhXC/eAPANSRtIsYklZ5iDnI568c0ySUA7CCM8DB4pMa0EErtLulXYD/wIn8ewq6rysoRWGOuT1/Wq0JGGEeQSAF4JOfWkAZZ2kDhnz0PakDdyQwiDDlVcHqpGQT6077PiMrGQ6k5G4YI9h3psjvMm6Yt83AYNjI+lVVn8kEFWODjJJA//AF0hLUW+O91AZ1ccbRjmoZvJG0xFmUjnKhSPUEd8U+WZmVmkVsDqHADY71ReQlHSMnCjCkc7Qe3/ANepaLiTtJh9uGDBeCeFI+lObesYwqg5zjPT8qowHGRtkJJyCR2q7GQqMX3OOOM8is7FETOGw5DSOp4GOPrUM8H2iRnY726AnJxV1poudvyDpycVXed8qITsGDtY8/WiwXM9oiDiPGRxwOKjR5YbpEaMqgPzEjr3wPXNNM5mufLgkZ9vGQuPzP1qeKM/a4y7biv3R2H+JqkVuaFvEywkjMe8lmB9SemaiKyAkluCOQTn8BU5PAZtwOMc1XnuE2sF44xup3JJTLGArEbsc8VnT3GQ0i8YGfYZ6CqIml8t+QqsMJ+NVbqR5IEgXgOBkenpmtI6gy/fSh4YwhJ3EjJ7VSbDxCJAMElmOfQ4ApJdwiCr7qAe/vUNkNs7rIQA6kDnoRTJY62cwJIwIYmQrzyTVK6t/kzIcl3wVHQDP86sxbpDMqnlZCAe1U55JiTGxjffljwcoBx0oFKQ/UolEJB65woLZz64HtXEeLmC2qglQcqBnuM116SSTXW6UqBHxgDsB1rgvF7G5uCpYfIVUADpznNdFJanNXl7jKdrIpuys3yCNTjHTJzitzTUdJBOo2gDBYdz9awZR5hUHDSuQvB/nXUWbo9sqQMxCKEGeM465raoYUN7DJYWZ3cE7Uwc4qC3jWMvHKHyGyuD2rZLrtLlM9iPwrAv7ghopEBVicFmqI3Z0TstUY97L++myG2KDgj17VHpEPlfvCyky88c8Cq+oM5WcyPyx27COWH9K1NJjDR/IPmYADPYVs9EcC96RsQs+7918mPvHqR9au2UcYkXdhSRnr+pqG2tomicsct3yfSr0MsZKoYI5FkQrnGMdaxbO2KsWp0d2QkYQfMADjrUsNtFLE2xwCp3NnnIzVS3gLqIFlPmA/NnoQO+aliOzBjwqkEAg9T0rNs2STNmwuBZqBCySIH4JXKg/wCNajyTuIhI0ixle3AHsK5m3kxaqowGVtxbHOO1b1lO8m+IHzUXgoTnn1WspblpW3LllmYhFMWUbAyOdvetEw+W2+I+W4XZg5Ktz19qxdNuYPNkjy6sM4xhsD05rpYJFlVSJFlZVwUIIFRInqV42ljJDpGQBgsGzk+tKUfBkiIUsQWzzSqI1Vsbhg+nSrMTjaTG6bT19azeqNEQjzCH2sgUdTt5/wDrVLmV5OjGLoPmx+JqDzPMmCgYh6cjBatWH5kwVAGKiwElgphUIBnj8qupncCoHBwazVuFjLhj5YxwcZ59K0LBxNGcj8qpA01qSpLtlKMuFLfK3+NallHPDdSIuzeqjO5htINZ5jLMCSNqmiyhjaWd7t5BEi7mK9vSqW5m9jVkiuo97W1taQuQRuDgn8PSuaZJWTBI3BuTmtO2XTLyc26PcrI3QMwGf0qpfLFDbpLbtKbdmMTK3DIw5xmnPVXHDR2M7yjNIQ80qoOFXotP2RhvLiywXHyqoIPHPNUmSSMs3zk/e2r0q20yvb70TDHGM81YMj+1ncQ5CsMEBeQv1pqsELOUfeRlXB6fhVSe1kuJPPmk4xjAO3+VSW1t5nLSSGPnO44zSbKsrFtWLbfMIjQHdsDZZ/bjpUc1wVm+7iNhgEjoKeGVVVY4csBj5cDH1qKdJblI1kkjjEbbtoU4+p9aBIhj1FpG2w5Ixj/PFTxCUgERsB/HjoKgaTypwg+TPAyOB7irkYLsDvUHOSw6fpSYEd0rvGweSVwvQMOBWbEsiMVSLDMME7gAa0Jy2dqqNufmz/EfeqeUJZJBjJyAxxmpZS2HCWSMhWK7hwAvUf8A1qVpgi5kKEjsT96omKsC8BznkoRkfSnoCfmuIVPsOB9KgoivpE2bJEjZ/Qc1Elp5/DJhDzjOPwpLZEknmkESLGowh9ferx27QTzmgexFFBHChjjAXnHFRXjfKAqrG4OEI5ycVOZY0DYY9cdP6Vh61M2ZAVl+YEFk4KnHH41UVdgLNq0i4imGJDj7oOD61El0ZJtwTMYIHHpVa3g8+yQyySGZOGZuuPU0nnRr8q7hjqfUVra2grq1y9d3aGNlSPLnhMj7oHeqEJSNQ0jb27D39aYYzNIQj+XGerEUsmGcpAw8sLgyt9e1XbQkmd2lkYhMbBll/uD3qvCYzs6bf1obctsVjLJ5jYJHcVOkAbcCMBQFOen1NIGwXEkrLG+Bjc3btgCsy7uSLgNFIrPjkbsbR6VJLIEjlIIbzHMeAeorNvp0jiEdu4KHG89Dn3pxiTdFydhATcG4jKqm1iw6ZHFeeaz81/aiRnbe4JA9c5xW+5lvLW6uCp8mNSiqe/vXNa5HtvLUllMRwQd2MkDv6GuqktTiryvoTRxRbn+eUy5IUbcAc8nIrd0k+U43ghfQjistI1t53imEizoqZB6DcN2D+dacKBUcxsxAOSfSiY6MepbUeaJOoXJOQcZrn7uM3AiS2UuchSpOO9bc8wiUIgYMRgcVhXytEkxy5RBuba2OcjApQCs7Ix5CsupQQlS7+YS7E+nH5ZrpLQNCQuM5/u+3XFc3pNxNJqDXUce3aCBg5AB45rqgudhGcYGM1dRmNFdSyiAQjYCCPl+fnHpV2xgWayZjIscqnCoSMn/9dQrLHI8aRqRkAEH1q7btEiEPHH5i87j1znNYtnYkJYxzhyyxKcYyC36VfmmMu3zLZA6HgAAcUW6qNqxlpARuPHer12Y2jGxVBYYGetZNmqViOFIZIlV4/LJYjI6t04NOS1txcTEtJtX/AFZx8x9qhhz5Mi4yzAEHPIINXoVaa4C/MhKqc5z83qfbFQU2KlnAVzFGcA5HJBHqK3LRWjILyEsQM+hH1qtbRSyWz3FzKMMD8i9Ae3NaNoquCJWOQAQCDwKmRJJBHujKb3JBOcj8aV4ykZlUegb6U543iYmJ1ClTwG60LIduC+1O4xxUFIfGisocDHPAPJP+FW45mSIjysg8cmoDHGpKRyCTGMlelWI9zbSM465qBjo4i8YAByTnpmrEAa3GE6E/lToIWVN4J546dKb5nmM6Kx9CelNLqDdyy0nmAbix+nT6VJbTmOR0aLzkmXy3j7t34rPmAWRQAVx78UunXkiz3cEQzdtF+5ZTjvz+OKfUXLoa0dvBZZvIrC5WY9HmIITj2qjcTxy2cdrGGCq3mSSMfvMe9S+HDeLJF56zrGA3mtLnaR75rEncpLK0RwjMcYHbPFDYox1LAeKeJC/ByQT93mo0kXLr84ReVQdAPeqtm9tGcTOI+SzbhnGeh4pbyPdE72rB0zwynaD9RWu5KLgkg8z96GZCOo6Z7YqQ53SfuxGuAAp6/X2rJtoZZwFkd8ryobt9KtrEU6qrEHqT0pNDsXHlLKqHaQBjpT5VBj+VtuMDj1rJnvfKQjk4JBAPGKq3Wsi1hzGVdmGNq/eH1oCzNRUgQSNcEnBwpJ4/+vVFribBRGSKA8fKPmaorSTcqvd4mPUDkKuauvcJcSL5UCbFwDjnLfXtSGJHAsTDDO4GM89TSywmRzuUZByoB/nTHvFD+Wsf7w87R0A96uRzeYBtPGMf596ljKLQMZNwYK2PmA4BFZuoXTQk28XMkpwDu4X8a1ppkQYl6dfc+2aw73y0kkuAo83AA3Dgf/Xqd2ax1LEUhhtQjFcgemKZ9sT94XLDAz8o6fU1z91qqiQq0j5IONq8Z96sWztNCZmVow46Z+//AJNXyJGzp8quzTW63xeYEbL/ADDIx+tUWLyr95f3jbvWkshIwSQkBvRjxioGV/MZIkVlUFwW649BihKxhJ22JJLsiOW3KKRvDB88ggYqjEk0uTuJZj2HSpViALPOFwcEY6e5qwd0aHy2YHocHge9aEFSeJzksW2qOEJxk0qh0jBYKcdB6Vct0VlVmkye2eOfWo7tkCsN5I9+AcU7sL2Gxkbi7tu2ZPpUaSN9n3iQ5YFiP6VC80ipu/h7rjsajmmke+G9gsT5wAcYP1oSZMmEYBIXJJX5t2PUdKpXemQyXCSS4iLduw98VZjldWIUjrjn+IfWnQzma6fbuG37+5chTirVzNmDPEySeTFyF4HuevQVy91b+ZrctpJGYwAr/P3weeK9H0v7EN93POjKhJweASK4nVtQgv8AxYZlVliZSq54yMcH863ps568EktRkTNPdzTO28t8zMW6nv8A4VetzK8eIG+UZZmPp3xWTpG+4knznyhKQfr6VtMpiWPtnOc9KcwpPTQhnxEuFyZpMKpPJHv+VZGsuLe2uDENwVVy2MjOeTWzNsXZJtxIxO4dcDFYuvRyNBFArFTcSE4zxt4xn34qoIyqvQdotqI4Ikd02McvIehzzk/SujiC3MRMSLshADOBjOO+KxYgsc8kK/wYUYHHTmtSy3BVDNIsLclc8GpnqXSNK0jCzKzoCg9DVgxkzFk2g/TPBqtbnLOUIT5M4PPPYfjWlMphizEOPLBxjkev0rBs64aEumRrC5WMAnPLEkAVeuLePYzEgMHGOfzrGgV1idt5HI6Hoa0jOs9qFA5BRV46+p+tZs1e1xLqPaPlUt8x4/LFXdLVhEbwkYL+UoxwR3qC4nVbG8IVGkRQVfPI5/nUmj3MhgtxGCWGco5BBPrQ9riNaBXjt2iUqyE+YoPVSR0rRtUUz7mPMgwozVV0je8iZkMe87WZjwT61LLGRkiU7c8MFwBWbEtSdlUOygDKnCH39KBGTIVkA3gggn+lJbQyMzzxeU7KBwpxn3wamY7i7MPmXna/pUSKiSwxshfK554B6U6ONkuQSSVIwPrT4uzbvlYZx6VcjiDMOD68iosMabow4BAAI5J7+2KZC6AyMjZLHJq3cwJLAwTGUHOaz4oWUkbTsXrjv7VexN0Pa4Egzg8n0qgId1wZAGBXJUg9O1aioHU5OPY1ejfSY5ArWc/3eok/+vRa4c1tkU7Rpb67t7W5uJpIWcKRvPTFV75ABJg/KpOMD0yK02u9Ltpo5ILO4LIcg+Zx+NYrah5ksiJFlSx+709etDslqON272M+JVNvGJDlB8wz1qdGEXET+S5yGyuQc+1VtzNErAMCB19fbNSwsqD95tQHnk8tWxmZt1e3EUvlqmFU8Oeg+laCXkbJGxld5B9/pTbiQTRlbZzn+8DuH8qyLmyeK4ytw1wxwWIOMZ6igq6kW72/jnhaKFGTLYLv29hRa28SRF2TLPwCwzu9qZtcxKhj/dKQzMW6VdSJ3lEjyHco+RcY/HFSwuSkRQxeXtO88Y6bTUPEPEO7JPQNhj7mm7trlWLHdySOQD9ajRy6mWQltnCjoT9KQ7BLI8T7mY+d9/cw5z/hSxTTtIJGP7uUnO1sBW/+vUjsrqBIp3j5gpHb3rJnvGWeSKEuCeVVeM//AFqlq40a+8KGl8xd6fwk9PbmqV0yvI4AEhzzt5rOeYXCxszL5p6nHGaku3uPLQAHaB/rRjA9qEik7bEEmnxvlmC7ieFPXJqWVCrCBSCQM898ds1DjymAEreYQcZPFLNcRRJuYsQpBDEd6pXKlNvcLYkS+W2dvQ85xVyVYrXcwwQE53HBA74FZFxqSA+bESuSDn3qJbieeUyPMXXPLY457U0r7mTd9iWW6YSB4trMCCxP3QPaozM7/uvMyR95j09jViCxg8o7EYtk5BPQVRujHaqQVVSrcjPJXtV2GaMBcYI2vszgk1FNIjyYwMZwB13etUBcAbmZsKo4A75qOE+bOkcGVz/GxxjPeqUSJM0rn90ihhukJ6DtnpUN6oMUcSkZGcnufU0kkiKFkMjSFAVd2PUjvmk88T7CUEZ24OB196ErErUSbEkKh+IgMK3Q5psH7mCWNSMk9D6UXLNNGzTYAAAH+zzx9aofacxSrI3zLIVyO644OKtIUnYwjbyTTurz/uVDHy8Y4FYl8jxXOn3ESq0hG/cRxkHgV0N7Otuk5dCCwDAqCdvGCDXNXkwlawRpFZFHYdec8/jiummmcNTfUv2EsjSSMQw86Qyso6Kx/wAK1reOScq83/LM4Cg8VQsEaORmmUt6Anp61txbCCqrtJXOOtQzakvd1K14im5RQdrbcD0PvXOaiN+qwR73lmA3hRgKuD3966RthuyZNwRYzyD3rkrNBd3VzcD5F37UZu2PerjsZTd3ZG8vlJOD8+Hbl8Z5610Fq+yAhgGifkqy857fhWJpshEq71iaEcKR19624Mkny22xoPlEpyPwNZTN6SuTFbaIFryEgOnHlnBH1FWHuZMhY4y8LgojNyyjsCe9UbsS2D/Z7qM7XHU88HuD/SrtgQthhgJIxy0ZOcN2INQ9jZLUfFdSmQWzokRdsMSMfjirqSDzViR1Ztwf5TnjscVGltE0UZQFnBByTyB1zSWkvlHyyQMZC8dvY1FjW1hXkiGoxo+7yblD8x4G8c4J6VsxtHvIWNVDY+52z3H41jhN8K28oyEkEhbBIXA/nVuE/ZjGXLqWG1ndTtUZ70pEWszctysamVfmTeDtflW571bWdd5jiRdpGDuGQD1rNiny2+Tyk2uc7T976CtNJIZYHePafX2zWLRaC2RQjg8ODjA6GpY1I/d43owwc0loBDKyBlIYcFlz+VWQmRuXj2B9azZSYsEeyXYeVIwBt71pWEA3ktx6A+lV7JSw3nAYZ6n3qeSf93kYUjg5pruxN30FlQ+Uyqzb5GwpHp6U+FSDhgQcEYpllPC58uQ/OBuAHr2qQqysWZuDySabJsPNszBsAlR1qSLTJ3VZCEhiPGZGxkfSq9tcTq7p92Jhkj1rWvIm1BfMgliO5AvlyNtZCO1OKTE3YxtS0e78qR7by5VVST5bgnp6VnpHAIo3hO5CAcEfoR61t6dC9jema6mt40Q52o+Wb2xWeY0muZtg2hj5m0D3NJq5SbOHjvHCncmw5wN54qWCSTdhG9iQc49hUa2qSfedN78YLAkVbjUQxhZAvmdN/c/WtSSQ4Y4O4Y6g9DTbiOIj5FAlYcL3NKoZAd8ilR91ScE0LIXIYFCR39PagSKtvOILZvOVwrnEcWB+dWVkupgnnz+XuGPlOeO3NV5rcg72lJcLgY7fjTt0yKkbOgTbgsACV+lKxbVxlwsqkIs8gBORx275qwJoY0Hko4foCecfjT45CkgMjtuA5Ygcj2quxRrhnaQHb0I/hotYZJIYyvmxln7lm71kXaOJjMWDMTubA6e1XvNyTuwFxnjgfhUaNFMpYD92DgKw6n1qWO9ioVR40wzGXGGyOFHY0Sfu0Uq25/7vrVzbFGrbThT948ZPt7VWJhwCE2EDgMOgoFcqtP5W/H38ZyTwaoSA3SKiylg3OOmKvS2xkUjdlcZ2KOtU1tJAxVQojHPA4zVIZVjso0bMjswXO4k8H2AqxDqDRurFMBOEU01hsZwyYIOTVSWRPMLEbuM1duYh6Gk2p9sEZ+9isq58ydiYizBetV3uNvygHB4qaxklZglrGdpP3ie9WopEORXSKXesaEuWPGa17a1yrHO7H3mPQewpiRtDnLhXIwWHJq20MkUCSJ8iYz16/h3p3JS1G2/lt50Un+o3BmC87iOwqfy5CS+0HIx/uCqFtcjeuX2eYCqkdG9/arskpitJS0gwvHB79jSsUVL5wIFXcCck/wCFZ1mrGWW4bIZVXLdl9KtuqrEWl5Zhkj2qhJM7xXKxMRb4Xco6M3v9KuKIm7mbrVy0cEzrlsoQT+NcnaoXJLtE0jMJVJ7gfw57Vva/cFLSWLbu81lUD2zziskO8FzFKqhQqBCpHGe9dMNjhqv3jpdPG9d6NuDDn2NXLyQxeS2NyLwQOqg/zqjpiD7P9pR0ba4UxjO4KR1/pVrUQXtXKuSSM4z0FZPc6E/dMm/1A2sdzLgHcGjUj+PPpVbTLdo7JFfOA2SM9Seap3LLeTxRKSFQbsK3Q56H61uwOxVFVDGuwBgTnnua0emiMIe87ly3SOS0x5YMzMPm5GBWtpssiqLa8gk77XGCp4rOsEwxO3pwB6D1rorZQLOaVt2Y/kTHqR1rCTudkU0U7xZJpY7eRdpZUYMTnjP86BDJb206JsePOc45+tWY/KuFlZi0cnDR8DB7YJ7cVJGCp8pCfKc4Vjzx/wDWqLmidmQ2920cjs4IGzAHpVuAC4mbeMBmwpHUEinpYwG2k818Ej5SvQiotMlFqQGJkXkOpGcHscUmzVltIZIndYpAwPOCOo9vetK32yxN8295U27ZTkZ9M9qoC6cMreSWiZgHGCcYHBHpV+OHD74lVC2AwY5HqD/Ss2yfUnhh/cEsw2rwoTHB9KWJpoXG1VUOPmAGeahnSZpVnjVDwMbeQ4z+hqzDKro7YG1sgpjlaljRbtFOQ+7Eg/iPerKysCCCGJ4Oe1UrNkDFC2AOg6c1ZVflI6ODwR6Vk09ijQWYRRj+E9ieaieUtI+SCFBJJHaqUrShN8Umxh3Wo7SVpTskJLH7x9qLDstzbsVVAspzvI5q3IxYgZzjr9KzxIUBI3be/wBKbbXJBLDb3zn0o8ibGrEyqpDenWr8ulp5Uc4voBG4wpycfTpWJJJIYGdVjwCP4jg1JY2uqz6fNDbqghkbONnGfUEniqSJlda3Htp0EciyvqFmiucZyev5VnSmZZS0ThZN2c56AcD86STRdRtYzLdRyyKnIbIbb+XSq8CsWJ3Bg3Y9qh6dDSOvW5gyoiTbmjy/8Lnlv0qcASIv8EfHJ9aZFeRhdjKqg8ZI6j6037RI65SLC9FwC2fxrcxG3QVAdxHPPXPGecVKfJ8oeVtJIOAB+lZtxNNtEYi2lz1den0qSCdok2yQ4bHzEDAI9aLAyYoVk3MXAHJU/Nilk+zpLiSZl3cgqPlz7jtTHdpWzDhSecqOhpwXzAykxtu+ViRzQNMY7SyyKrOCuMZQ/eX3qx5kflsibI3JxgDrWXerJbDcrSMg6qjcUltM00IuDl8cAhskfUUWHctMd0m0gb+pHqB2pZVWSfzCMAKNnOAp9Kr9Yyef55+lM81QSjbiz8jA4496B7lzLAYK7GxnPBFV4nCMxL7u/A6VFIXjyY29xuOeag85yQQcNnL9sfSpsGxbkYPnymBY87cc/nUTRDy3kklgjHTY75b8qhlE7ABn+hJ7VWkiLqDJJtAPFUoi5iK6dSrBNrFjjJIOB9Kptaq7fu3z2JINTG2JkLSOSewxtzS7gvB2JznJHStUrEORCltEh3SSYC+g/wAaleSMx7bcvgdADg59TUTTIrMwfzD6bf5UrXCShYiHiP8AdIA596qxLZLDGZHXczZPQ9qWcT7QMswbIJJ7VAS6Op3JI6856gfhVu+aRlSR7zdLKd7qi4AHYDsKGgRQnQFsx5ABAA/u0jzbztONikAKhyWPvTLs7gcyqqufuqMkD61GpUEMi4f+FicmqSJch80u9hGZDkH5uOB7VTVh9nYjiIPlsnjAqaZWTC7wC43EH196zb2ZBCsKsFZco2O9WkZORka/deZFvQ45+X254pZIzMlmwLl/lZzgEc9aXxJGghj8tNkaqN3qzDvT44WWGJsAhu3vWq2ObeRsaciweYv3hnIBPJFPncx2bbh95SAfxqFS0bwvtIUtjH9Kj12fy7ObH3Ik8tf94nms+pu3aJgaIiS6hNIFdtvyo3brzmumt433ncFK54APSuc0QZ05fLU79xLMe/pXUaYcxRBj8w5bPr1pzIoqxr2cKbGZTtY8/wD66tMClqEBLBwXOD0I61CsT7SyMoQgFs9xVyIRtF+6ci4VjgHvnqM1zs7kyKxGw3KSOFZVBCHkMO9WbKSEhbe5QIyklXVclcdQabBHFPdN52XcruAIwfpVkxQwOxmWSSOSLKlOSrfWkJK5PA7pCttAI51m+YZXDr/Q1Jb2QMpDHaXPJPGKpaewDgPI42riM/3SfWtZGZAFlhYu3Dbe+P4ge9TI0WhQMAilDKXKkYODjj3q5vdpdsS9VAOecCnyTK0KZUeePl5XIP1PapYpYZIIo1SSOVQTJMWz5vocdqyuytya3MTQXABUPGBhTwcetRvclJw0CDcR93PD1SuYmtpNzAnHbvinfaUIddmc/dyOlAramhayJNIzRqYsEEK+OtXYLhd6b8Lu9eM/Ws6E4VdvAPBZv4atBIpPNYtI8gX5Fxwx9/ak0Vcnup02lYSHc9AvTH1qe38sxDaSHYfMMdPasy2wsnz4Bq6CHJJcBcZPHJpWAllvkton8wgNjg5702AeYm9zuBHIB+WqFxB50qsygBTgLn9T71o7itskeF2w5HAx1OakbdkQMNh+UkYzx/8AWrpJYrm7uI5bQ/aLERKFjVwDGQMEEHFc35sJZ2lIYkDbnPX0ret7Cyt5VguJrlb2RQ7tGPlTIzjHeqiTMt2cdzbXImnP2a2UndvcfMMcjGe9cteTtHcsYcodxKj0BrUFi667b2l3ukjbLCRTkOMcYrD1CaA+YIi/mq5wWHTnFFtC6KTlqUbuRZI8eYDuQbBt4JPUH0p147TiBtkCGJdp8tipf6j1rIeba7FpxtOCoI6fjTxdQsxy4Vx0Kc5PrW5iosvvLIm5kUR4wcPwc1SMks02+fcq5OPRqWSWRhzI4HHLYJzTby6YJtOZOCDgDNAmiW4uGjK7sc8Aj5f8mqxk4LQhQ2cn15quLjbEQfmRsHB5/D/69SCaN0/dgHsTnpQFyVJZJSY5MDdjHA61TcSWkrsoJTOSD/8AWpZkLMMNwvtnH40CIvGY3kxntnABpJdwutiYXqlMOeB27rTDdr8rxgNg5yW/pVNrZ45DtkBx/nrVqyCbAFUN13Fun4UWC5Ya7SRQVdRgc/WoJIXD7/N3K3QetK8KBS4UA9ieQaQKpQMCN/pnOKLBcafMIcBAzAcA9qpv5jnac5P3gSRU8ilicBgeg+XOTUckQ27XZy/GAG4UVVhEfl73G6RiwPG3t7c0yQFPlFuCTzuznNSOjxplQuw8YIyaq88FkLL/AHs1aJZAJyJPlUhumCOlLJImxNo3NzuDDAFNfJIJlZdp+8npUUh2yNvm84hcE9KtGTlqQuGBBZST1HlnHFSqymArBHPJJ7ZCj86Emj3KpYRoRjcDz/OrEq2rhSJ5C68ZbIp6E7lSCKdSN69c8Y6VYjQyzqkR5IwDimMyK7QqSQOSVH9agnm8qBjKWZhwFB5/SgUnyi6ijqZVhkGwYUybs47nA71lQn7RcYRXaGLJ3OMEn1qybV5kRJC5eTsDgIPp3q6sUVlH5cK5YsGJZcjOKtaaGTu9TA8TygWyDcA7MBt/nUlmgl2xtnAAKgHpUWrIkuoWcbKVQsDIzjgc8fnVyyRQIyobO7r3x/hVvYiKvI1YldrOWOYkMnzAn2rnvEszf2eIdwDv+8I9fX+ddOoB3BwdpIG4nrXEeJm83V1gU/cIAHbn3qIGlV6WNLT1/wBEEUY52Z29+2a2Y/3ZV1+84BwR096z4o2jkt3TLgqChPXjgitiCLKOX4IAO3uKJlU0aFteM0SRTs2FPGAAQK0Ik87D2OMuQAoO1lPqPXNZqRo6qqZ3c7gO3pVywhkkMhXh40JUrWD1OpE1pKV1QrM4i+bJfptPbNaEETSz7I/nPRQG+9VWNUvYGnnA3OuzOPukCktpTbpvVcyIy4XORyDmpZaNNgLdmAQL/CyHIIIPP6VatmEdwp+by3HQnPy/0qKOKS6tXmBUsw+QsRyBTrTIifehZhjBzjHrms5XNXHS5bfDuoBhTdheR8r+596f5QaWWWPyxH0aNen4E1Xt7hJmWF4WjZckyK33uODioZdQNo6ho45VUAY7nryTU3EWpvmiJdcsvBDHBIqKdoJGX7Fl9q4JIwM9xVuKRLlXMi+YrgHd/dz/AIVE8IBkhZTkHIbHGBSArQwM0DzxnciHDFuxJ9Kcs0rYZxlhn58849Kle1eIuu4hNw3AE4INDwAqwQFcd+xFAxDL5jDdwxOMZ5GKk3ukhbngjg/1qjMWj+9kscgketSS37yRLDNCq4BJKtjccUirF+3lIfMoJJOSfWrttJBKAkzBC+Tk9xmsC3ncngFt2AuDV++a2uIJFKMuAAAByD04pNA1ctTWmJmZJCYlOAFJHPrVvXLsTxw3C+dFfqAjyq3DqBj8+lUba58qFQ+AFRRweTj+tTpYteos80y2tryEMmSZMeijmhJkve5o+FtSNukMd8DIquWV2IDISO3tXP3qKJZfKJyWJCkZ4ya25dNV7QtbXKXKqPmCAq6/geawpIntwMc46A809epUGr3RiiO3lRvPmm3DOUEXJ/GoF08EgxvImc8YAOa10a0jdlnE0R6qWjJGakubaJ9pngODghyD+fFa8xHKYMtrcQsA84L/AIcVHHFcTKyoIXkHJKZzW2dLjYERqxQjIc8c0+HRYZGbZ5asoI3O+2nzCa7mFGFEbRs2GHAyDj9KW1t3fJjmhAHBLc5/Cult7aSO18hGVrfduwwGcjup7VJFpFlIzFo7aObqRIT+ho5yeU5UW0yyFIrv72QCp25HcUx7a7hA8zynJAIYkkoPcCuhm0d3RmbbH5bArhvujHUY6mq9lEhhG0yK2ccd+f50KRXs01dGV5cka+ZJJBIp4BRiSD7ioZIg+XVJUPT5Bx+VdN9gwks7IQcZ3OB645qRbOF0LqIPlySV4z7Uc5HIcnl0XEUbSAcZ2nH5VGy3GSEikOORtHSuqOlNM5+y70Q4DbDw3tUUmm3MMqvDKgK9SRwPY0c6DkOVk89SoWS4yVPDKRjNJ5YK5+1bTjG3B3V1CWilcvKsgxyR2znpioTaxE5VTwCNzLRzi5TnPJdh/wAf525Aw3NPlsBHGuL0PuGQhHFa221SP9/5nmt8oGz5evUmh9KCWrXBISMvtBxyfanzj5DDW3kDkqsbZ4G7IzUFxpk6MUlQjPP0ropLSOVFEAxL05PGfWh7S4YFpplJPQCnzk+zucwtg+0pFFG/fnrVKaCaMMVhKPjGVP8A9aumFkyHajlSO5HFR3lpcM6tK2U6/L2/CrUxOlY5uK3u5HEbS7VPXrnFTwQg3GXKkgEBQevoTV65iMNuzYYZ4Hq30qlFH5aYLlJSQSCOg96u5hKFi9BHjdI3zPjj1/8ArVDdt5ku1kKoO+ehp7OHGWuYl7c5/kKyNSusDEu9UbIMg4Uj0qoq5lOVkZesukmrJJ5ZGxNi4Odx9a0bMFAsh28rjp3rHtU+1W5uGUksSAQcBQD1/KtXSgGRUySuw4A7EHGfyrSWxEXrc0hdK8LebgMOduf1rlrGGLUfEMkpLOQDIkYA5YdAfatrxBLFaWRAjzI4+Vjxla5XQLiS11ATxjJXnAFKOwTleSTO3WydFjhEbQucSBHGCuev9av2bqgV2TLklSG6dDio01MXU8V0QUcr8rdQSeMEGtGxJkhXcYmkEBCswxnkAj9aydzpjq9AsXWKfcw3lfvH0pumltPa6ZHlczMTmRs446CrDwGKRI5FIZk2hyMe+Pekjtv3XzSAKMMRnB5rNm3ItxbVpBEWyRGCDsHQ1ZzAIlV/llRzlM9R2Oafo0UCOY5iFjc5y2eo6Cp2ijkmlCpuVm6dwPUGobsaIy9NlMN5AkkmxUk3B3YgbfQ10UV6ZXYopaKTKgMvPsc1ktbhGA274yOWIzkZ4zW7ptj9oguNrYdFDIB0IqXqac6QsUG2cuqHDD5vmziop7USBEccAkB/5VOi3FrOc4VZPkJ21aghLxgM5yCQc1mK+pRtY5IwwALrgjIPerhkFwjeb9/HUD0pfM+xXPmRKHjdSFU8cmiJFndcja5PGD1pAC37ztsuUG5UCOwHDjsfrQJ/LY8bkXhsdx2NIsTROwZQ2Rtzjg00tCSscgZJGBXodp9KBtDpJYpSTsKoT0I6GmNaK0XnIhkjHcdBTzG6Rq8q4B4yBn2qNkuIxJ5Ej+S33lXgflQFyfTY4QY47kKgB5Y8fQ1Yv7ZbZwpm3M6jAOAKp3i+ZFhE+YgcYqnB+6IV9wG7J3cjNBUVdXLlvA/3/mfG5WNdHeymIaiI7Xz3QxxRbBlo4dmQyj69656GeS1XdBIEf3G4H2wauWmsJKYVvklMkK7UntzscDP3SOhFNMhxbdzY0vzVhsJZoQk/nhFJG0sjZ3g+w65rnbi4mklmt3CNCrlFYDHGTjmt17218qR7ZpnkZdpknbLqp4wq1hT23ljcq7k7AnvSbHBa3Ymtf8fl1/vmrFp/yD7X/dFFFX0GMl/j/wB4fzqndf6l/wDfb+VFFIRHZf6iD/PerV995/x/9CFFFBEdzGb/AFs/1qbTusX1ooq+g4bMm1Tov1NWNP8AuR/7tFFQ9xxNXS/8azbn78v1oooJKXhn/j4k+jVTtv8Ajyb/AHjRRVAyA/cf6tUM/wDx6W//AF2/wooplLYlH8X0P86jk/5B1v8A570UUISIf4X+tTN/rZP93+lFFUhSM3Uv9dB/u1mdj/1yNFFbHPMqf8t3/wCuVU/F3/IHT6j+dFFaQ3OSrsyjY/8AIGh/64H+dWNF/wCQof8AdH86KKuZMBfHnS1/3DXOeGf+Qqn+7RRSjsZz+I6vTv8AkFR/9dv61uQ/cH/XJ/6UUVnI7qex0Mf/ACJ+j/8AXZv5Gs246x/9ch/OiisWbo1oP+PeX6j+lSWv3pP98fyoorN7lokt/wDUn6J/6FWnof8Ay0/3WoooYnsXL/8A49/+Bf1qO2/1Ef8A11FFFZlCy/6o/wDXQfzqKH/j/tf+urfyoopFGtd/8sf93/Gsu/8AvRf7lFFA2Sw/8er/AO8f50+x/wBU/wBKKKBFqbrH/nvWXc/fj/H+dFFBcdhmpf6p/qKr2/8ArBRRSNVsX0/1if7tSR/cl+v+FFFSYrc//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16006=[""].join("\n");
var outline_f15_40_16006=null;
var title_f15_40_16007="Severe hyperthermia (heat stroke) in adults";
var content_f15_40_16007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Severe hyperthermia (heat stroke) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16007/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16007/contributors\">",
"     C Crawford Mechem, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16007/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16007/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/40/16007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia is defined as elevation of core body temperature above the normal diurnal range of 36&ordm; to 37.5&ordm;C due to failure of thermoregulation. Hyperthermia is not synonymous with the more common sign of fever, which is induced by cytokine activation during inflammation, and regulated at the level of the hypothalamus.",
"   </p>",
"   <p>",
"    The evaluation of severe hyperthermia in adults and the management of nonexertional heat stroke will be reviewed here. Malignant hyperthermia, fever in adults, and exertional heat illness (including exertional heat stroke) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8361?source=see_link\">",
"     \"Pathophysiology and treatment of fever in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link\">",
"     \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11594?source=see_link\">",
"     \"Exertional heat illness in adolescents and adults: Management and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body temperature is maintained within a narrow range by balancing heat load with heat dissipation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The body's heat load results from both metabolic processes and absorption of heat from the environment. As core temperature rises, the preoptic nucleus of the anterior hypothalamus stimulates efferent fibers of the autonomic nervous system to produce sweating and cutaneous vasodilation.",
"   </p>",
"   <p>",
"    Evaporation is the principal mechanism of heat loss in a hot environment, but this becomes ineffective above a relative humidity of 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/3\">",
"     3",
"    </a>",
"    ]. The other major methods of heat dissipation &ndash; radiation (emission of infrared electromagnetic energy), conduction (direct transfer of heat to an adjacent, cooler object), and convection (direct transfer of heat to convective air currents) &ndash; cannot efficiently transfer heat when environmental temperature exceeds skin temperature.",
"   </p>",
"   <p>",
"    Temperature elevation is accompanied by an increase in oxygen consumption and metabolic rate, resulting in hyperpnea and tachycardia. Above 42&ordm;C (108&ordm;F), oxidative phosphorylation becomes uncoupled, and a variety of enzymes cease to function. A cytokine-mediated systemic inflammatory response develops, and production of heat-shock proteins is increased. Blood is shunted from the splanchnic circulation to the skin and muscles, resulting in gastrointestinal ischemia and increased permeability of the intestinal mucosa. Hepatocytes, vascular endothelium, and neural tissue are most sensitive to increased core temperatures, but all organs may ultimately be involved. In severe cases, patients develop multi-organ system failure and disseminated intravascular coagulation (DIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of hyperthermia is extensive and includes infectious, endocrine, central nervous system, and toxic etiologies (",
"    <a class=\"graphic graphic_table graphicRef53571 \" href=\"UTD.htm?10/52/11084\">",
"     table 1",
"    </a>",
"    ). The most important causes of severe hyperthermia (greater than 40&ordm;C or 104&ordm;F) caused by failure of thermoregulation are heat stroke, neuroleptic malignant syndrome, and malignant hyperthermia. Each of these conditions may be associated with severe systemic complications and death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139843\">",
"    <span class=\"h2\">",
"     Malignant hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant hyperthermia is a rare autosomal dominant disorder that manifests following treatment with anesthetic agents, most commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    and halothane. The onset of malignant hyperthermia is usually within one hour of the administration of general anesthesia, but rarely may be delayed up to 10 hours after induction. Early clinical findings include muscle rigidity (especially masseter stiffness), sinus tachycardia, hypercarbia, and skin cyanosis with mottling. Marked hyperthermia (up to 45&ordm;C [113&ordm;F]) occurs minutes to hours later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139850\">",
"    <span class=\"h2\">",
"     Neuroleptic malignant syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction most frequently associated with classic and atypical antipsychotic agents. In addition to hyperthermia, NMS is also characterized by \"lead pipe\" muscle rigidity, altered mental status, choreoathetosis, tremors, and evidence of autonomic dysfunction, such as diaphoresis, labile blood pressure, and dysrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2141946\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat stroke is defined as a core body temperature usually in excess of 40&ordm;C with associated central nervous system dysfunction in the setting of a large environmental heat load that cannot be dissipated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]. Frequently encountered complications include acute respiratory distress syndrome (ARDS), DIC, acute kidney injury (ie, acute renal failure), hepatic failure, hypoglycemia, rhabdomyolysis, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two types of heat stroke:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classic (nonexertional) heat stroke",
"      </strong>",
"      &ndash; Classic heat stroke affects individuals, most often the elderly, with underlying chronic medical conditions that either impair thermoregulation or prevent removal from a hot environment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/8\">",
"       8",
"      </a>",
"      ]. These conditions include cardiovascular disease, neurologic or psychiatric disorders, obesity, anhidrosis, extremes of age, and use of drugs, such as anticholinergic agents or diuretics [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/9-11\">",
"       9-11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Exertional heat stroke",
"      </strong>",
"      &ndash; Exertional heat stroke generally occurs in young, otherwise healthy individuals who engage in heavy exercise during periods of high ambient temperature and humidity. Typical patients are athletes and military recruits in basic training. In vitro muscle fiber testing reveals evidence of susceptibility to malignant hyperthermia in some patients who present in this fashion [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link\">",
"       \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical findings in heat stroke may include flushing (cutaneous vasodilation), tachypnea, crackles due to noncardiogenic pulmonary edema, excessive bleeding due to DIC, and evidence of neurologic dysfunction such as altered mentation or seizures. The skin may be moist or dry, depending upon underlying medical conditions, the speed with which the heat stroke developed, and hydration status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/7\">",
"     7",
"    </a>",
"    ]. Not all victims of heat stroke are volume-depleted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR INCREASED MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present to the hospital with heatstroke have high mortality, with rates ranging from 21 to 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Mortality correlates with the degree of temperature elevation, time to initiation of cooling measures, and the number of organ systems affected [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/18\">",
"     18",
"    </a>",
"    ]. According to one prospective cohort study, the risk of death increases substantially in patients who present with anuria (HR 5.24; 95 percent CI 2.29-12.03), coma (HR 2.95; 95 percent CI 1.26-6.91), or cardiovascular failure (HR 2.43; 95 percent CI 1.14-5.17) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients who take long-term antihypertensive medications, lack access to air conditioning, or are socially isolated or unable to care for themselves are also at high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/16,19-21\">",
"     16,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of heat stroke, neuroleptic malignant syndrome (NMS), or malignant hyperthermia is based upon a careful history and physical examination. The full differential diagnosis of hyperthermia should be considered in each patient (",
"    <a class=\"graphic graphic_table graphicRef53571 \" href=\"UTD.htm?10/52/11084\">",
"     table 1",
"    </a>",
"    ). The context in which symptoms develop usually suggests the etiology (eg, exertional heat stroke following exercise in high ambient temperature; malignant hyperthermia after anesthetic agents; NMS among patients treated with antipsychotic agents).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1408332\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal temperature should be obtained in all patients. Vital sign abnormalities in severe hyperthermia include sinus tachycardia, tachypnea, a widened pulse pressure, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chest radiograph may demonstrate pulmonary edema, while the electrocardiogram may reveal dysrhythmias, conduction disturbances, nonspecific ST-T wave changes, or heat-related myocardial ischemia or infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory studies may reveal coagulopathy, acute renal failure, acute hepatic necrosis, respiratory alkalosis, and a leukocytosis as high as 30,000 to",
"    <span class=\"nowrap\">",
"     40,000/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory studies to obtain in the patient with heat stroke include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count, electrolytes, blood urea nitrogen, plasma creatinine concentration, and liver enzymes.",
"     </li>",
"     <li>",
"      Prothrombin time (PT) and partial thromboplastin time (PTT) because of the risk of disseminated intravascular coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies to detect rhabdomyolysis (eg, serum creatine kinase) and its complications (eg, hypocalcemia, hyperphosphatemia, myoglobinuria, and acute renal failure) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/26\">",
"       26",
"      </a>",
"      ]. Myoglobinuria should be suspected in any patient with brown urine supernatant that is heme-positive, and clear plasma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"       \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Toxicologic screening may be indicated if a medication effect is suspected.",
"     </li>",
"     <li>",
"      A head CT and lumbar puncture should be performed as indicated if central nervous system etiologies are suspected [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140551\">",
"    <span class=\"h2\">",
"     General treatment and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of classic heat stroke requires ensuring adequate airway protection, breathing, and circulation; initiation of rapid cooling; and treatment of complications. The management of exertional heat stroke is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11594?source=see_link\">",
"     \"Exertional heat illness in adolescents and adults: Management and prevention\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Tracheal intubation is needed for patients unable to protect their airway or with deteriorating respiratory function. Central venous pressure monitoring is useful for assessing volume status and determining the need for fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/14\">",
"     14",
"    </a>",
"    ]. Alpha-adrenergic agonists should be avoided, since the resultant vasoconstriction decreases heat dissipation. Instead, hypotension or volume depletion is treated with discrete intravenous (IV) boluses of isotonic crystalloid (eg, isotonic saline 500 mL). Continuous core temperature monitoring with a rectal or esophageal probe is mandatory, and cooling measures should be stopped once a temperature of 38&ordm; to 39&ordm;C (100.4&ordm; to 102.2&ordm;F) has been achieved in order to reduce the risk of iatrogenic hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/7\">",
"     7",
"    </a>",
"    ]. Seizures are treated with benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    5 mg IV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cooling measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaporative cooling is the method used most often to treat classic heat stroke because it is effective, noninvasive, easily performed, and does not interfere with other aspects of patient care. When used to treat elderly patients with classic heat stroke, evaporative cooling is associated with decreased morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With evaporative cooling, the naked patient is sprayed with a mist of lukewarm water while fans are used to blow air over the moist skin. Special beds called body cooling units have been made for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/4\">",
"     4",
"    </a>",
"    ]. Shivering induced by evaporative cooling or other treatments may be suppressed with IV benzodiazepines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    (5 mg IV) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (1 to 2 mg IV) or, if NMS is",
"    <strong>",
"     not",
"    </strong>",
"    suspected, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    (25 to 50 mg IV). Benzodiazepines may also improve core body cooling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other effective cooling methods are less commonly used. Immersing the patient in ice water (cold water immersion) is an efficient, noninvasive method of rapid cooling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/28\">",
"     28",
"    </a>",
"    ], but it complicates monitoring and access. An alternative method that allows greater access to the patient is water ice therapy (WIT), in which the patient is placed supine on a porous stretcher positioned on top of a tub of ice water. Medical personnel continuously pour ice water from the bath onto the patient and massage major muscle groups with ice packs to increase skin vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/29\">",
"     29",
"    </a>",
"    ]. Applying ice packs to the axillae, neck, and groin, areas adjacent to major blood vessels, is another effective cooling technique, but may be poorly tolerated by the awake patient.",
"   </p>",
"   <p>",
"    Cold thoracic and peritoneal lavage results in rapid cooling. However, it is invasive and peritoneal lavage is contraindicated in pregnant patients and those with previous abdominal surgery. Cooled oxygen, cooling blankets, and cold (ie, room temperature, or approximately 22&deg;C) intravenous fluids may be helpful adjuncts. Cold gastric lavage may cause water intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for the treatment of heat stroke are based primarily upon small observational studies. A systematic review of clinical studies investigating the treatment of heat stroke noted the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no definitive studies supporting any particular approach to cooling in classic heat stroke.",
"     </li>",
"     <li>",
"      Evaporative cooling methods in the treatment of classic heat stroke are better tolerated.",
"     </li>",
"     <li>",
"      Immersion in ice water is rapid and effective in young patients with exertional heat stroke. However, immersion therapy is associated with increased mortality when used to treat elderly patients with classic heat stroke.",
"     </li>",
"     <li>",
"      Pharmacologic therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"       dantrolene",
"      </a>",
"      ) is ineffective and",
"      <strong>",
"       not",
"      </strong>",
"      indicated in the treatment of exertional or classic heat stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy is not required in heat stroke. There is no role for antipyretic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the management of heat stroke, since the underlying mechanism does not involve a change in the hypothalamic set-point and these medications may exacerbate complications such as hepatic injury or DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/7\">",
"     7",
"    </a>",
"    ]. Alcohol sponge baths should be avoided because large amounts of the drug may be absorbed through dilated cutaneous vessels and produce toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     Dantrolene",
"    </a>",
"    has been found to be ineffective in patients with severe temperature elevation",
"    <strong>",
"     not",
"    </strong>",
"    caused by malignant hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16007/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140572\">",
"    <span class=\"h2\">",
"     Treatment of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hyperthermia may lead to a wide range of complications. These are generally treated in standard fashion while cooling measures are instituted. Complications may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory dysfunction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"       \"Advanced emergency airway management in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"       \"Rapid sequence intubation in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seizures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link&amp;anchor=H19#H19\">",
"       \"Status epilepticus in adults\", section on 'Benzodiazepines'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vomiting and diarrhea",
"     </li>",
"     <li>",
"      Rhabdomyolysis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"       \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute kidney injury",
"     </li>",
"     <li>",
"      Hepatic injury",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=see_link\">",
"       \"Patient information: Heat stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2140224\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body temperature is maintained within a narrow range by balancing heat load with heat dissipation. Evaporation is the principal mechanism of heat loss in a hot environment, but becomes ineffective above a relative humidity of 75 percent. The other major methods of heat dissipation, including conduction and convection, cannot efficiently transfer heat when environmental temperature exceeds skin temperature. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of hyperthermia is extensive and includes infectious, endocrine, central nervous system, and toxic etiologies (",
"      <a class=\"graphic graphic_table graphicRef53571 \" href=\"UTD.htm?10/52/11084\">",
"       table 1",
"      </a>",
"      ). The most important causes of severe hyperthermia (greater than 40&ordm;C) caused by failure of thermoregulation are heat stroke, neuroleptic malignant syndrome, and malignant hyperthermia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe hyperthermia carries a high mortality rate. Mortality correlates with the degree of temperature elevation, time to initiation of cooling measures, and the number of organ systems affected. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors for increased mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of heat stroke is based upon a careful history and physical examination. The full differential diagnosis of hyperthermia should be considered in each patient (",
"      <a class=\"graphic graphic_table graphicRef53571 \" href=\"UTD.htm?10/52/11084\">",
"       table 1",
"      </a>",
"      ). The context in which symptoms develop usually suggests the etiology (eg, exertional heat stroke following exercise in high ambient temperature). Diagnostic studies are generally nonspecific but may reflect cardiovascular, renal or hepatic dysfunction or coagulopathy. Studies to be obtained are described in the text. (See",
"      <a class=\"local\" href=\"#H2141946\">",
"       'Definitions and clinical findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1408332\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of classic (nonexertional) heat stroke consists of ensuring adequate airway protection, breathing, and circulation; rapid cooling; and treatment of complications. (See",
"      <a class=\"local\" href=\"#H2140551\">",
"       'General treatment and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that rapid cooling of patients with classic (nonexertional) heat stroke be performed using evaporative techniques (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Evaporative cooling techniques are safe and effective in classic heat stroke and do not interfere with patient access or monitoring or other treatments. The management of exertional heat stroke is discussed separately. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cooling measures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11594?source=see_link\">",
"       \"Exertional heat illness in adolescents and adults: Management and prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypotension or volume depletion is treated with discrete intravenous boluses of isotonic crystalloid. Continuous core temperature monitoring with a rectal or esophageal probe is mandatory in all patients being treated for heat stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93021035\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/1\">",
"      Khosla R, Guntupalli KK. Heat-related illnesses. Crit Care Clin 1999; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/2\">",
"      Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002; 346:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/3\">",
"      Bross MH, Nash BT Jr, Carlton FB Jr. Heat emergencies. Am Fam Physician 1994; 50:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/4\">",
"      Bouchama A, Dehbi M, Chaves-Carballo E. Cooling and hemodynamic management in heatstroke: practical recommendations. Crit Care 2007; 11:R54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/5\">",
"      Leon LR, Helwig BG. Heat stroke: role of the systemic inflammatory response. J Appl Physiol 2010; 109:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Heat-related deaths--Chicago, Illinois, 1996-2001, and United States, 1979-1999. MMWR Morb Mortal Wkly Rep 2003; 52:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/7\">",
"      Tek D, Olshaker JS. Heat illness. Emerg Med Clin North Am 1992; 10:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/8\">",
"      Klenk J, Becker C, Rapp K. Heat-related mortality in residents of nursing homes. Age Ageing 2010; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/9\">",
"      Brody GM. Hyperthermia and hypothermia in the elderly. Clin Geriatr Med 1994; 10:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/10\">",
"      Dann EJ, Berkman N. Chronic idiopathic anhydrosis--a rare cause of heat stroke. Postgrad Med J 1992; 68:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/11\">",
"      Flynn A, McGreevy C, Mulkerrin EC. Why do older patients die in a heatwave? QJM 2005; 98:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/12\">",
"      Bendahan D, Kozak-Ribbens G, Confort-Gouny S, et al. A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg 2001; 93:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/13\">",
"      Hirshey Dirksen SJ, Larach MG, Rosenberg H, et al. Special article: Future directions in malignant hyperthermia research and patient care. Anesth Analg 2011; 113:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/14\">",
"      Seraj MA, Channa AB, al Harthi SS, et al. Are heat stroke patients fluid depleted? Importance of monitoring central venous pressure as a simple guideline for fluid therapy. Resuscitation 1991; 21:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/15\">",
"      Dematte JE, O'Mara K, Buescher J, et al. Near-fatal heat stroke during the 1995 heat wave in Chicago. Ann Intern Med 1998; 129:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/16\">",
"      Argaud L, Ferry T, Le QH, et al. Short- and long-term outcomes of heatstroke following the 2003 heat wave in Lyon, France. Arch Intern Med 2007; 167:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/17\">",
"      Misset B, De Jonghe B, Bastuji-Garin S, et al. Mortality of patients with heatstroke admitted to intensive care units during the 2003 heat wave in France: a national multiple-center risk-factor study. Crit Care Med 2006; 34:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/18\">",
"      Pease S, Bouadma L, Kermarrec N, et al. Early organ dysfunction course, cooling time and outcome in classic heatstroke. Intensive Care Med 2009; 35:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/19\">",
"      Bouchama A, Dehbi M, Mohamed G, et al. Prognostic factors in heat wave related deaths: a meta-analysis. Arch Intern Med 2007; 167:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/20\">",
"      Naughton MP, Henderson A, Mirabelli MC, et al. Heat-related mortality during a 1999 heat wave in Chicago. Am J Prev Med 2002; 22:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/21\">",
"      Semenza JC, Rubin CH, Falter KH, et al. Heat-related deaths during the July 1995 heat wave in Chicago. N Engl J Med 1996; 335:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/22\">",
"      al-Harthi SS, Nouh MS, al-Arfaj H, et al. Non-invasive evaluation of cardiac abnormalities in heat stroke pilgrims. Int J Cardiol 1992; 37:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/23\">",
"      Akhtar MJ, al-Nozha M, al-Harthi S, Nouh MS. Electrocardiographic abnormalities in patients with heat stroke. Chest 1993; 104:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/24\">",
"      Garc&iacute;a-Rubira JC, Aguilar J, Romero D. Acute myocardial infarction in a young man after heat exhaustion. Int J Cardiol 1995; 47:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/25\">",
"      al-Mashhadani SA, Gader AG, al Harthi SS, et al. The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah. Blood Coagul Fibrinolysis 1994; 5:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/26\">",
"      Becker BN, Ismail N. The neuroleptic malignant syndrome and acute renal failure. J Am Soc Nephrol 1994; 4:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/27\">",
"      Hostler D, Northington WE, Callaway CW. High-dose diazepam facilitates core cooling during cold saline infusion in healthy volunteers. Appl Physiol Nutr Metab 2009; 34:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/28\">",
"      Smith JE. Cooling methods used in the treatment of exertional heat illness. Br J Sports Med 2005; 39:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/29\">",
"      McDermott BP, Casa DJ, O'Connor FG, et al. Cold-water dousing with ice massage to treat exertional heat stroke: a case series. Aviat Space Environ Med 2009; 80:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/30\">",
"      Zuckerman GB, Singer LP, Rubin DH, Conway EE Jr. Effects of dantrolene on cooling times and cardiovascular parameters in an immature porcine model of heatstroke. Crit Care Med 1997; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16007/abstract/31\">",
"      Bouchama A, Cafege A, Devol EB, et al. Ineffectiveness of dantrolene sodium in the treatment of heatstroke. Crit Care Med 1991; 19:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 176 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16007=[""].join("\n");
var outline_f15_40_16007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2140224\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139843\">",
"      Malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139850\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2141946\">",
"      DEFINITIONS AND CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS FOR INCREASED MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1408332\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2140551\">",
"      General treatment and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cooling measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2140572\">",
"      Treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2140224\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93021035\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/176\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/176|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/52/11084\" title=\"table 1\">",
"      Differential dx of hyperthermia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=related_link\">",
"      Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11594?source=related_link\">",
"      Exertional heat illness in adolescents and adults: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8361?source=related_link\">",
"      Pathophysiology and treatment of fever in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=related_link\">",
"      Patient information: Heat stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_40_16008="General principles of the use of cyclophosphamide in rheumatic and renal disease";
var content_f15_40_16008=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of the use of cyclophosphamide in rheumatic and renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16008/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16008/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16008/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16008/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16008/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16008/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/40/16008/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    (CYC), an alkylating agent, is one of the most potent immunosuppressive therapies available. It has been used extensively for more than three decades to treat severe manifestations of a variety of autoimmune and inflammatory diseases. It is a prodrug that is converted to its active form within the body and it can be administered either orally or intravenously.",
"   </p>",
"   <p>",
"    Oral administration usually corresponds to daily dosing and intravenous use to intermittent dosing (eg, every three to four weeks), but some exceptions exist. For example, extremely ill patients who are unable to ingest medications orally may receive daily doses of CYC via the intravenous route, at the same doses they would otherwise receive orally.",
"   </p>",
"   <p>",
"    Although very effective, CYC has the potential for devastating toxicity both in the short- and long-term (potentially occurring even after the medication has been stopped). Concerns about such drug toxicity, especially malignancy, have restricted its use to patients with the most severe disease. The indications for the drug include lupus nephritis and other forms of glomerulonephritis; rheumatoid vasculitis, interstitial lung disease associated with connective tissue diseases; and many types of systemic vasculitis.",
"   </p>",
"   <p>",
"    The types of systemic vasculitis that most frequently require CYC are granulomatosis with polyangiitis (Wegener&rsquo;s), polyarteritis nodosa, Churg-Strauss syndrome, Beh&ccedil;et&rsquo;s disease, vasculitis of the central nervous system, refractory cutaneous vasculitis, and isolated vasculitic neuropathy. These diseases share a potential to threaten either the patient's life or the function of major organs. In view of the potential for death, end-stage renal disease, crippling mononeuritis multiplex, bowel perforation, and major toxicities associated with long-term glucocorticoid use, the rationale for CYC use is usually clear.",
"   </p>",
"   <p>",
"    Two major aims govern the use of CYC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prompt control of the underlying disease, to limit the extent and severity of damage",
"     </li>",
"     <li>",
"      Discontinuation of the medication as soon as possible and replacement with a less toxic alternative, in order to minimize the short- and long-term morbidity that often results from CYC itself.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is also discussed in the appropriate disease-specific topic review elsewhere. (See treatment sections of appropriate disease-specific topic reviews).",
"   </p>",
"   <p>",
"    The pharmacology, administration, and monitoring of both oral and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    will be reviewed here. The mechanism of action of cyclophosphamide and other alkylating agents and the general toxicity of these drugs are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism and excretion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CYC) are important issues related to its toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;CYC tablets should be stored in covered containers. Refrigeration is not necessary, although the drug may be unstable at temperatures exceeding 25&ordm;C.",
"   </p>",
"   <p>",
"    For intravenous use, CYC powder is reconstituted in sterile or bacteriostatic water. Reconstituted solutions should be refrigerated and infused within six hours unless bacteriostatic water is used. Reconstituted solutions may then be mixed with 50 to 150 mL of five percent dextrose, 0.45 percent or 0.9 percent saline, or lactated Ringer's solution for infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absorption, metabolism, and distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral CYC is rapidly and almost completely absorbed. It is metabolized in the liver to 4-hydroxy",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and aldophosphoramide (",
"    <a class=\"graphic graphic_figure graphicRef70026 \" href=\"UTD.htm?30/20/31054\">",
"     figure 1",
"    </a>",
"    ); the latter compound is then converted to the active metabolite phosphoramide mustard and the non-alkylating, bladder-toxic metabolite acrolein. The active metabolites are highly protein bound and distributed to all tissues including brain and cerebrospinal fluid. The active metabolites are assumed to cross the placenta and are known to be present in breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both active and inactive metabolites are primarily excreted unchanged in the urine, with elimination complete by 48 hours. Consequently, the dose of CYC should be adjusted according to the degree of renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. When using daily CYC, the authors adjust the dose according to the algorithm in table 1, based upon the patient's creatinine clearance (",
"    <a class=\"graphic graphic_table graphicRef60883 \" href=\"UTD.htm?6/31/6652\">",
"     table 1",
"    </a>",
"    ). When using intermittent CYC in patients with renal dysfunction, the dose should also be modified, albeit precise guidelines for dose reductions in this setting are not established. In a patient with advanced renal dysfunction, the initial dose of pulse CYC should not exceed 500 mg per square meter of body surface area (BSA). Subsequent doses can be adjusted based on the bone marrow response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interaction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with three types of drugs should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Drugs that alter activity of hepatic enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that induce hepatic microsomal enzymes (eg, barbiturates, alcohol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) may accelerate the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    into its active metabolites, and thus, can increase both the pharmacologic and toxic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Conversely, drugs which inhibit the hepatic microsomal enzymes (eg, corticosteroids, antimalarials, tricyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ) slow the conversion of CYC to active metabolites, and thus may decrease both therapeutic and adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Succinylcholine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    reduces plasma pseudocholinesterase activity, thus co-administration or subsequent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    and may lead to prolonged neuromuscular blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Anesthesiologists should be aware of recent cyclophosphamide treatment prior to administering succinylcholine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anticholinergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants and other anticholinergic agents delay bladder emptying and may lead to prolonged bladder exposure to acrolein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions represent relative contraindications to the use of CYC:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    , like other alkylating agents, is teratogenic and is generally contraindicated in pregnancy. In women of childbearing potential, pregnancy testing may be prudent. In life-threatening circumstances, use after the first trimester may be safe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, it is assumed that active",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    toxic metabolites may be present in breast milk of women receiving CYC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Active infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risk of neutropenia, CYC therapy should be avoided in the presence of active systemic or potentially life-threatening infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;CYC use in neutropenic patients should be avoided, unless the neutropenia is believed to be immune-mediated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bladder toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of CYC should be avoided in patients with bladder cancer or a history of prior CYC-induced cystitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of CYC is associated with a significant risk of infertility in both males and females, and of premature menopause in women. The likelihood of these reproductive toxicities rises with increasing age of the patient (at least in women) and the cumulative dose of CYC received. As an example, among women with lupus nephritis treated with CYC, premature ovarian failure occurred in all of those over the age of 30 years, one-half of those aged 20 to 30 years, and 13 percent of those younger than 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/9\">",
"     9",
"    </a>",
"    ]. This potential CYC toxicity must be explained clearly to patients.",
"   </p>",
"   <p>",
"    If the pace and severity of disease permit, male patients may bank sperm or females may store eggs before instituting CYC. However, the ovarian stimulation regimen employed prior to egg harvesting may be contraindicated in active systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    The life-threatening nature of the underlying disease may permit insufficient time for these measures, and, in severely ill patients, institution of CYC therapy should not be delayed. Infertility is less common with intermittent dosing of CYC, but the risk of this complication remains substantial.",
"   </p>",
"   <p>",
"    Use of a gonadotropin releasing hormone agonist (GnRH-a) may have a role in gonadal protection in women and intramuscular testosterone for men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H8#H8\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Gonadal toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     AVOIDANCE OF OTHER ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive effects of CYC, especially when combined with corticosteroids or other immunosuppressive agents, increase the risk of development of opportunistic infections, particularly infection with Pneumocystis carinii. Toxic metabolites can cause cystitis and bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures that may reduce the risk of these complications of CYC therapy are (",
"    <a class=\"graphic graphic_table graphicRef60160 \" href=\"UTD.htm?14/22/14699\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prophylaxis for Pneumocystis jirovecii (carinii) pneumonia infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the route of administration, Pneumocystis jirovecii (previously carinii) pneumonia (previously PCP) prophylaxis is indicated for any patients on CYC. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    <span class=\"nowrap\">",
"     (TMP/SMX)",
"    </span>",
"    (either one single-strength tablet daily or one double-strength tablet 3",
"    <span class=\"nowrap\">",
"     times/week)",
"    </span>",
"    virtually eliminates PCP as a potential complication. Because",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    is removed by hemodialysis, the medication should be administered after dialysis in patients on renal replacement therapy. In patients who are allergic to either component of",
"    <span class=\"nowrap\">",
"     TMP/SMX,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    (1500",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or monthly aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    are all effective alternatives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of drug-induced cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced cystitis may pose major problems in CYC-treated patients. Severe cases may require urinary diversion procedures or even cystectomy. Consequently, under most circumstances, the development of drug-induced cystitis is a strong contraindication to further CYC therapy. Mercaptoethane sulfonate (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    ), which binds and detoxifies acrolein is used to minimize the risk of bladder toxicity during the administration of intermittent CYC. In general, the total dose of MESNA administered is the same as the total dose of CYC administered and is given in the following manner: half the total MESNA dose is given intravenously before the CYC infusion and the other half of MESNA is administered 2 hours after the CYC-infusion (either intravenously or orally). An oral formulation of MESNA may be used in patients on daily CYC regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     USE OF DAILY ORAL CYCLOPHOSPHAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    remains an important treatment for life-threatening manifestations of systemic vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;CYC, available in 25 mg and 50 mg tablets (Cytoxan&reg;, Bristol-Myers), can be taken on either an empty or full stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Initial dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard starting dose of daily CYC in a patient with normal renal function is 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Unfortunately, many patients on CYC have diseases associated with decreased renal function. In such settings, the dose of CYC must be modified (",
"    <a class=\"graphic graphic_table graphicRef60883 \" href=\"UTD.htm?6/31/6652\">",
"     table 1",
"    </a>",
"    ). Conversely, doses lower than 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day may not be effective in patients with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CYC tablets should be administered in the morning and the patient advised to drink liberal quantities of fluid throughout the day (eight 8-ounce glasses of water are recommended). Patients should also attempt to empty their bladders before going to sleep. These measures decrease the time the bladder is exposed to the toxic metabolite acrolein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Dose modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of daily CYC should be modified in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resistant disease &mdash; In patients with resistant disease, cautious upward titration of CYC dose may be attempted. Clinicians must be as certain as possible that disease \"refractoriness\" is truly due to active disease rather than to irreversible damage (the latter will not respond to more CYC). In prescribing CYC, the authors do not exceed 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of CYC; higher doses are associated with substantially increased risks of hematologic toxicity, opportunistic infections, and drug-induced cystitis.",
"     </li>",
"     <li>",
"      Renal insufficiency &mdash; Subsequent doses of CYC must be adjusted downward if renal function worsens during the treatment course (",
"      <a class=\"graphic graphic_table graphicRef60883 \" href=\"UTD.htm?6/31/6652\">",
"       table 1",
"      </a>",
"      ). Conversely, marked improvement in renal function may allow for increased doses.",
"      <br/>",
"      <br/>",
"      A moderate quantity of CYC is removed from circulation at dialysis. Thus, a supplemental dose of CYC should be given after a hemodialysis session if the dialysis patient received their usual daily dose of CYC prior to the session. The supplemental dose is generally equal to 50 percent of their usual daily dose.",
"     </li>",
"     <li>",
"      Obesity &mdash; In an obese patient, the initial dose should be adjusted based upon an approximation of the ideal body weight rather than the actual patient weight [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients on CYC, regular and frequent laboratory evaluations are required to screen for bone marrow toxicity, to monitor renal function, and to avoid major drug-induced bladder complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Blood counts and differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood counts with differential should be obtained very frequently. As an example, we repeat cell counts and differential at least every two weeks for as long as the patient is on CYC. Total white blood cell counts of less than",
"    <span class=\"nowrap\">",
"     3500/mm3",
"    </span>",
"    should lead to dose reductions, because lower counts are associated with a markedly increased risk of opportunistic infection. (In contrast, isolated lymphopenia, an anticipated effect, but not a goal, of therapy does not indicate a need for alteration of the CYC dose.)",
"   </p>",
"   <p>",
"    Marked lymphopenia is common during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy and is not a major cause for concern. However, the total white blood cell count should be maintained above",
"    <span class=\"nowrap\">",
"     3500/mm3",
"    </span>",
"    and the dose reduced or held if leukopenia occurs. The goal of treatment is clinical improvement. This usually occurs without needing to induce leukopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine, urea nitrogen, and electrolytes should also be measured frequently. We repeat these studies at least every 2 weeks for as long as the patient is on CYC. Patients' underlying disease or other medications (eg, nonsteroidal antiinflammatory drugs) may affect renal function adversely. Declines in renal function may necessitate adjustment of the CYC dose (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CYC-treated patients should have urinalyses every month while on CYC, and at least annually after its discontinuation. The presence of blood on dipstick should prompt a microscopic examination of the urine sediment. Hematuria may signal drug-induced cystitis, premalignant changes in the bladder epithelium, the development of frank bladder cancer, or the occurrence (or recurrence) of glomerulonephritis. In the absence of clinical findings that strongly suggest glomerulonephritis (eg, significant",
"    <span class=\"nowrap\">",
"     new/increasing",
"    </span>",
"    proteinuria, red blood cell casts, and a rising serum creatinine), cystoscopy should be performed promptly as the next test in the evaluation of hematuria.",
"   </p>",
"   <p>",
"    Interpreting the presence of hematuria is clearly more difficult in patients with lupus or vasculitis who have hematuria at baseline because of renal involvement. In this setting, a clue to the development of bladder toxicity is an increase in hematuria, in the absence of other signs of active systemic disease and without laboratory evidence of worsening renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hepatic, cardiac, and pulmonary effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used in nonmyeloablative doses for rheumatic and renal diseases, CYC is rarely associated with hepatitis, cardiac damage, or pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Drug-induced hepatitis due to CYC can be detected by regular monitoring of serum aminotransaminase enzymes. The authors typically obtain liver enzymes every month during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INTERMITTENT (PULSE) CYCLOPHOSPHAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent CYC, usually administered intravenously every three or four weeks is an alternative to daily dosing. One of the principal reasons for using intermittent CYC in severe lupus was concern about the long-term bladder complications of daily oral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For lupus nephritis, intermittent CYC was shown to be equal to daily CYC in efficacy, but to have less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/14\">",
"     14",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intermittent CYC therapy is also sometimes used to treat systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/5\">",
"     5",
"    </a>",
"    ]. However, no study to date has had sufficient power to evaluate fully the relative efficacies of daily and intermittent CYC when used to treat any of the systemic vasculitides. The current consensus is that these two routes of CYC administration are approximately equivalent with regard to the induction of remission, but that durable remissions are more likely with daily CYC therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/2,15-17\">",
"     2,15-17",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared with oral daily CYC, intermittent CYC regimens are associated with approximately 50 percent less cumulative CYC. Moreover, with intermittent pulses (eg, monthly) the bladder is exposed to acrolein for only one or two days each cycle, rather than every day. Hemorrhagic cystitis has been noted in a few patients with lupus nephritis treated exclusively with intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . We are not aware of any cases of bladder cancer in patients so treated.",
"   </p>",
"   <p>",
"    When using intermittent pulses of CYC, it is our practice to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     MESNA",
"    </a>",
"    concomitantly, through the intravenous route as described above (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Prevention of drug-induced cystitis'",
"    </a>",
"    above). Where an enteral formulation of MESNA is available, as it is in Europe, the oral route may be employed instead [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/18\">",
"     18",
"    </a>",
"    ]. MESNA lessens the risk of drug-induced cystitis, but does not eliminate it entirely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;When using intermittent CYC in women of reproductive age,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    (3.75 mg intramuscular depot injections) may be administered two weeks before each CYC infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/19\">",
"     19",
"    </a>",
"    ]. Although of unproven efficacy, the administration of leuprolide is designed to \"rest\" the ovaries during the period of CYC use, thereby diminishing (in theory) the risk of premature",
"    <span class=\"nowrap\">",
"     menopause/infertility.",
"    </span>",
"    A detailed discussion concerning infertility and its avoidance in patients receiving treatment with CYC is presented separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H8#H8\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Gonadal toxicity'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For men, there are limited data to suggest that intramuscular injections with testosterone may help to prevent CYC-induced testicular failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H8#H8\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Gonadal toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Intermittent dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of the initial dose of CYC for intravenous infusion is based upon estimated body surface area (BSA) expressed in square meters (m",
"    <sup>",
"     2",
"    </sup>",
"    ) and is further adjusted for renal function as estimated by a calculated creatinine clearance, advanced age, and obesity. Subsequent doses are further adjusted based upon the patient&rsquo;s response to therapy and the nadir of the white blood cell count. Most pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    protocols in lupus nephritis begin with six to seven monthly pulses for induction followed by quarterly pulses for at least one addition year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Initial dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with normal renal function, the recommended initial dose of intermittent CYC is 750",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    of BSA. Up to 1",
"    <span class=\"nowrap\">",
"     gram/m2",
"    </span>",
"    BSA is administered to some patients with rheumatologic or renal disease. To diminish the risk of toxicity, the initial dose should be reduced to 500",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    BSA in patients who are obese or elderly (eg, age greater than 70 years). The dose should also be reduced to 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    BSA in the setting of renal dysfunction (especially if the estimated creatinine clearance is less than 40",
"    <span class=\"nowrap\">",
"     mL/minute).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Subsequent doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    the leukocyte nadir after the first administration of CYC is less than",
"    <span class=\"nowrap\">",
"     3500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the absolute neutrophil count is less than",
"    <span class=\"nowrap\">",
"     1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    the dose at the next infusion should be reduced by 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    BSA. If, on the other hand, the total white cell nadir is greater than 4000 per mm",
"    <sup>",
"     3",
"    </sup>",
"    and the patient has not improved, the CYC dose at the next infusion may be increased by 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    BSA, to a maximum dose of 1",
"    <span class=\"nowrap\">",
"     gram/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    BSA.",
"   </p>",
"   <p>",
"    Most intermittent CYC protocols in lupus nephritis begin with six monthly infusions, followed by pulses every three months for at least an additional 18 months (total duration of treatment: two years) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/14\">",
"     14",
"    </a>",
"    ]. In the treatment of systemic vasculitis, six monthly CYC infusions may be followed by a switch to a less toxic alternative agent for the maintenance of remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are stable, intermittent intravenous CYC can be administered safely in the outpatient setting. Exceptions should be made for patients with heart failure (who may not tolerate the required pretreatment hydration well), for those with severe nephrotic syndrome (who may be unable to maintain brisk urine outputs), and for those who, for reasons of frailty, may tolerate even moderate nausea poorly. The aggressive use of diuretics and bladder irrigation through three-way Foley catheters are more feasible in inpatients. Even in the outpatient setting, however, intravenous fluids, anti-emetics, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     MESNA",
"    </a>",
"    may be used to prevent toxicities commonly associated with CYC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients must be hydrated adequately before, during, and immediately after the intermittent CYC infusions. Patients receiving intermittent CYC in the outpatient setting should receive one liter of intravenous fluid (eg, 0.45 or 0.9 percent saline) over a two to four hour period before the infusion. CYC is usually infused over one hour. After the administration of CYC, all patients should be instructed to drink at least one liter of fluid every six to eight hours for 24 hours afterwards, and to void as frequently as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Antiemetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea is nearly universal in patients treated with intermittent CYC. Without antiemetics, severe vomiting may occur.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (10 mg by mouth four hours after the infusion) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    (4 to 8 mg intravenously 30 minutes before the infusion, and again four and eight hours afterwards) alleviates nausea substantially. An alternative approach for patients with mild nausea is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , 25 mg orally or by suppository every four hours, as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Bladder protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The entire",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     MESNA",
"    </a>",
"    dose can be added to the liter of intravenous fluids in patients receiving one liter of hydration over two to four hours. Alternatively, MESNA can be infused in two to four divided doses every four hours in patients receiving longer hydration regimens. Clinicians should be aware that MESNA is associated with high rates of fixed drug eruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16008/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;To detect the leukocyte nadir, a complete blood count with differential should be measured at 7, 10, 14, and 18 days after the infusion. If severe leukopenia occurs (ie, a total white cell count less than 3500 per mm3 or an absolute neutrophil count of less than 1500 per mm3), the subsequent dose should be reduced as described above. Similarly, changes in renal function between the cycles of intermittent CYC administration should prompt dose adjustments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     CYCLOPHOSPHAMIDE IN THE INTENSIVE CARE UNIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumstances may occasionally arise where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is administered to a patient on a mechanical ventilator or with a decreased level of consciousness. Either daily or pulse dosing regimens can be given in this setting (either by feeding tube for the former or intravenously for either).",
"   </p>",
"   <p>",
"    The major concern is bladder protection. Catheter drainage should adequately protect the bladder if the urine output is greater than 100",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    Continuous bladder irrigation through a three-way catheter is necessary in patients with a lower urine output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6408508\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    (CYC), an alkylating agent, is one of the most potent immunosuppressive therapies available. It is a prodrug that is converted to its active form within the body and can be administered either orally or intravenously. Although very effective, CYC has the potential for devastating toxicity both in the short- and long-term. Two major aims in the use of CYC are prompt control of the underlying disease and discontinuation of the medication as soon as possible, replacing it with a less toxic alternative to minimize the short- and long-term morbidity that often results from CYC itself. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The metabolism and excretion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (CYC) are important issues related to its toxicity. Specific precautions are required to maintain the stability of the medication. Oral CYC is rapidly and almost completely absorbed, then metabolized in the liver and converted to the active metabolite phosphoramide mustard and the non-alkylating, bladder-toxic metabolite acrolein. The active metabolites are highly protein bound and distributed to all tissues. Both active and inactive metabolites are primarily excreted unchanged in the urine, with elimination complete by 48 hours. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interaction of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with three types of drugs should be considered, including drugs that alter activity of hepatic enzymes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      , and anticholinergic agents. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relative contraindications to the use of CYC include pregnancy, lactation, active infection, neutropenia and bladder cancer or a history of prior CYC-induced cystitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of CYC is associated with a significant risk of infertility in both males and females, and of premature menopause in women. The likelihood of these reproductive toxicities rises with increasing age of the patient (at least in women) and the cumulative dose of CYC received. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The immunosuppressive effects of CYC, especially when combined with corticosteroids or other immunosuppressive agents, increase the risk of development of opportunistic infections, particularly infection with Pneumocystis carinii. Toxic metabolites can cause cystitis and bladder cancer. Specific measures should be taken to reduce these risks. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Avoidance of other adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      remains an important treatment for life-threatening manifestations of systemic vasculitis. Appropriate measures should be taken to reduce the risk of bladder toxicity. The daily dose should be modified in patients with diminished or improving renal function or on hemodialysis, with resistant disease, and in the setting of obesity. Regular and frequent laboratory evaluations are required to screen for bone marrow toxicity, to monitor renal function, and to avoid major drug-induced bladder complications. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Use of daily oral cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermittent CYC, usually administered intravenously every three or four weeks, is an alternative to daily dosing. One of the principal reasons for using intermittent CYC in severe lupus was concern about the long-term bladder complications of daily oral therapy. When compared with oral daily CYC, intermittent CYC regimens are associated with less cumulative CYC and less exposure of the bladder to acrolein. Intravenous fluids, anti-emetics, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       MESNA",
"      </a>",
"      may be used to prevent toxicities commonly associated with CYC. Selection of the initial dose of CYC for intravenous infusion is based upon estimated body surface area (BSA) expressed in square meters (m2) and is further adjusted for renal function. Subsequent doses are further adjusted based upon the patient&rsquo;s response to therapy and the nadir of the white blood cell count. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Intermittent (pulse) cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either daily or pulse dosing regimens can be used for patients on a mechanical ventilator or with a decreased level of consciousness to whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is administered in the intensive care setting. Particular attention should be given to measures for bladder protection. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Cyclophosphamide in the intensive care unit'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/1\">",
"      Wiernik PH, Duncan JH. Cyclophosphamide in human milk. Lancet 1971; 1:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/2\">",
"      Regan MJ, Hellmann DB, Stone JH. Treatment of Wegener's granulomatosis. Rheum Dis Clin North Am 2001; 27:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/3\">",
"      Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/4\">",
"      Donelli MG, Bartosek I, Guaitani A, et al. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect. Cancer Treat Rep 1976; 60:395.",
"     </a>",
"    </li>",
"    <li>",
"     Bingham S, Emery P. Renal toxicity of antirheumatic drugs. In: Rheumatology and the Kidney, Adu D, Emery P, Madaio M (Eds), Oxford University Press, 2001. p.445.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/6\">",
"      Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. Bone Marrow Transplant 1999; 24:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/7\">",
"      Vigouroux D, Voltaire L. [Prolonged neuromuscular block induced by mivacurium in a patient treated with cyclophosphamide]. Ann Fr Anesth Reanim 1995; 14:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/8\">",
"      Walker IR, Zapf PW, Mackay IR. Cyclophosphamide, cholinesterase and anaesthesia. Aust N Z J Med 1972; 2:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/9\">",
"      Balow JE, Austin HA 3rd, Tsokos GC, et al. NIH conference. Lupus nephritis. Ann Intern Med 1987; 106:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/10\">",
"      Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/11\">",
"      Lidsky MD, Sharp JT, Billings S. Double-blind study of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum 1973; 16:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/12\">",
"      Sostman HD, Matthay RA, Putman CE. Cytotoxic drug-induced lung disease. Am J Med 1977; 62:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/13\">",
"      Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/14\">",
"      Boumpas DT, Austin HA 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/15\">",
"      Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/16\">",
"      Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/17\">",
"      Haubitz M, Schellong S, G&ouml;bel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/18\">",
"      Stofer-Vogel B, Cerny T, Borner M, Lauterburg BH. Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol 1993; 32:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/19\">",
"      Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 2002; 41:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16008/abstract/20\">",
"      Zonzits E, Aberer W, Tappeiner G. Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis. Arch Dermatol 1992; 128:80.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7963 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16008=[""].join("\n");
var outline_f15_40_16008=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6408508\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absorption, metabolism, and distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Elimination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Drugs that alter activity of hepatic enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Succinylcholine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anticholinergic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Active infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bladder toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      AVOIDANCE OF OTHER ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prophylaxis for Pneumocystis jirovecii (carinii) pneumonia infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of drug-induced cystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      USE OF DAILY ORAL CYCLOPHOSPHAMIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Initial dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Dose modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Blood counts and differential",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Renal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hepatic, cardiac, and pulmonary effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INTERMITTENT (PULSE) CYCLOPHOSPHAMIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Intermittent dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Initial dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Subsequent doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Hydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Antiemetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Bladder protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      CYCLOPHOSPHAMIDE IN THE INTENSIVE CARE UNIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6408508\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7963|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/20/31054\" title=\"figure 1\">",
"      Metabolism of cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7963|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/31/6652\" title=\"table 1\">",
"      Adjusting cyclophosphamide dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/22/14699\" title=\"table 2\">",
"      Safe use of cyclophosphamide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_40_16009="Hoarseness in adults";
var content_f15_40_16009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hoarseness in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16009/contributors\">",
"     Jean M Bruch, DMD, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16009/contributors\">",
"     Dipti V Kamani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16009/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16009/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/40/16009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Hoarseness\" is a term often used to describe any change in voice quality. This reflects a variety of complaints including vocal tremor, weakness, fatigue, altered pitch, breathiness, or strained voice quality.",
"   </p>",
"   <p>",
"    The approach to the adult who presents with hoarseness will be reviewed here. The approach to hoarseness in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4102?source=see_link\">",
"     \"Evaluation of the child with hoarseness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LARYNGEAL ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main functions of the larynx involve phonation, respiration, swallowing, and valsalva:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phonation refers to production of a primary vocal tone at the level of the vocal folds. Vocal quality is then modified by resonation through the upper airway and sinonasal tract and articulated into speech.",
"     </li>",
"     <li>",
"      Airway patency&nbsp;and protection is important during respiration and swallowing. The normal swallow mechanism includes laryngeal elevation, posterior deflection of the epiglottis, inhibition of respiration, and closure of the vocal folds to prevent aspiration of ingested material.",
"     </li>",
"     <li>",
"      Valsalva represents generation of increased pressure against a tightly closed glottis. This enables functions such as cough, straining, throat clearing, and defecation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anatomy of the larynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx is comprised of a cartilaginous skeleton, muscles (extrinsic and intrinsic), and a mucosal lining (",
"    <a class=\"graphic graphic_figure graphicRef79855 \" href=\"UTD.htm?24/1/24599\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cartilages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx is suspended from the hyoid bone in the anterior neck by soft tissue attachments. The laryngeal skeleton consists of nine cartilages. The arytenoid, corniculate, and cuneiform cartilages are paired, whereas the thyroid, cricoid, and epiglottis are unpaired (",
"    <a class=\"graphic graphic_figure graphicRef56206 \" href=\"UTD.htm?15/23/15733\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The thyroid cartilage is the largest, and forms a protective shield-like shape in front of the vocal folds. Its midline projection is commonly referred to as the \"Adam's apple\" and tends to be more prominent in men.",
"   </p>",
"   <p>",
"    The cricoid cartilage, which lies below the thyroid cartilage and above the entrance to the trachea, is the only complete ring of the laryngeal skeleton. The cricoid cartilage encloses the subglottic region of the larynx. Stenosis may form if the mucosa in this region is injured, as can occur with prolonged endotracheal tube intubation.",
"   </p>",
"   <p>",
"    The arytenoids are pyramidal shaped cartilages positioned on the upper border of the posterior cricoid cartilage; these attach at the synovial cricoarytenoid joints (",
"    <a class=\"graphic graphic_figure graphicRef56206 \" href=\"UTD.htm?15/23/15733\">",
"     figure 2",
"    </a>",
"    ). The arytenoids serve as attachment sites for some of the intrinsic muscles of the larynx and allow complex movement and fine adjustment of the vocal folds. Fibrosis or fixation of the cricoarytenoid joint, as can be seen with rheumatoid arthritis or following trauma, can result in vocal fold immobility and respiratory or phonatory impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Vocal folds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true vocal folds are bands of tissue comprised of muscle, fibrous ligament, and mucosa extending from the arytenoids posteriorly to the midline thyroid cartilage anteriorly.",
"   </p>",
"   <p>",
"    The false (or \"ventricular\") vocal folds are situated superior to the true vocal folds and are separated from them by a lateral recess termed the laryngeal ventricle. The ventricle contains mucus producing glands that provide lubrication for the true vocal folds, which are themselves devoid of glandular elements. The false vocal folds are adducted only during effortful closure, as with valsalva and reflex laryngeal closure due to noxious stimuli. They do not normally approximate during phonation; however this may be observed in pathologic conditions, such as in patients with incompetent true vocal fold closure due to vocal fold paralysis, mass lesion, or presbyphonia (vocal fold changes due to aging of the larynx).",
"   </p>",
"   <p>",
"    The larynx is subdivided into three regions: the supraglottis, glottis, and subglottis. The supraglottis encompasses the area above the true vocal folds and includes the epiglottis, false vocal folds, aryepiglottic folds, and arytenoids. The glottis consists of the true vocal folds and the immediate subjacent area extending 1 cm inferiorly. The subglottis refers to the region beginning at the inferior edge of the glottis and extending down to the inferior border of the cricoid cartilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Extrinsic and intrinsic muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscles of the larynx are divided into extrinsic and intrinsic muscles. The extrinsic group, including the anterior strap muscles and digastrics, affects the position of the entire larynx in the neck. This is important for laryngeal elevation during swallowing and fixation of the larynx during valsalva. The intrinsic muscles are much more delicate and are responsible for movement of the vocal folds within the larynx as well as subtle tension adjustments related to phonation. The main intrinsic muscles are: posterior cricoarytenoid (PCA), lateral cricoarytenoid (LCA), interarytenoid (IA), thyroarytenoid (TA), and cricothyroid (CT).",
"   </p>",
"   <p>",
"    The thyroarytenoid muscle makes up the bulk of the true vocal fold. Movement at the cricoarytenoid joint allows the vocal folds to be approximated in the midline (adducted) during phonation or drawn apart laterally (abducted) during inspiration.",
"   </p>",
"   <p>",
"    The vocal fold mucosa is composed of non-keratinizing stratified squamous epithelium, whereas the remainder of the larynx is lined by respiratory (ciliated pseudostratified columnar) epithelium; this enables the surface of the vocal fold to better withstand the repetitive trauma of high-velocity contact with the contralateral vocal fold. The subepithelial layer, known as Reinke's space or superficial lamina proria (SLP), contains mucopolysaccharides and mucoproteins that give it a viscous consistency. This facilitates vibration of the vocal fold mucosa over the deeper tissue layers which are more dense and fibrous. Scarring and stiffness of these layers can impair vibration with subsequent degradation of vocal quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nerve supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vagus nerve innervates the laryngopharynx. The recurrent laryngeal nerves branch from the vagus in the upper chest and reenter the neck in the thoracic inlet. The recurrent laryngeal nerve travels underneath the subclavian artery on the right side, and around the arch of the aorta on the left side.",
"   </p>",
"   <p>",
"    The recurrent laryngeal nerve innervates all intrinsic muscles except for the cricothyroid muscle, which is innervated by the external branch of the superior laryngeal nerve. Additional motor function of the lower pharynx and upper esophagus is supplied by direct pharyngeal branches of the vagus and recurrent laryngeal nerve. A mass lesion along the course of these nerves can result in vocal fold paralysis.",
"   </p>",
"   <p>",
"    Sensory function above the level of the vocal folds is mediated by the internal branch of the superior laryngeal nerve. Sensory function below the level of the vocal folds is transmitted through the recurrent laryngeal nerve. The vagus nerve receives sensory information from the external auditory canal as well as the hypopharynx. Thus, a reflex cough can be provoked by instrumenting the ear during cleaning, and cancer present in the hypopharynx may result in ear pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Phonation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phonation is generated by the interaction of aerodynamic forces of the exhaled air column with the viscoelastic properties of the true vocal fold mucosa as the vocal folds are held approximated (adducted) in the midline. This results in a vibratory, oscillating wave in the superficial layers of the vocal fold as air is expelled from the lungs.",
"   </p>",
"   <p>",
"    Oscillation occurs about 100 to 300 times per second (Hz) during speech, and is greater than 1000 Hz in a soprano while singing. This is too fast for the human eye to perceive, and special techniques (such as videostroboscopy) are needed to capture vocal fold vibration. The frequency of vibration is perceived by the ear as pitch. Pitch is mainly determined by vocal fold length and tension, and is regulated by minute adjustments of the cricothyroid muscle. Increase in mass of the vocal fold can also alter pitch, as seen with polyps or an increased amount of tissue in Reinke's space in smokers.",
"   </p>",
"   <p>",
"    The glottic vocal tone is produced at the level of the glottis (true vocal folds); it then resonates in the pharynx and nose, adding harmonics and timbre, and is articulated by fine motor control of the tongue, palate, and lips. A patient with cleft palate may have normal vocal fold function, but will have a hypernasal voice due to the palatal defect and poor velopharyngeal closure (resulting in excess air escape through the nose). In contrast, a patient with nasal congestion may exhibit hyponasal resonance due to inadequate air escape through the nose. The dysarthric patient may have normal vocal fold function, but abnormal articulation secondary to neurologic dysfunction of the tongue or lips.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CAUSES OF HOARSENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hoarseness may be due to either functional or organic causes. Any patient with persistent hoarseness should be evaluated in order to establish a diagnosis. In the absence of symptoms of an acute upper respiratory infection, patients with hoarseness persisting for more than two weeks should be referred for a complete otolaryngologic examination. This is especially important in the setting of associated risk factors for head and neck cancer (primarily tobacco and alcohol use), or worrisome coexistent symptomatology such as severe cough, hemoptysis, unilateral ear or throat pain, odynophagia, dysphagia, or unexplained weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Causes of hoarseness may be considered in the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute laryngitis, which is self-limited and related to acute respiratory illness or acute voice misuse",
"     </li>",
"     <li>",
"      Chronic laryngitis, which is related to irritants, reflux, chronic infection (such as fungal), or habitual vocal misuse",
"     </li>",
"     <li>",
"      Benign vocal fold lesions",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Neurologic dysfunction",
"     </li>",
"     <li>",
"      Non-organic (\"functional\") issues",
"     </li>",
"     <li>",
"      Systemic conditions and rare causes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute laryngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute laryngitis is a common and self-limited inflammatory condition lasting less than three weeks, and usually associated with either an upper respiratory tract infection or acute vocal strain. Moraxella catarrhalis, Hemophilus influenzae, and Streptococcus pneumoniae have been isolated from the nasopharynx of adults with acute laryngitis, even though the etiology of infection in most cases is thought to be viral [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/3\">",
"     3",
"    </a>",
"    ]. Hoarseness resulting from an upper respiratory tract infection is often associated with rhinorrhea, cough, and mild sore throat. Acute vocal strain, such as screaming or protracted coughing, can also result in submucosal microtrauma of the vocal fold, with focal edema and hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic laryngitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Irritants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic laryngitis is typically associated with one or more chronic irritants which, over time, lead to persistent inflammation. Examples include inhaled toxins (such as chemical fumes), GERD, chronic sinusitis with postnasal drip, chronic alcohol use, and chronic vocal strain. In addition to increasing the risk of squamous cell carcinoma of the larynx, tobacco smoke irritates the vocal folds and can cause benign changes such as keratosis and polypoid corditis (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Polypoid corditis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Laryngopharyngeal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngopharyngeal reflux (LPR) results from the retrograde movement of gastric contents (acid and enzymes such as pepsin) beyond the upper esophageal sphincter, leading to morphologic and functional changes in the larynx and pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Substantial evidence suggests a relationship between reflux and posterior laryngitis, including interarytenoid hypertrophy and contact ulceration with or without granuloma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"     \"Complications of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link\">",
"     \"Laryngopharyngeal reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common symptoms associated with LPR are throat clearing (98.3 percent), persistent cough (96.6 percent),",
"    <span class=\"nowrap\">",
"     heartburn/dyspepsia",
"    </span>",
"    (95.7 percent), globus sensation (lump in the throat feeling) (94.9 percent), and voice quality change-hoarseness (94.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/4\">",
"     4",
"    </a>",
"    ]. Other symptoms include sore throat, dysphagia, and laryngospasm or choking sensation. Symptoms characteristically vary over time. Reflux esophagitis may not be present in patients with symptomatic reflux affecting the laryngopharynx and testing may not definitively demonstrate the presence of acid. The diagnosis of LPR is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link&amp;anchor=H8#H8\">",
"     \"Laryngopharyngeal reflux\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Muscle tension dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx can be affected by abnormal hyperfunctional mechanisms and imbalance of tension in muscles involved in voice production leading to dysphonia. Muscle tension dysphonia is considered neither a psychological or neurological dystonic disorder.",
"   </p>",
"   <p>",
"    In the primary form of vocal hyperfunction, true vocal fold morphology and motion are observed to be normal. Inappropriate contraction and closure (adduction) of the false vocal folds occurs during phonation, with generation of excessive strain and effort. There may also be contraction of the entire supraglottis, obscuring visualization of the true vocal folds.",
"   </p>",
"   <p>",
"    In the secondary form, false vocal fold compression may be seen as a compensatory mechanism for incompetence at the level of the true vocal folds. Such incomplete closure of the true vocal folds may be due to vocal fold paralysis, atrophy (as seen with aging, where superficial lamina propria is lost from Reinke's space), and mass lesions preventing approximation of the vocal fold edges (such as nodules or polyps).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Benign vocal fold lesions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Polypoid corditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polypoid corditis is also known as Reinke's edema (",
"    <a class=\"graphic graphic_picture graphicRef60165 \" href=\"UTD.htm?22/27/22975\">",
"     picture 1",
"    </a>",
"    ). Viscous material accumulates in the superficial lamina propria (Reinke's space) of the true vocal folds as a result of chronic irritation and inflammation secondary to smoking. The vocal folds appear swollen and &ldquo;floppy&rdquo; and may cause respiratory symptoms in severe cases. The condition is frequently seen in middle-aged women, and causes a husky, low-pitched voice. In these cases, the patient often complains of &ldquo;sounding like a man.&rdquo; A similar clinical appearance can be seen in patients with hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Polyps and nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both polyps and nodules on the vocal fold are manifestations of chronic vocal fold irritation. Etiologic factors include smoking, reflux, and muscle tension dysphonia. Some polyps form following traumatic hemorrhage into the vocal fold from vocal abuse or coughing (\"hemorrhagic polyp\"). Polyps tend to be unilateral, although a contralateral smaller \"contact lesion\" is often seen which arises from damage to the opposing vocal fold in the setting of repeated contact against the primary mass lesion (",
"    <a class=\"graphic graphic_picture graphicRef64623 graphicRef77614 \" href=\"UTD.htm?21/18/21796\">",
"     picture 2A-B",
"    </a>",
"    ). They present in the anterior one-third of the vocal fold and are seen more frequently in men.",
"   </p>",
"   <p>",
"    Nodules are sometimes also called \"singer's\" or \"screamer's\" nodes. They occur bilaterally and generally appear relatively symmetric (",
"    <a class=\"graphic graphic_picture graphicRef73976 \" href=\"UTD.htm?40/14/41199\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/7\">",
"     7",
"    </a>",
"    ]. They are more common in women and children, and are also frequently seen in the setting of vocal abuse. The early nodule is edematous and becomes thickened and fibrotic with ongoing vocal fold microtrauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laryngeal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of laryngeal cancer is squamous cell carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef53676 \" href=\"UTD.htm?28/15/28913\">",
"     picture 4",
"    </a>",
"    ). Major risk factors include smoking and alcohol abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Squamous cell carcinoma is epithelial, arising from the mucosal surface of the larynx, and tends to metastasize to regional cervical nodes. Early lesions may appear initially as white (leukoplakic) plaques; they can be asymptomatic or present with hoarseness depending on location within the larynx. Advanced malignant lesions can be large and exophytic or deeply ulcerative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Neurologic dysfunction",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Unilateral paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral recurrent laryngeal nerve (RLN) injury causes the affected vocal fold to rest in the paramedian (or partially lateralized) position. The glottic airway is usually adequate and airway complaints are rare. The contralateral vocal fold may or may not compensate to provide adequate glottic closure during phonation. If closure is not achieved, the residual glottal gap results in air escape with a weak, breathy voice secondary to a \"leaky valve\" phenomenon. Glottal incompetence also presents risk of aspiration, particularly with thin liquids. Cough, which requires transient tight glottic closure, may be ineffectual. Associated sensory loss (particularly in the case of stroke) may also complicate swallowing.",
"   </p>",
"   <p>",
"    The etiology of unilateral vocal fold paralysis includes: [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/8\">",
"     8",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extra-laryngeal malignancy of the skull base, neck, or thorax invading the vagus or recurrent laryngeal nerve. Vocal fold paralysis in the setting of a thyroid nodule should raise suspicion of invasive thyroid cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iatrogenic injury to the recurrent laryngeal or vagus nerves during procedures in the neck, chest, and skull base (eg, thyroid and parathyroid surgery, carotid endarterectomy, cardiothoracic procedures and anterior cervical approaches to the cervical spine for disk surgery), as well as complication of endotracheal intubation. [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link\">",
"       \"Surgical treatment of differentiated thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neck and chest trauma, or laryngeal trauma.",
"     </li>",
"     <li>",
"      Degenerative neural disorders including bulbar palsies (eg, polio, amyotrophic lateral sclerosis) and demyelinating disease.",
"     </li>",
"     <li>",
"      Approximately one-third of cases are ultimately diagnosed as idiopathic, many of which may be of viral etiology. A review of over 700 cases of idiopathic unilateral paralysis found that complete and partial recovery of motion occurred in approximately 40 percent of patients with complete and partial voice recovery in 60 percent; spontaneous recovery was rare after one year [",
"      <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 20-year retrospective study of causes of vocal fold immobility shows that nonthyroid neck surgery has become the most common cause of vocal fold paralysis over the past ten years, whereas extralaryngeal malignancies had previously been the most common cause [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Bilateral paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral vocal fold paralysis causes a different constellation of symptoms. The bilaterally denervated vocal folds may be positioned near the midline, with a narrow glottic aperture. Voice is usually good with this glottic configuration, but respiratory function can be compromised. Symptoms range from minimal dyspnea or inspiratory stridor to severe respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral vocal fold paralysis is usually iatrogenic, secondary to neck surgery or tracheal intubation. Neurologic disorders, including ALS, diabetic neuropathy, myasthenia gravis, neurologic sequelae of organophosphate pesticide toxicity or therapeutic administration of vinca alkaloids, stroke, head injury, and hydrocephalus or brainstem compression associated with Arnold-Chiari malformation may also be etiologic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Bilateral cricoarytenoid joint fixation can occur in association with rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Spasmodic dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasmodic (previously called spastic) dysphonia is a voice disorder believed to represent a focal laryngeal dystonia and can be associated with other dystonic disorders. The adductor type is most common and is characterized by a halting, strained, strangled voice quality. This is especially notable with vowels and results from uncoordinated forceful adduction during phonation. This occurs intermittently, in contrast to the patient with muscle tension dysphonia. The abductor type of spasmodic dysphonia results in voiceless gaps in speech secondary to dysregulation of vocal fold abduction. Spasmodic dysphonia is not felt to be psychogenic in origin, although many patients report initial onset of symptoms following a stressful life event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Neurologic disease associated with voice disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Parkinson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 to 90 percent of patients with Parkinson disease exhibit laryngeal findings. The voice is typically hypophonic with a soft breathy and monotone quality. Resting vocal fold tremor occurs in about 55 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The finding of vocal fold paralysis should raise the possibility of a Parkinson-related syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Motor neuron diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness secondary to progressive degeneration of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower motor neurons frequently affects the laryngopharyngeal complex, causing dysphagia, aspiration, dysphonia, and vocal fold paralysis. Approximately one quarter of patients with amyotrophic lateral sclerosis (ALS) present with voice or other otolaryngologic symptoms as their initial complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremor is a rhythmic, oscillatory movement occurring at rest or with action. Several primary neurodegenerative disorders, including Parkinson disease and multiple sclerosis, can cause resting and intention laryngeal tremors. Tremors may also occur with stroke and tumor. Approximately 25 to 30 percent of patients with essential tremor have laryngeal tremor; laryngeal tremor may present in isolation, but more commonly occurs with tremor elsewhere in the body [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with myasthenia gravis may develop fluctuating hoarseness, sometimes associated with dysphagia and stridor. The voice tends to fatigue with repetitive use and recover with rest. Rarely, laryngeal symptoms may precede the appearance of ocular symptoms, in which case the diagnosis can be made with an anticholinesterase test [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Functional voice disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Functional dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional dysphonia is impairment of voice production without an identifiable organic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/21\">",
"     21",
"    </a>",
"    ]. Functional dysphonia often affects people in occupations that cause vocal stress, with teachers representing the largest occupational group seeking help in vocal clinics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Laryngeal conversion disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx and throat are potential somatization targets for patients with psychological issues. Findings vary, but patients may present with intermittent episodes of respiratory distress, stridor, hoarseness or aphonia, without a clear-cut diagnosis. Episodes may be triggered by illness such as upper respiratory tract infections or asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Paradoxical vocal cord motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal fold adduction occurring with inspiration and abduction occurring with expiration results in marked inspiratory stridor and can be mistaken for asthmatic wheezing. Paradoxical vocal cord motion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Leukoplakia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukoplakia is a clinical description of a white lesion representing a thickened patch of epithelium. Focal leukoplakic lesions may be benign (keratosis), precancerous (dysplasia), or frankly malignant and require biopsy for definitive tissue diagnosis. Benign lesions typically result from chronic exposure to smoking, alcohol, vocal strain, chemical irritants, and GERD.",
"   </p>",
"   <p>",
"    A keratotic lesion implies the development of keratin on the normally non-keratinized stratified squamous epithelium of the vocal cord. Lesions with increasing degrees of atypia carry an increased risk of developing carcinoma. Approximately 2 to 10 percent of keratotic lesions ultimately develop into carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Laryngeal amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal amyloidosis most often represents a localized form of amyloidosis, though can occasionally be associated with systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/22\">",
"     22",
"    </a>",
"    ]. Laryngeal amyloidosis usually causes hoarseness or progressive dysphonia, though patients may also present with dyspnea, cough, stridor, odynophagia, and rarely hemoptysis. Laryngeal examination typically reveals a firm orange-yellow to grey epithelial nodule. Primary treatment is with endoscopic microsurgical removal of deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term follow-up is important, as localized disease may be slowly progressive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/23\">",
"     23",
"    </a>",
"    ]. Patient evaluation should include blood and urine tests to exclude systemic amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Infections and inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory or infectious disorders of the neck, skull base and mediastinum, including radiation-induced fibrosis and tuberculosis, may cause unilateral vocal fold paralysis. Vocal fold paralysis can also be seen following viral upper respiratory tract infection. Unilateral vocal fold paralysis associated with herpesvirus infection has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammatory conditions, such as rheumatoid arthritis, can arise in the cricoarytenoid joints, resulting in joint fixation with vocal fold immobility. Rheumatoid nodules can also be seen on the true vocal folds.",
"   </p>",
"   <p>",
"    Wegener's granulomatosis and sarcoid can also affect the larynx.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864174232\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864174261\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of a voice disorder should include the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duration of voice complaints",
"     </li>",
"     <li>",
"      Character of onset (ie, sudden or gradually progressive) and pattern (ie, worse with voice use or worse in the morning upon arising)",
"     </li>",
"     <li>",
"      Potential triggering factors (vocal abuse, concurrent upper respiratory tract infection, change in medications, exposure to known allergens or toxins)",
"     </li>",
"     <li>",
"      Exacerbating and ameliorating factors, such as improvement with voice rest, or fatigue with use",
"     </li>",
"     <li>",
"      Other head and neck symptoms (eg, dysphagia, otalgia, odynophagia, bleeding, postnasal drip)",
"     </li>",
"     <li>",
"      History of smoking and alcohol use",
"     </li>",
"     <li>",
"      History of reflux or sinonasal disease",
"     </li>",
"     <li>",
"      History of past surgery involving the neck (especially thyroid, carotid, and cervical spine), base of skull, or chest",
"     </li>",
"     <li>",
"      History of trauma or endotracheal intubation",
"     </li>",
"     <li>",
"      Occupation, hobbies, and habits impacting voice use",
"     </li>",
"     <li>",
"      Medical comorbidities which may affect voice (eg, rheumatoid arthritis or tremor)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms that raise a flag for underlying malignancy, when not associated with an acute respiratory infection, include shortness of breath, stridor, cough, hemoptysis, throat pain, dysphagia, odynophagia, and weight loss. A history of smoking and alcohol use increases the risk for squamous cell carcinoma of the larynx. Referred ear pain via cranial nerves IX and X may represent one of the first symptoms of laryngopharyngeal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864174268\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should begin by noting the quality of the patient's voice. Many voice disturbances are typically described by the catch-all term \"hoarseness,\" but should be more critically evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hoarseness is a coarse, scratchy sound that frequently correlates with irregularity of the medial, or vibratory, edge of the true vocal fold. Underlying pathology may relate to laryngitis, an early vocal fold malignancy, a benign mass lesion, vocal fold hemorrhage, or mucosal disruption.",
"     </li>",
"     <li>",
"      Breathiness is a term describing the perception of excessive air escape during phonation, in which the voice sounds or feels \"weak\". This is usually secondary to incomplete closure of the vocal folds, as seen with vocal fold paralysis, atrophy, mass lesions preventing contact of the vocal fold edges, and pathology of the cricoarytenoid joint.",
"     </li>",
"     <li>",
"      Vocal fatigue refers to degradation in vocal quality and loss of control of vocal quality with extended periods of voice use. This can be secondary to local anatomic or physiological factors at the level of the vocal folds; poor vocal technique with misuse of neck or abdominal musculature; or systemic conditions such as dehydration, neuromuscular disorders, generalized malaise, or de-conditioning.",
"     </li>",
"     <li>",
"      The voice may sound wet, gurgling, full, or \"hot-potato-like\", as with peritonsillar abscess or supraglottic tumor mass with salivary pooling.",
"     </li>",
"     <li>",
"      The voice may exhibit a tremulous quality, and tremor may be seen on exam. Inability to produce any sound is described as aphonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not absolutely definitive, various voice qualities may correlate with underlying etiologies for the voice disorder.",
"   </p>",
"   <p>",
"    The physical examination should include an assessment of the ears, upper airway mucosa, oral cavity (including tongue mobility), cranial nerve function, and respiration. Systemic diseases should be considered when suggested by symptoms or examination, including hypothyroidism, neurologic conditions such as tremor, Parkinson disease, amyotrophic lateral sclerosis, or multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hoarseness persisting for more than two weeks, in the absence of symptoms of an acute respiratory infection, should have a complete head and neck examination with visualization of the laryngopharynx by an otolaryngologist. This may be performed on the awake patient by indirect laryngoscopy using a mirror or via transnasal or transoral laryngoscopy with a digital or fiberoptic endoscope. In some cases, examination under general anesthesia may be necessary.",
"   </p>",
"   <p>",
"    The examination should emphasize complete visualization of the true and false vocal folds, epiglottis, pyriform sinus, and vallecula. CT scanning or other radiographic evaluation is not a substitute for direct laryngeal examination, although may serve as a valuable adjunct. Additional evaluation of the vibratory characteristics of the vocal fold may be necessary, which is most commonly achieved using high-magnification endoscopy under stroboscopic lighting (strobovideolaryngoscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295003\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for hoarseness vary depending on the underlying etiology. Treatment generally consists of voice rest, voice therapy, pharmacotherapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Voice rest is used&nbsp;for acute laryngitis, vocal fold hemorrhage, and&nbsp;other conditions where there is acute&nbsp;laryngeal edema&nbsp;and&nbsp;swelling. During voice rest, patients refrain from abusive vocal behaviors to prevent further damage to the vocal folds from fibrosis and scarring.&nbsp;Duration ranges from one week to several weeks depending on the problem and balancing other issues such as patient needing to use their voice for work.&nbsp;",
"   </p>",
"   <p>",
"    Voice therapy involves teaching techniques to minimize harmful behaviors and altering voice production. One aim of therapy is to enable the patient to functionally adapt to laryngeal pathology that may be unalterable, such as vocal fold scarring. Voice therapy may be effective for select conditions such as vocal cord nodules and functional voice disorders.",
"   </p>",
"   <p>",
"    Pharmacologic therapy includes antibiotics, glucocorticoids, mucolytics, antireflux medication, and nonsteroidal anti-inflammatory drugs. These drugs are usually used as ancillary therapy.",
"   </p>",
"   <p>",
"    Surgical interventions include but are not limited to microlaryngoscopy with endolaryngeal excision, open neck procedures, and office-based procedures (eg, injections, laser treatments).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295011\">",
"    <span class=\"h2\">",
"     Acute laryngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute laryngitis resolves without specific treatment other than hydration, humidification, and voice rest.",
"   </p>",
"   <p>",
"    Antibiotics for acute laryngitis are usually unnecessary and may lead to bacterial resistance. A systematic review of studies evaluating antibiotics for acute laryngitis found only two randomized trials that met inclusion criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/30\">",
"     30",
"    </a>",
"    ]. One of these trials found no difference in time to voice recovery in patients randomly assigned to penicillin or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/31\">",
"     31",
"    </a>",
"    ]. The second trial found no difference in objective voice scores between patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or placebo; however, subjective reports of voice and cough improvement at one week favored erythromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/32\">",
"     32",
"    </a>",
"    ]. While antibiotic therapy may shorten the course of the voice complaints slightly, acute voice symptoms generally respond within one week regardless of therapy. Thus, antibiotics are not indicated unless there is clear evidence of coexistent bacterial pharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/3,32\">",
"     3,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic glucocorticoids have a limited role in the treatment of acute laryngitis, and should be reserved for patients who have a pressing need to use their voice (eg, professional speaking engagement or vocal performance). Although clinical experience suggests that the administration of steroids can lead to rapid resolution of vocal fold inflammation and an improvement in vocal quality, there are no randomized trials of steroid use for laryngitis in adults. Glucocorticoid use should be balanced by the adverse systemic effects of steroids, as well as the risk of masking underlying vocal fold pathology. If the performer strains an already compromised larynx, it can lead to vocal fold hemorrhage with the potential for permanent scarring and voice change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295032\">",
"    <span class=\"h2\">",
"     Chronic laryngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic laryngitis due to irritants generally resolves with removal of the offending agent.",
"   </p>",
"   <p>",
"    Treatment of chronic laryngitis due to laryngopharyngeal reflux is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link&amp;anchor=H14#H14\">",
"     \"Laryngopharyngeal reflux\", section on 'Treatment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Muscle tension dysphonia may be amenable to voice therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/33\">",
"     33",
"    </a>",
"    ]. A typical course of voice therapy includes retraining of the vocal muscles, education regarding proper care of the voice (vocal hygiene), and avoidance of counterproductive vocal behaviors, such as yelling or straining to speak over background noise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295089\">",
"    <span class=\"h2\">",
"     Benign vocal cord lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for polypoid corditis includes smoking cessation, reflux management, and voice therapy. Surgical",
"    <span class=\"nowrap\">",
"     debulking/recontouring",
"    </span>",
"    may be necessary in certain cases or when focal irregularity warrants biopsy.",
"   </p>",
"   <p>",
"    The treatment of polyps usually requires surgery, whereas treatment for nodules is aimed at correcting vocal strain and maladaptive vocal habits, and usually does not require surgery. Surgery is generally reserved for cases in which vocal quality is judged to be inadequate following voice therapy. A 2012 systematic review found no randomized trials that compared the effectiveness of surgical versus nonsurgical management for vocal cord nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295096\">",
"    <span class=\"h2\">",
"     Laryngeal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five-year cure rate is over 90 percent for small, early stage vocal fold lesions, with laryngeal and voice preservation. Cure rates are reduced by half once the lesion metastasizes to regional cervical lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295151\">",
"    <span class=\"h2\">",
"     Vocal fold paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recurrent laryngeal nerve that has been surgically transected or infiltrated with malignancy will not resume function. However, speech and swallowing therapy can be helpful by developing compensatory behaviors. In nerves that have sustained bruising or stretch injury without transection (neuropraxia), function generally returns within six months to one year. Laryngeal EMG can offer prognostic information regarding the likelihood of return of function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711973954\">",
"    <span class=\"h3\">",
"     Unilateral paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical procedures are available for unilateral fold paralysis to reposition (medialize) the immobile vocal fold in order to achieve adequate glottal closure and improve voice as well as swallowing and cough [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/35\">",
"     35",
"    </a>",
"    ]. Techniques include transoral or transcervical injection (injection laryngoplasty) of permanent or resorbable material, such as autologous fat, collagen, hyaluronic acid, or hydroxylapatite, lateral to the vocal fold. Medialization thyroplasty involves transcervical placement of an implant (usually silicone or Gortex) through a surgically created window in the thyroid cartilage. Laryngeal reinnervation has also been performed with varying degrees of success [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711973961\">",
"    <span class=\"h3\">",
"     Bilateral paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of bilateral vocal fold paralysis primarily relates to the need to provide an adequate airway. Procedures to widen the airway are usually performed at the expense of vocal quality. Available treatments include tracheotomy, vocal fold lateralization, resection of a portion of the posterior vocal fold",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arytenoid, and laryngeal reinnervation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295232\">",
"    <span class=\"h3\">",
"     Spasmodic dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Voice therapy is generally not effective. Injection of botulinum toxin into the affected laryngeal muscles helps to reduce severity of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, retreatment is typically required every three to six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711973989\">",
"    <span class=\"h2\">",
"     Neurologic disease associated with voice disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for voice disorders associated with neurologic disease is aimed at the underlying illness. For Parkinson disease, the mainstay of treatment is behaviorally-based intensive voice therapy (Lee Silverman Voice Treatment, or LSVT), designed to improve loudness by increasing phonatory effort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H292295239\">",
"    <span class=\"h2\">",
"     Functional dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of six randomized trials in patients with functional dysphonia found that voice therapy, compared with no intervention, improved perceived and objective measures of vocal function that persisted for at least 14 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16009/abstract/21\">",
"     21",
"    </a>",
"    ]. Prophylactic voice therapy for high risk occupations was not effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864174329\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hoarseness that lasts for more than two weeks, in the absence of symptoms of an acute upper respiratory infection, requires a complete otolaryngologic examination to rule out potentially serious causes such as malignancy. This is particularly a concern in patients with a history of tobacco or alcohol use who are at high risk for cancer of the head and neck.",
"   </p>",
"   <p>",
"    Patients with associated symptoms concerning for malignancy should also be referred to an otolaryngologist. (See",
"    <a class=\"local\" href=\"#H864174232\">",
"     'Clinical evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/29/26066?source=see_link\">",
"       \"Patient information: Laryngitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The laryngopharynx is composed of a cartilage framework, true and false vocal folds, extrinsic and intrinsic muscles, a neurovascular supply, and overlying soft tissues. It functions to allow phonation, valsalva, airway patency during respiration, and airway protection during swallowing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomy of the larynx'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shortness of breath, stridor, cough, hemoptysis, throat pain, difficulty swallowing, unilateral otalgia, and weight loss in a patient with voice symptoms raise concern for cancer. (See",
"      <a class=\"local\" href=\"#H864174232\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of sustained hoarseness is broad and includes infection, laryngeal irritants, benign vocal fold lesions, laryngeal cancer, neurologic dysfunction, and functional disorders. Evaluation by an otolaryngologist with direct visualization of the vocal folds is necessary to determine the etiology and treatment of voice disorders. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Causes of hoarseness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of hoarseness depends on the underlying cause. Treatment options include removal of offending agents, voice therapy, medications, treatment of underlying systemic disease, and surgery. (See",
"      <a class=\"local\" href=\"#H292295003\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute laryngitis, associated with an upper respiratory infection or acute vocal strain, generally lasts less than three weeks. We recommend not treating patients with antibiotics for acute laryngitis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Acute laryngitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical observation suggests that a course of oral glucocorticoids can speed the resolution of acute laryngitis, although this may increase the risk of additional vocal fold damage, such as scarring or hemorrhage. In certain circumstances (professional singers or speakers), it may be appropriate to offer such therapy with informed consent and is best managed by a specialist in voice disorders. For all other patients, we recommend not treating patients with glucocorticoids for acute laryngitis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Acute laryngitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hoarseness that lasts for more than two weeks, in the absence of symptoms of an acute upper respiratory infection, requires a complete otolaryngologic examination, particularly in patients with a history of tobacco or alcohol use. (See",
"      <a class=\"local\" href=\"#H864174329\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Citardi MJ, Gracco CL, Sasaki CT. The anatomy of the human larynx. In: Diagnosis and Treatment of Voice Disorders, Rubin JS, Sataloff RT, Korovin GS, Gould GS, Gould (Eds), Igaku-Shoin, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/2\">",
"      Schwartz SR, Cohen SM, Dailey SH, et al. Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg 2009; 141:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/3\">",
"      Reveiz L, Cardona AF, Ospina EG. Antibiotics for acute laryngitis in adults. Cochrane Database Syst Rev 2007; :CD004783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/4\">",
"      Remacle M, Lawson G. Diagnosis and management of laryngopharyngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/5\">",
"      Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/6\">",
"      Cherry J, Margulies SI. Contact ulcer of the larynx. Laryngoscope 1968; 78:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/7\">",
"      Bouchayer M, Cornut G. Microsurgery for benign lesions of the vocal folds. Ear Nose Throat J 1988; 67:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/8\">",
"      Havas T, Lowinger D, Priestley J. Unilateral vocal fold paralysis: causes, options and outcomes. Aust N Z J Surg 1999; 69:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/9\">",
"      Randolph GW, Kamani D. The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy. Surgery 2006; 139:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/10\">",
"      Baron EM, Soliman AM, Gaughan JP, et al. Dysphagia, hoarseness, and unilateral true vocal fold motion impairment following anterior cervical diskectomy and fusion. Ann Otol Rhinol Laryngol 2003; 112:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/11\">",
"      Sulica L. The natural history of idiopathic unilateral vocal fold paralysis: evidence and problems. Laryngoscope 2008; 118:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/12\">",
"      Ramadan HH, Wax MK, Avery S. Outcome and changing cause of unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 1998; 118:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/13\">",
"      Rosenthal LH, Benninger MS, Deeb RH. Vocal fold immobility: a longitudinal analysis of etiology over 20 years. Laryngoscope 2007; 117:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/14\">",
"      Ishman SL, Halum SL, Patel NJ, et al. Management of vocal paralysis: a comparison of adult and pediatric practices. Otolaryngol Head Neck Surg 2006; 135:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/15\">",
"      Yin SS, Qiu WW, Stucker FJ, et al. Evaluation of bilateral vocal fold dysfunction: paralysis versus fixation, superior versus recurrent, and distal versus proximal to the laryngeal nerves. Am J Otolaryngol 1997; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/16\">",
"      Bosley B, Rosen CA, Simpson CB, et al. Medial arytenoidectomy versus transverse cordotomy as a treatment for bilateral vocal fold paralysis. Ann Otol Rhinol Laryngol 2005; 114:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/17\">",
"      Merati AL, Heman-Ackah YD, Abaza M, et al. Common movement disorders affecting the larynx: a report from the neurolaryngology committee of the AAO-HNS. Otolaryngol Head Neck Surg 2005; 133:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/18\">",
"      Sewall GK, Jiang J, Ford CN. Clinical evaluation of Parkinson's-related dysphonia. Laryngoscope 2006; 116:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/19\">",
"      Kent RD, Kent JF, Weismer G, et al. Impairment of speech intelligibility in men with amyotrophic lateral sclerosis. J Speech Hear Disord 1990; 55:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/20\">",
"      Liu WB, Xia Q, Men LN, et al. Dysphonia as a primary manifestation in myasthenia gravis (MG): a retrospective review of 7 cases among 1520 MG patients. J Neurol Sci 2007; 260:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/21\">",
"      Ruotsalainen J, Sellman J, Lehto L, Verbeek J. Systematic review of the treatment of functional dysphonia and prevention of voice disorders. Otolaryngol Head Neck Surg 2008; 138:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/22\">",
"      Bartels H, Dikkers FG, van der Wal JE, et al. Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapy. Ann Otol Rhinol Laryngol 2004; 113:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/23\">",
"      Alaani A, Warfield AT, Pracy JP. Management of laryngeal amyloidosis. J Laryngol Otol 2004; 118:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/24\">",
"      Motta G, Salzano FA, Motta S, Staibano S. CO(2)-laser treatment of laryngeal amyloidosis. J Laryngol Otol 2003; 117:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/25\">",
"      Bachor E, Bonkowsky V, Hacki T. Herpes simplex virus type I reactivation as a cause of a unilateral temporary paralysis of the vagus nerve. Eur Arch Otorhinolaryngol 1996; 253:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/26\">",
"      Parano E, Pavone L, Musumeci S, et al. Acute palsy of the recurrent laryngeal nerve complicating Epstein-Barr virus infection. Neuropediatrics 1996; 27:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/27\">",
"      Rosen CA, Anderson D, Murry T. Evaluating hoarseness: keeping your patient's voice healthy. Am Fam Physician 1998; 57:2775.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnosis and Treatment of Voice Disorders, Rubin JS, Sataloff RT, Korovin GS (Eds), Plural Publishing, San Diego 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/29\">",
"      Sulica L. Hoarseness. Arch Otolaryngol Head Neck Surg 2011; 137:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/30\">",
"      Reveiz L, Cardona AF. Antibiotics for acute laryngitis in adults. Cochrane Database Syst Rev 2013; 3:CD004783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/31\">",
"      Schal&eacute;n L, Christensen P, Eliasson I, et al. Inefficacy of penicillin V in acute laryngitis in adults. Evaluation from results of double-blind study. Ann Otol Rhinol Laryngol 1985; 94:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/32\">",
"      Schal&eacute;n L, Eliasson I, Kamme C, Schal&eacute;n C. Erythromycin in acute laryngitis in adults. Ann Otol Rhinol Laryngol 1993; 102:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/33\">",
"      Ruotsalainen JH, Sellman J, Lehto L, et al. Interventions for treating functional dysphonia in adults. Cochrane Database Syst Rev 2007; :CD006373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/34\">",
"      Pedersen M, McGlashan J. Surgical versus non-surgical interventions for vocal cord nodules. Cochrane Database Syst Rev 2012; 6:CD001934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/35\">",
"      Montgomery WW, Montgomery SK. Montgomery thyroplasty implant system. Ann Otol Rhinol Laryngol Suppl 1997; 170:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/36\">",
"      Aynehchi BB, McCoul ED, Sundaram K. Systematic review of laryngeal reinnervation techniques. Otolaryngol Head Neck Surg 2010; 143:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/37\">",
"      Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord 1998; 33 Suppl:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16009/abstract/38\">",
"      Troung DD, Rontal M, Rolnick M, et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991; 101:630.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6851 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16009=[""].join("\n");
var outline_f15_40_16009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LARYNGEAL ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anatomy of the larynx",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cartilages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Vocal folds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Extrinsic and intrinsic muscles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nerve supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Phonation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CAUSES OF HOARSENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute laryngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic laryngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Irritants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Muscle tension dysphonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Benign vocal fold lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Polypoid corditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Polyps and nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laryngeal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Neurologic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Unilateral paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Bilateral paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Spasmodic dysphonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Neurologic disease associated with voice disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Motor neuron diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Tremor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Functional voice disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Functional dysphonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Laryngeal conversion disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Leukoplakia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Laryngeal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Infections and inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864174232\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H864174261\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H864174268\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H292295003\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H292295011\">",
"      Acute laryngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H292295032\">",
"      Chronic laryngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H292295089\">",
"      Benign vocal cord lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H292295096\">",
"      Laryngeal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H292295151\">",
"      Vocal fold paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H711973954\">",
"      - Unilateral paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H711973961\">",
"      - Bilateral paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H292295232\">",
"      - Spasmodic dysphonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H711973989\">",
"      Neurologic disease associated with voice disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H292295239\">",
"      Functional dysphonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864174329\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6851|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/1/24599\" title=\"figure 1\">",
"      Laryngeal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/23/15733\" title=\"figure 2\">",
"      Laryngeal musculature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6851|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/27/22975\" title=\"picture 1\">",
"      Reinkes edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/6/26720\" title=\"picture 2A\">",
"      Left vocal fold polyp A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/58/24495\" title=\"picture 2B\">",
"      Left vocal fold polyp B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/14/41199\" title=\"picture 3\">",
"      Vocal fold nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/15/28913\" title=\"picture 4\">",
"      Vocal fold squamous ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4102?source=related_link\">",
"      Evaluation of the child with hoarseness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/29/26066?source=related_link\">",
"      Patient information: Laryngitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_40_16010="Etiology of hypoglycemia in infants and children";
var content_f15_40_16010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology of hypoglycemia in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16010/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16010/contributors\">",
"     Agneta Sunehag, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16010/contributors\">",
"     Morey W Haymond, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16010/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16010/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/40/16010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/40/16010/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/40/16010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary disorders caused by a deficiency of specific enzymes involved in mobilization, interconversion, or utilization of metabolic substrates frequently are associated with hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"     1",
"    </a>",
"    ]. These enzymatic defects may involve carbohydrate, amino acid, or fat metabolism and are individually rare; almost all are inherited as autosomal recessive traits. Because of the interactions of fat, carbohydrate, and amino acid metabolism in the maintenance of normal fuel homeostasis, abnormalities in the metabolism of a single substrate can have primary and secondary effects on other metabolic pathways. A common expression of these derangements is the development of biochemical or symptomatic hypoglycemia. If hypoglycemia is not promptly recognized in children, they may develop symptoms and suffer permanent neurologic sequelae.",
"   </p>",
"   <p>",
"    The etiology of hypoglycemia in infants and children will be presented here. The approach to hypoglycemia in infants and children and to hypoglycemia in neonates is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hypoglycemia to occur, the rate of appearance of glucose into the plasma space must be less than its rate of utilization. This can be due to defective glucose production, increased glucose utilization, or some combination of the two. In many cases of hypoglycemia, a clear pathophysiologic mechanism cannot be assigned. However, we would encourage the reader to envision mechanisms that would lead to an imbalance in the rate of glucose production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucose utilization based on known physiologic principles that we believe are fundamental to glucose homeostasis in infants, children, and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DISORDERS OF CARBOHYDRATE METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of carbohydrate metabolism that can lead to hypoglycemia include deficiencies of hepatic enzymes in the pathways of the metabolism of glycogen (",
"    <a class=\"graphic graphic_table graphicRef51949 \" href=\"UTD.htm?42/46/43756\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71999 \" href=\"UTD.htm?34/38/35436\">",
"     table 2",
"    </a>",
"    ), galactose, and fructose.",
"   </p>",
"   <p>",
"    The time of onset of hypoglycemia in relation to the last meal may provide a clue to the diagnosis. Patients with galactosemia or hereditary fructose intolerance become hypoglycemic within several hours of ingestion of galactose or fructose, respectively. Patients with hepatic enzyme deficiencies of glycogenolysis and gluconeogenesis typically become symptomatic between 2 and 20 hours after the last meal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Disorders of glycogenolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of glycogen metabolism should be considered in patients who present with fasting hypoglycemia and mild to moderate ketosis, with or without hepatomegaly, and whose symptoms improve with eating or glucose administration. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glycogen synthetase deficiency (glycogen storage disease type 0, GSD 0)",
"     </li>",
"     <li>",
"      Absolute or functional glucose-6-phosphatase deficiency (GSD Ia and Ib) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Debrancher enzyme (amylo-1,6 glucosidase) deficiency (GSD III)",
"     </li>",
"     <li>",
"      Phosphorylase deficiency (GSD VI)",
"     </li>",
"     <li>",
"      Phosphorylase kinase deficiency &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The GSD are discussed in detail separately. Highlights of the clinical features of the GSD in which hypoglycemia is a prominent clinical feature are summarized below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Glycogen synthetase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen storage disease type 0 (GSD 0,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/240600\">",
"     MIM #420600",
"    </a>",
"    ) is caused by deficiency of glycogen synthetase (glycogen synthase), which catalyzes the rate-limiting step by forming the alpha 1,4 glycosyl bonds that create the linear polymers of glucose in glycogen.",
"   </p>",
"   <p>",
"    Clinical features include preprandial ketotic hypoglycemia (especially after overnight fasting) and postprandial hyperglycemia and lactic acidemia. Hepatomegaly is absent. Hypoglycemia in neonates may be severe. Morning fatigue, relieved by eating, may be the presenting symptom in older children. The differential diagnosis includes ketotic hypoglycemia, early diabetes mellitus (because of the episodic hyperglycemia), and stress hyperglycemia. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Ketotic hypoglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by mutation analysis of the GYS2 gene on leukocyte DNA. Recommended treatment involves frequent protein-rich meals, avoidance of fasting, and administration of uncooked cornstarch (a complex glucose polymer that is slowly digested over a two- to six-hour period) before bedtime. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6836?source=see_link\">",
"     \"Liver glycogen synthase deficiency (glycogen storage disease 0)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Glucose-6-phosphatase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen storage disease type I (GSD I) is caused by deficiency of hepatic glucose-6-phosphatase, as the hydrolysis of glucose-6-phosphate is the final common enzymatic event in the hepatic release of glucose from gluconeogenic and glycogenolytic pathways (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ). There are two subtypes of GSD type I: Ia and Ib. Type Ia (von Gierke disease,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/232200\">",
"     MIM #232200",
"    </a>",
"    ) accounts for 80 percent of cases and is caused by deficiency in glucose 6-phosphate hydrolase activity. GSD type Ib (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/232200\">",
"     MIM #232220",
"    </a>",
"    ) is a defect in the microsomal transport of glucose-6-phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Glucose-6-phosphatase deficiency usually results in severe hypoglycemia after a brief fast or in the usual interval between meals. It is associated with marked lactic acidosis (from the metabolism of glucose-6-phosphate) and ketosis. Additional clinical features include hepatomegaly, growth retardation, delayed puberty, hyperuricemia, platelet dysfunction, and hyperlipidemia (particularly hypertriglyceridemia, which can lead to xanthoma formation and pancreatitis). Glycogen accumulation in the kidney causes nephromegaly, and inadequately treated patients may develop progressive renal disease, proteinuria, and hypertension due to focal segmental glomerulosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link&amp;anchor=H21#H21\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\", section on 'Renal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with GSD type Ib present with identical clinical and biochemical findings, but also have chronic or intermittent neutropenia and neutrophil dysfunction, and are susceptible to recurrent infections. GSD type Ib also is associated with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type I GSD should be suspected in patients who have hypoglycemia, lactic acidemia, hyperlipidemia, and hepatomegaly with or without neutropenia. The first step in confirming the diagnosis is DNA testing for common mutations. If none is identified, a liver biopsy should be performed.",
"   </p>",
"   <p>",
"    The goal of treatment is the maintenance of normal glucose levels. Other biochemical parameters, such as lactic acidemia and hypertriglyceridemia, frequently improve in parallel with improved glucose control. Glucose concentrations are maintained with frequent administration of uncooked cornstarch (UCS). A high-protein diet is",
"    <strong>",
"     not",
"    </strong>",
"    useful in patients with GSD I because glucose-6-phosphate also is required in the final step of gluconeogenesis. The treatment of GSD I is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Debrancher deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen storage disease type III (GSD III, also known as debrancher deficiency, Cori disease, and Forbes disease,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/232400\">",
"     MIM #232400",
"    </a>",
"    ), is caused by deficiency of amylo-1,6-glucosidase, 4-alpha-glucanotransferase. A large number of genetic defects have been identified in many of the exons of the debrancher enzyme gene. The enzyme defect may be isolated to the liver or present in both liver and muscle. The clinical features depend upon the involved tissue(s). Only those with hepatic involvement present with hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13861?source=see_link\">",
"     \"Glycogen debrancher deficiency (glycogen storage disease III)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Debrancher deficiency may present during infancy and childhood with hepatomegaly, \"ketotic\" hypoglycemia, and growth retardation. Hypoglycemia may be milder than in type I GSD because hepatic gluconeogenesis is preserved and defects in glycogenolysis are rarely complete; asymptomatic hepatomegaly may be the only finding. Additional manifestations, when muscle is involved, include weakness and wasting of skeletal muscle and involvement of the heart.",
"   </p>",
"   <p>",
"    Biochemical features include fasting ketosis, hyperlipidemia, and elevated transaminases; plasma creatine kinase is elevated in patients with muscle involvement. Diagnosis is confirmed by mutation analysis.",
"   </p>",
"   <p>",
"    Symptomatic treatment involves avoidance of hypoglycemia by frequent administration of cornstarch",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    continuous nighttime feedings. Because gluconeogenesis is preserved, a high-protein diet can be of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13861?source=see_link\">",
"     \"Glycogen debrancher deficiency (glycogen storage disease III)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hepatic phosphorylase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen storage disease type VI (GSD VI,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/232700\">",
"     MIM #232700",
"    </a>",
"    ), also known as Hers disease, is caused by deficiency of hepatic phosphorylase.",
"   </p>",
"   <p>",
"    Clinical features include presentation in early childhood with growth retardation and hepatomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/5\">",
"     5",
"    </a>",
"    ]. Most patients have mild hypoglycemia, hyperlipidemia, ketosis, and mildly elevated transaminases; plasma concentrations of lactic acid and uric acid are usually normal. The diagnosis is confirmed by mutation analysis.",
"   </p>",
"   <p>",
"    Treatment may not be necessary if the child is asymptomatic and growing normally. However, patients with symptomatic hypoglycemia should have frequent high-carbohydrate feedings and those with nocturnal ketosis and poor growth benefit from supplementation of uncooked cornstarch at bedtime. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20916?source=see_link\">",
"     \"Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hepatic phosphorylase b kinase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphorylase b kinase is required for the activation of phosphorylase and the conversion of glycogen synthase from a more to a less active form. Because of these activities, glycogen degradation is active when glycogen synthesis is inactive, and vice versa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25237?source=see_link\">",
"     \"Phosphorylase b kinase deficiency\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Most cases of hepatic phosphorylase kinase deficiency are relatively mild. Clinical features include presentation in early childhood with growth retardation, hepatomegaly, and sometimes hypoglycemia.",
"   </p>",
"   <p>",
"    Biochemical features include fasting ketosis, and elevated plasma concentrations of cholesterol and triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/6\">",
"     6",
"    </a>",
"    ]. The response to a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    challenge in these patients is usually normal. The diagnosis is confirmed by mutation analysis.",
"   </p>",
"   <p>",
"    Treatment is usually not necessary because of the typically mild course. However, patients with hypoglycemia should have frequent high-carbohydrate feedings, and those with nocturnal ketosis and poor growth benefit from supplementation of uncooked cornstarch at bedtime.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Disorders of gluconeogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children who have disorders of gluconeogenesis develop ketotic hypoglycemia and lactic acidosis after fasting long enough to deplete hepatic glycogen stores. Thus, in the fasted state, they have no response to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Gluconeogenesis is impaired by deficiency of hepatic enzymes, alcohol intoxication, and salicylate poisoning, and possibly by lack of substrate (eg, galactose, fructose, and amino acids). Hepatic enzyme deficiencies (",
"    <a class=\"graphic graphic_table graphicRef71999 \" href=\"UTD.htm?34/38/35436\">",
"     table 2",
"    </a>",
"    ) are discussed in this section. Other causes of impaired gluconeogenesis (galactosemia, hereditary fructose intolerance, and disorders of amino acid metabolism) are discussed separately. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Galactosemia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Hereditary fructose intolerance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Disorders of amino acid metabolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Important enzymes in the gluconeogenetic pathway include (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glucose-6-phosphatase, which is discussed above because it is also involved in glycogenolysis (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Glucose-6-phosphatase deficiency'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Fructose 1,6, bisphosphatase",
"     </li>",
"     <li>",
"      Pyruvate carboxylase",
"     </li>",
"     <li>",
"      Phosphoenolpyruvate carboxykinase (PEPCK)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fructose 1,6, bisphosphatase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fructose 1,6, bisphosphatase deficiency (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/229700\">",
"     MIM #229700",
"    </a>",
"    , also known as fructose 1,6 diphosphatase deficiency) is a rare autosomal recessive disorder that results in impaired gluconeogenesis; glycogenolysis is not affected. Because glycogenolysis is intact, hypoglycemia occurs only during caloric restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of fructose 1.6, bisphosphatase deficiency are similar to those of GSD type I (eg, failure to thrive and fasting-induced hypoglycemia, lactic acidosis, ketosis, hyperlipidemia, and hyperuricemia). However, because glycogenolysis is normal, glycogen accumulation does not occur. Hepatomegaly is typically mild (and a result of lipid accumulation rather than glycogen storage). Liver function studies also are typically normal.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     Glucagon",
"    </a>",
"    administration produces a rise in plasma glucose only in the immediate postprandial period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of fructose 1.6, bisphosphatase deficiency can be supported by provocative testing (a glycemic response is seen after administration of galactose, but not with fructose, alanine, or glycerol) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/9\">",
"     9",
"    </a>",
"    ]. However, liver biopsy, confirming decreased enzyme activity or mutation analysis is necessary for definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fructose 1.6, bisphosphatase deficiency is treated with a high-carbohydrate diet and frequent feeding. These measures usually can prevent hypoglycemia and lactic acidosis, permitting normal growth and development. However, catabolic stress (eg, infection, burns) can cause life-threatening lactic acidosis, ketoacidosis, and hypoglycemia, requiring hospitalization for parenteral glucose administration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pyruvate carboxylase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyruvate carboxylase converts pyruvate to oxaloacetate. This is the first enzymatic step of gluconeogenesis from three-carbon precursors such as pyruvate, lactate, and alanine (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinical features of pyruvate carboxylase deficiency (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/266150\">",
"     MIM #266150",
"    </a>",
"    ) include severe developmental delay, subacute necrotizing encephalopathy, and death in early infancy. Hypoglycemia is an inconsistent finding. Biochemical manifestations of pyruvate carboxylase deficiency include metabolic acidosis, ketonuria, and elevated plasma concentrations of lactate, pyruvate, and alanine. The long-term prognosis is poor. Therapy with high doses of citrate and aspartate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/13\">",
"     13",
"    </a>",
"    ] or liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/14\">",
"     14",
"    </a>",
"    ] has been reported to improve metabolic control but have little effect on the neurologic outcome. A somewhat milder phenotype has been described, with less severe biochemical and neurologic abnormalities. However, affected individuals die in infancy or childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     PEPCK deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphoenolpyruvate carboxykinase (PEPCK) is the rate-limiting enzyme in gluconeogenesis. A small number of cases of PEPCK deficiency (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/261650\">",
"     MIM 261650",
"    </a>",
"    ) have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/10,16\">",
"     10,16",
"    </a>",
"    ], and hypoglycemia was a consistent finding in these cases. Descriptions of other biochemical findings are limited; reported findings during acute episodes include lactic acidosis with or without ketosis; elevated plasma concentration of alanine, aminotransferases, and lipids; and abnormal coagulation studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/10\">",
"     10",
"    </a>",
"    ]. Additional clinical features include fatty liver, liver failure, and fatty kidneys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Galactosemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactose is the major dietary carbohydrate for infants who are fed with breast milk or cow's milk-based infant formulas. Lactose is a disaccharide that is hydrolyzed to glucose and galactose by the intestinal enzyme",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    . Galactose must first be converted to glucose in the liver before it can be used as an energy source (",
"    <a class=\"graphic graphic_figure graphicRef50614 \" href=\"UTD.htm?43/16/44301\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Various enzymatic defects in galactose metabolism can cause galactosemia, which is discussed in detail separately; the most common and severe form is caused by a deficiency of galactose-1-phosphate uridyl transferase (GALT). Clinical features of galactosemia include hypoglycemia, diarrhea, and vomiting after ingestion of lactose or galactose. Infants may present with failure to thrive or sepsis. Urine ketones are usually low or absent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"     \"Clinical features and diagnosis of galactosemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The postprandial hypoglycemia seems to be caused by hepatic accumulation of galactose-I-phosphate, which inhibits enzymes of glycogenolysis, including glucose-6-phosphatase, glucose-6-phosphate dehydrogenase, phosphoglucomutase, and glycogen phosphorylase (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ). The hepatic accumulation of galactose-1-phosphate also results in hepatic dysfunction with hepatosplenomegaly and elevation of hepatic enzymes and bilirubin. Accumulation of galactose-1-phosphate in other tissues may cause lenticular cataracts, mental retardation, and aminoaciduria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most infants with galactosemia are identified through neonatal screening programs. The diagnosis of galactose-1-phosphate uridyl transferase deficiency is confirmed by determining activity of the enzyme in red blood cells. Management involves elimination of galactose from the diet, and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36950?source=see_link\">",
"     \"Management and outcome of galactosemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hereditary fructose intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary fructose intolerance (HFI, also called fructosemia,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim\">",
"     MIM #229600",
"    </a>",
"    ) is a recessive disorder caused by deficiency of fructose 1-phosphate aldolase, isozyme b, which catalyzes the cleavage of fructose-1-phosphate to form dihydroxyacetone phosphate and D-glyceraldehyde.",
"   </p>",
"   <p>",
"    The hypoglycemia following fructose ingestion is presumed to be the result of accumulation of fructose l-phosphate, which inhibits the activation of hepatic phosphorylase and gluconeogenesis at the level of fructose 1,6-diphosphatase.",
"   </p>",
"   <p>",
"    Most cases present with recurrent hypoglycemia and vomiting at the age of weaning, when fructose or sucrose (a disaccharide that is hydrolyzed to glucose and fructose) typically is added to the infant diet. However, some infants may present earlier, because many commercial formulas and medications contain sucrose. Additional clinical manifestations include fructosuria, hepatomegaly, jaundice, aminoaciduria, metabolic acidosis, lactic acidosis, low or absent urine ketones [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/17\">",
"     17",
"    </a>",
"    ], and failure to thrive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/18\">",
"     18",
"    </a>",
"    ]. Older children and adults may avoid sweets and fruit.",
"   </p>",
"   <p>",
"    Historically, the diagnosis has required assay of fructoaldolase activity in tissue biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/19\">",
"     19",
"    </a>",
"    ]. However, newer techniques may avoid the need for biopsy. In patients with HFI, phosphorus-31 nuclear magnetic resonance spectroscopy after a fructose load demonstrates an increase in hepatic sugar phosphates and decrease in inorganic phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/20\">",
"     20",
"    </a>",
"    ]. Direct detection of several mutations in the human aldolase B gene on chromosome 9q facilitates the genetic diagnosis in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/19,21\">",
"     19,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy, which involves elimination of fructose from the diet, is difficult because sucrose is a common ingredient in prepared foods [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. Adherence to such a diet can reverse, prevent, or minimize nearly all of the manifestations of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DISORDERS OF AMINO ACID METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inborn errors of amino acid metabolism that can present with hypoglycemia include maple syrup urine disease, propionic acidemia and methylmalonic aciduria (also called methylmalonic acidemia), glutaric aciduria, and tyrosinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/23\">",
"     23",
"    </a>",
"    ]. These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=see_link\">",
"     \"Overview of maple syrup urine disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"     \"Disorders of tyrosine metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most organic acidemias become clinically apparent during the newborn period or early infancy. After an initial period of well-being, affected children develop a life-threatening episode of metabolic acidosis characterized by an increased anion gap. This presenting episode may be mistaken for sepsis and, if unrecognized, is associated with significant mortality. Children with disorders of amino and organic acid metabolism usually have associated failure to thrive and developmental delay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypoglycemia of these disorders appears to be related to liver disease (tyrosinemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/7\">",
"     7",
"    </a>",
"    ], protein malnutrition (maple syrup urine disease)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency from renal losses of carnitine and acylcarnitine derivatives (methylmalonic, propionic and isovaleric acidemia). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Disorders of fatty acid metabolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children with an organic acidemia are susceptible to metabolic decompensation during episodes of increased catabolism, such as intercurrent illness, trauma, or surgery. Parents and clinicians must be well-informed about the initial signs of decompensation and trained in applying an emergency regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DISORDERS OF FATTY ACID METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in fatty acid oxidation and ketone body formation are rare, but severe, metabolic disorders that result in hypoglycemia and hypoketonemia. Fatty acid oxidation disorders include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency, fatty acid transportation defects, and defects of beta-oxidation enzymes. These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During periods of fasting or intercurrent illness, free fatty acids (FFA) are mobilized from adipose tissue to be used directly for energy by various body tissues (eg, heart, skeletal muscle, gut, and skin). FFA undergo beta-oxidation in the liver, which produces ketone bodies (acetoacetic acid and beta-hydroxybutyric acid) that can be used as an alternate energy source for the brain. In infants and young children, mobilization of FFA usually begins when the plasma glucose decreases to &lt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and insulin secretion is suppressed, usually after approximately 12 hours of fasting. In older children, significantly increased mobilization of FFA and generation of ketone bodies typically occurs after 16 to 24 hours of fasting.",
"   </p>",
"   <p>",
"    The generation of ketone bodies by the liver (which is the only organ with the enzymatic capacity to generate acetoacetate and beta-hydroxybutyrate) involves mobilization of FFA, activation of fatty acids by acyl-CoA synthetase, transport into the hepatic mitochondrial matrix, and mitochondrial beta-oxidation of the fatty acids and transport of the ketone bodies into the circulation. Enzymes used in this pathway and the known defects in their activities are depicted in the table (",
"    <a class=\"graphic graphic_table graphicRef86411 \" href=\"UTD.htm?24/12/24780\">",
"     table 3",
"    </a>",
"    ). Medium-chain-acyl-CoA dehydrogenase (MCAD) deficiency is the most common defect, occurring in 1:10,000 births in a Caucasian population of northern European origin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/26\">",
"     26",
"    </a>",
"    ]. MCAD deficiency and other fatty acid oxidation defects are implicated in a small proportion of cases of sudden infant death syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36872?source=see_link&amp;anchor=H13236312#H13236312\">",
"     \"Sudden unexpected infant death including SIDS: Initial management\", section on 'Metabolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology of the hypoglycemia in these children is not known. Two possible mechanisms are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased hepatic glucose production, because gluconeogenesis and ketogenesis are intimately linked to the production and utilization of phosphopyridine nucleotides",
"     </li>",
"     <li>",
"      Accelerated rates of glucose utilization, because glucose may function as the primary substrate for all tissues in the absence of ketone body availability and defective FFA oxidation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of disordered lipid metabolism usually are induced by prolonged fasting or exercise,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a low-carbohydrate, high-fat diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/27\">",
"     27",
"    </a>",
"    ]. Symptomatic hypoglycemia is typically the first manifestation, and usually occurs during an illness in which anorexia or vomiting prevent oral intake for up to 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/28\">",
"     28",
"    </a>",
"    ]. However, symptoms may occur after only a brief fast [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who have disorders of fatty acid oxidation may present with profound hypoglycemia (plasma glucose concentration &lt;15 to 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&le;1",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    decreased plasma concentration of free and total",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    , relatively low plasma ketone concentrations, and elevated concentrations of free fatty acids. Their urine may contain dicarboxylic acids or acylglycines.",
"   </p>",
"   <p>",
"    In addition to hypoglycemia, children with fatty acid oxidation disorders may have severe disturbance of consciousness that does not improve with normalization of plasma glucose. Additional clinical features include hypotonia, hepatomegaly with microvesicular fat accumulation, elevated plasma activities of both liver and muscle enzymes, heart failure, rhabdomyolysis, and frequently, cerebral edema. This constellation of findings is similar to that seen in Reye syndrome. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Other causes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Disorders of fatty acid metabolism should be considered in children who have [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent episodes of hypoketotic hypoglycemia",
"     </li>",
"     <li>",
"      Involvement of fatty acid oxidation-dependent tissues, such as the heart, muscle, and liver",
"     </li>",
"     <li>",
"      Acute metabolic decompensation in association with fasting or severe catabolic conditions, such as severe thermal injury",
"     </li>",
"     <li>",
"      Alterations in plasma and tissue concentrations of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"     </li>",
"     <li>",
"      The presence of dicarboxylic acids or acylglycines in the urine",
"     </li>",
"     <li>",
"      Abnormal elevations of plasma acylcarnitines",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute hypoglycemia in disorders of fatty acid metabolism involves the administration of parenteral glucose at a rate sufficient to increase plasma insulin (5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a plasma glucose &gt;120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [6.7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    since increased plasma insulin concentration suppresses lipolysis and proteolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=see_link\">",
"     \"Insulin action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis is established, fasting should be avoided. Depending upon the enzymatic defect, enzyme replacement, special diets,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation may be necessary. However, these therapies should not be considered to be curative. Catabolic states (eg, illness, trauma, burns), during which endogenous substrate is mobilized, may provoke potentially devastating metabolic consequences. During these episodes, the child should eat frequent high-carbohydrate meals and parenteral glucose must be provided if oral carbohydrate is not tolerated. The treatment of individual disorders is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INCREASED UTILIZATION OF GLUCOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased utilization of glucose can be caused by hyperinsulinism of various etiologies (including exogenous administration of insulin or oral hypoglycemic agents), and conditions with increased metabolic rates (eg, sepsis, burns, hyperthyroidism). Hyperinsulinism is discussed here; disorders with increased metabolic rates are discussed separately. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Miscellaneous causes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hyperinsulinism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperinsulinism should be suspected when the plasma insulin concentration is inappropriately elevated for the level of hypoglycemia, and plasma ketones and FFA are inappropriately depressed.",
"   </p>",
"   <p>",
"    Endogenous hyperinsulinism in children is rare and may result from persistent hyperinsulinemic hypoglycemia of infancy (PHHI), insulin secreting tumors of pancreatic islet cells (insulinomas), and the ingestion of oral hypoglycemic agents. The ingestion of oral hypoglycemic agents is discussed below. Hyperinsulinism of infancy and insulinoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exogenous hyperinsulinism in children is usually an iatrogenic complication of therapy for diabetes mellitus (discussed below). However, it also may be a result of intentional poisoning (eg, Munchausen syndrome by proxy). Intentional poisoning of a child with insulin occurs rarely but must be considered if the parents or guardians of the child have access to these medications. Analysis of plasma for insulin and C-peptide agents may aid in the diagnosis and treatment of these children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    .) However, the widespread use of modified insulins and the newer \"sandwich\" analytical methodologies for measuring insulin complicate this diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/31\">",
"     31",
"    </a>",
"    ]. Many of these newer assays do not detect these modified insulins (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/50/17190?source=see_link\">",
"     insulin glargine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/50/24358?source=see_link\">",
"     insulin aspart",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/40/14982?source=see_link\">",
"     insulin lispro",
"    </a>",
"    ). Thus, a high index of suspicion must be maintained, particularly when the measured insulin and C-peptide concentrations are low at the time of hypoglycemia, but a brisk glycemic response to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    is observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H6857143#H6857143\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Glucagon challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with rare genetic mutations of the insulin receptor can also develop hypoglycemia without ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/32\">",
"     32",
"    </a>",
"    ]. These patients can be differentiated from patients with hyperinsulinemia by their elevated plasma insulin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Oral hypoglycemics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of oral hypoglycemic agents (sulfonylurea derivatives such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/39/10870?source=see_link\">",
"     glipizide",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/22/37222?source=see_link\">",
"     glyburide",
"    </a>",
"    ) in the treatment of type 2 diabetes mellitus is common. The ingestion of these compounds must be considered in any child who presents with hypoglycemia and has access to these drugs. The ingestion may be unintentional or intentional (eg, suicide attempt or malicious poisoning [eg, Munchausen syndrome by proxy]). With the advent of child-protective containers for these medications, the incidence of unintentional poisonings has been dramatically reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13687?source=see_link\">",
"     \"Sulfonylurea agent poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Questions regarding access to these medications should be asked in the history of children and adolescents who present with hypoglycemia.",
"   </p>",
"   <p>",
"    Analysis of plasma or urine for oral hypoglycemic agents may aid in the diagnosis and treatment of these children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with type 1 diabetes who try to maintain glycemic control may have two to five (or more) mild hypoglycemic episodes per week. A number of factors contribute to these episodes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Errors in insulin administration or failure to thoroughly mix the NPH or ultralente insulin, which can result in hyper- or hypoglycemia",
"     </li>",
"     <li>",
"      Failure to consume the planned carbohydrates, which leaves the insulin unopposed",
"     </li>",
"     <li>",
"      Late afternoon or evening exercise",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Young children with type 1 diabetes are particularly at risk for severe hypoglycemia because their exercise and food intake are not predictable, they have increased sensitivity to insulin, and it may not be possible to make sufficiently small adjustments to their insulin regimen. Studies have demonstrated that the use of insulin pumps in this patient population decreases the variance of plasma glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/33\">",
"     33",
"    </a>",
"    ]. This approach permits better glycemic control with less severe hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Insulin pump'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with type 1 diabetes who receive intensive therapy have a threefold increased risk of severe hypoglycemia compared with patients receiving standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/35\">",
"     35",
"    </a>",
"    ]. Nocturnal hypoglycemia, which may go undetected, is a particular problem in these patients. The protective",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    and epinephrine responses to hypoglycemia often become impaired in patients with recurrent hypoglycemia, so that they are less likely to develop warning symptoms such as sweating and anxiety. This phenomenon is called hypoglycemia unawareness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H7#H7\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Response to hypoglycemia in diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic children and their parents, families, and friends should be educated about the symptoms of hypoglycemia and the importance of prompt treatment. The treatment of hypoglycemia in children with diabetes involves the administration of glucose (orally or parenterally)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    . The administration of mini-dose glucagon also may be necessary during episodes of acute illness when the child is unable or unwilling to consume or retain oral carbohydrate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miscellaneous causes of hypoglycemia in infants and children include ketotic hypoglycemia, hormone deficiencies, and ingestions (eg, ethyl alcohol, salicylates).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ketotic hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ketotic hypoglycemia (also called accelerated starvation, idiopathic hypoglycemia, and substrate-limited hypoglycemia) typically presents in children between the ages of 18 months and 5 years, and spontaneously remits by eight to nine years of age. The prevalence of this disorder has decreased during the past 20 years for unknown reasons and is still not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The pathogenesis of ketotic hypoglycemia is not understood. Neither defects in hepatic gluconeogenesis, nor functional disturbances of insulin,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    , or cortisol have been identified. When hypoglycemia occurs, glycogenolysis is stimulated by epinephrine and glucagon. However, glycogen stores can only sustain glycogenolysis for a limited time, after which gluconeogenesis, stimulated by growth hormone (GH) and cortisol ensues. Substrate for gluconeogenesis (alanine, lactate, glycerol) is derived from skeletal muscle and adipose tissue. Ketotic hypoglycemia was thought to be caused by decreased availability or impaired mobilization of muscle amino acids and other substrates in children. However, since amino acids contribute little to gluconeogenesis, except in the acidotic condition, there is little direct proof of \"substrate limited hypoglycemia.\"",
"   </p>",
"   <p>",
"    The most likely cause is an imbalance in the suppression of glucose utilization by ketone bodies and a limited rate of hepatic glucose production. This could be caused by rapid depletion of the hepatic glycogen stores, resulting in a decrease in glucose production before the plasma ketone bodies and FFA have reached a concentration to cause an equivalent decrease in glucose utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/38\">",
"     38",
"    </a>",
"    ]. Alternatively, there may be a failure to appropriately increase renal gluconeogenesis. This proposed functional mechanism is supported by the spontaneous remission of the disorder at a time when the brain to body weight is decreasing, and endogenous substrate availability is increasing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Glucose homeostasis in normal infants and children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of ketotic hypoglycemia requires exclusion of other causes of hypoglycemia, particularly GH deficiency, hypopituitarism, adrenocorticotropic hormone (ACTH) unresponsiveness, and glycogen synthase deficiency, all of which may have similar presentations. A controlled fast of 16 to 24 hours' duration may be helpful in making the diagnosis. Such a fast should be undertaken only after fatty acid oxidation disorders have been excluded by documentation of normal plasma concentrations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    and acylcarnitines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H25#H25\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Elective fast'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biochemical findings during the hypoglycemic episode that are consistent with ketotic hypoglycemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Appropriately decreased insulin levels (&le;2",
"      <span class=\"nowrap\">",
"       microM/mL",
"      </span>",
"      [15",
"      <span class=\"nowrap\">",
"       pmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Normal lactate and pyruvate",
"     </li>",
"     <li>",
"      Elevated GH, cortisol, FFA, and ketones",
"     </li>",
"     <li>",
"      Decreased alanine on quantitative plasma amino acids",
"     </li>",
"     <li>",
"      Normal thyroxine (excludes hypopituitarism)",
"     </li>",
"     <li>",
"      Normal free and total",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      , normal distribution of the fatty acid length in the acylcarnitines",
"     </li>",
"     <li>",
"      No response to administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      at time of hypoglycemia, but normal response after an overnight fast",
"     </li>",
"     <li>",
"      Negative urine reducing substances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the diagnosis of ketotic hypoglycemia is established, hypoglycemic episodes can be prevented with a diet that includes frequent high-protein, high-carbohydrate meals. Because ketonuria typically precedes hypoglycemia, families should be instructed to monitor blood beta-hydroxybutyrate or urinary ketones and to increase carbohydrate intake when ketones are present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hormone deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia may occur in association with various hormone deficiencies. It is common among children with primary or secondary growth hormone (GH) and cortisol deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/39-42\">",
"     39-42",
"    </a>",
"    ], and has been reported in children with hypothyroidism. However, in our experience we have not observed a child with hypoglycemia secondary to isolated hypothyroidism.",
"   </p>",
"   <p>",
"    The pathogenesis of hypoglycemia in these disorders is incompletely understood. When patients who have GH or cortisol deficiency are hypoglycemic, they become ketotic and have a blunted glycemic response to exogenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    (indicating depleted glycogen stores) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/43\">",
"     43",
"    </a>",
"    ]. They also typically have low plasma concentrations of alanine and glutamine, which are potential gluconeogenic substrates in the liver and kidney. Cortisol deficiency reduces gluconeogenesis and hepatic glucose production; cortisol also plays an important role in activation of the enzymes of carbohydrate metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/39\">",
"     39",
"    </a>",
"    ]. Most patients with GH and cortisol deficiency have decreased insulin concentrations. However, several cases of hyperinsulinemia have been reported in children with hypopituitarism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of GH deficiency are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cortisol deficiency may be caused by Addison's disease, congenital adrenal hyperplasia, ACTH deficiency, or ACTH unresponsiveness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=see_link\">",
"     \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features of cortisol deficiency include hypoglycemia, vascular collapse, postural hypotension, tachycardia, fatigue, anorexia, weight loss, and eosinophilia (weakness, hyperpigmentation). Hypothalamic-pituitary dysfunction should be considered in patients who have hypoglycemia and midline defects (eg, hypertelorism, cleft lip or palate, microphallus, cryptorchidism) septo-optic dysplasia, short stature or decelerating height velocity, or a history of cranial irradiation.",
"   </p>",
"   <p>",
"    The management and prevention of hypoglycemic episodes in children who have associated hormone deficiencies center on diagnosis of the deficiency and appropriate hormone replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ingestions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intentional or unintentional ingestion of various agents can cause hypoglycemia in children and adolescents. These include oral hypoglycemic agents, ethanol, salicylates, beta blockers,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/12/19655?source=see_link\">",
"     quinine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"     pentamidine",
"    </a>",
"    , and unripe ackee fruit (a staple in the Jamaican diet) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/45\">",
"     45",
"    </a>",
"    ]. The ackee fruit contains hypoglycin, which impairs fatty acid oxidation, and causes the Jamaican vomiting sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Oral hypoglycemics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Ethanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of ethanol, particularly by young children, can cause severe hypoglycemia, seizures, and in some cases, death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Young children may have access to alcoholic beverages during or after parties when the children are unsupervised and the beverages unattended. Mouthwash is another important source of ethanol ingestion in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypoglycemia is caused by inhibition of gluconeogenesis via increased",
"    <span class=\"nowrap\">",
"     NADH/NAD",
"    </span>",
"    ratio, decreased release of alanine from muscle, and decreased uptake of gluconeogenic substrate by the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/7,50\">",
"     7,50",
"    </a>",
"    ]. Ethanol ingestion should be considered in hypoglycemic children who have a metabolic acidosis with increased anion gap and elevated lactate, and no response to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    (because glycogen stores already have been utilized) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Salicylates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of salicylates or their ester derivatives occasionally is associated with hypoglycemia and ketosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinical features of salicylate ingestion include vomiting, confusion, delirium, and hyperventilation. Similar findings may be observed in children with pneumonia, encephalitis, Reye syndrome, or diabetic ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"     1",
"    </a>",
"    ]. Even if a history of salicylate exposure or inappropriate salicylate administration is lacking, the diagnosis should be considered in patients with hypoglycemia, metabolic acidosis, and increased anion gap. The diagnosis is confirmed by measurement of plasma salicylate concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers, via beta-adrenoreceptor blockade, facilitate hypoglycemia by blunting the typical autonomic response to hypoglycemia (stimulation of glycogenolysis and gluconeogenesis, inhibition of glucose utilization by several tissues, and inhibition of insulin secretion). These effects can retard recovery from hypoglycemia. In addition, because the early symptoms of hypoglycemia are mediated by the autonomic nervous system, early warning signs may not occur, and the patient may present only after developing neuroglycopenic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Autonomic response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These effects are most frequent with nonselective beta blockers and are less common with beta-1 selective drugs or those with intrinsic sympathetic activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Pentamidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"     Pentamidine",
"    </a>",
"    is cytotoxic to the pancreatic beta cell [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Patients with pentamidine mediated hypoglycemia have inappropriately high levels of insulin at the time of hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have congenital heart disease or congestive heart failure appear to be at increased risk for the development of hypoglycemia. The pathogenesis of hypoglycemia is unclear, although perhaps decreased hepatic perfusion compromises the rate of glucose production [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia may occur in infants and young children as a complication of surgery. Factors contributing to hypoglycemia in these patients include prolonged preoperative fasting, intraoperative stress, or intraoperative medications. These episodes can be prevented by minimizing the duration of the preoperative fast, providing parenteral glucose during the preoperative fast, and appropriate monitoring of the plasma glucose in the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia can be caused by a number of other problems in children that either increase glucose requirements (eg, sepsis, shock, burns, tumors) or affect the liver's ability to produce glucose (eg, Reye syndrome, hepatitis, alpha-1 antitrypsin deficiency).",
"   </p>",
"   <p>",
"    Clinical manifestations of Reye syndrome include hypoglycemia, recurrent vomiting, altered consciousness, hyperpnea, elevated free fatty acids, and elevated ammonia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/40/16010/abstract/42\">",
"     42",
"    </a>",
"    ]. Recurrent symptoms consistent with Reye syndrome should prompt an evaluation for a fatty acid oxidation defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13486427\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary disorders associated with a deficiency of specific enzymes involved with substrate mobilization, interconversion, and utilization have diverse pathogenic mechanisms, but frequently are associated with hypoglycemia. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Disorders of carbohydrate metabolism",
"      </strong>",
"      &ndash; The following disorders of carbohydrate metabolism can lead to hypoglycemia (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Disorders of carbohydrate metabolism'",
"      </a>",
"      above): &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Deficiencies of enzymes involved in hepatic glycogen metabolism (",
"      <a class=\"graphic graphic_table graphicRef51949 \" href=\"UTD.htm?42/46/43756\">",
"       table 1",
"      </a>",
"      ), which present with fasting hypoglycemia between 2 and 20 hours after the last meal and mild to moderate ketosis, with or without hepatomegaly. The symptoms improve with eating or glucose infusion. These disorders include several of the glycogen storage disorders. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Disorders of glycogenolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficiencies of enzymes regulating gluconeogenesis (",
"      <a class=\"graphic graphic_table graphicRef71999 \" href=\"UTD.htm?34/38/35436\">",
"       table 2",
"      </a>",
"      ), which present with ketosis, hypoglycemia and lactic acidosis after a fast sufficient to deplete glycogen stores (12 to 24 hours depending on the age of the child). These include deficiencies in fructose 1,6 bisphosphatase, pyruvate carboxylase, and phosphoenolpyruvate carboxykinase (PEPCK) (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Disorders of gluconeogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficiencies of enzymes regulating galactose metabolism. The most common form presents during infancy with hypoglycemia, diarrhea, and vomiting after ingestion of lactose in breast milk or formula,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with failure to thrive or sepsis. This is caused by deficiency of galactose-1-phosphate uridyl transferase which is included in newborn screening programs in the United States. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Galactosemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficiencies of enzymes regulating fructose metabolism. These disorders are characterized by recurrent hypoglycemia, hepatomegaly, and vomiting which usually presents at the age of weaning, when fructose or sucrose typically is added to the infant diet. Some infants may present earlier because many commercial formulas and medications contain sucrose. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hereditary fructose intolerance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Disorders of amino acid metabolism",
"      </strong>",
"      &ndash; Inborn errors of amino acid metabolism that can present with hypoglycemia include maple syrup urine disease, propionic acidemia and methylmalonic aciduria, glutaric aciduria, and tyrosinemia. Most of these disorders present during the newborn period or early infancy with a life-threatening episode of metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Disorders of amino acid metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Disorders of fatty acid metabolism",
"      </strong>",
"      &ndash; Abnormalities in fatty acid oxidation and ketone body formation include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      deficiency, fatty acid transport defects, and defects of beta-oxidation enzymes (",
"      <a class=\"graphic graphic_table graphicRef86411 \" href=\"UTD.htm?24/12/24780\">",
"       table 3",
"      </a>",
"      ). These disorders present with hypoglycemia and hypoketonemia, usually induced by prolonged fasting, catabolic stress, exercise, or a low-carbohydrate, high-fat diet. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"       \"Causes of metabolic myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hyperinsulinism",
"      </strong>",
"      &ndash; Hypoglycemia can be caused by hyperinsulinism of various etiologies, including persistent hyperinsulinemic hypoglycemia of infancy (PHHI) also referred to as congenital hyperinsulinism, insulin secreting tumors, or administration of insulin or oral hypoglycemic agents (insulin secretagogues). Hyperinsulinism should be suspected when the plasma insulin concentration is inappropriately elevated for the level of hypoglycemia, and plasma ketones and free fatty acids are inappropriately depressed. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hyperinsulinism'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Miscellaneous",
"      </strong>",
"      &ndash; Other causes of hypoglycemia in infants and children include ketotic hypoglycemia (idiopathic hypoglycemia), hormone deficiencies (growth hormone deficiency or cortisol deficiency), and ingestions (eg, ethyl alcohol or salicylates). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Miscellaneous causes'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/1\">",
"      Haymond MW. Hypoglycemia in infants and children. Endocrinol Metab Clin North Am 1989; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/2\">",
"      Haymond MW, Sunehag A. Controlling the sugar bowl. Regulation of glucose homeostasis in children. Endocrinol Metab Clin North Am 1999; 28:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/3\">",
"      Gerin I, Veiga-da-Cunha M, Achouri Y, et al. Sequence of a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type Ib. FEBS Lett 1997; 419:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/4\">",
"      Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 2002; 161 Suppl 1:S88.",
"     </a>",
"    </li>",
"    <li>",
"     Chen YT, Burchell A. Glycogen storage diseases. In: The Metabolic and Molecular Bases of Inherited Disease, 7th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw Hill, New York 1995. p.935.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/6\">",
"      Willems PJ, Gerver WJ, Berger R, Fernandes J. The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr 1990; 149:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/7\">",
"      Lteif AN, Schwenk WF. Hypoglycemia in infants and children. Endocrinol Metab Clin North Am 1999; 28:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/8\">",
"      Pagliara AS, Karl IE, Keating JP, et al. Hepatic fructose-1,6-diphosphatase deficiency. A cause of lactic acidosis and hypoglycemia in infancy. J Clin Invest 1972; 51:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/9\">",
"      Pagliara AS, Karl IE, Haymond M, Kipnis DM. Hypoglycemia in infancy and childhood. I. J Pediatr 1973; 82:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/10\">",
"      van den Berghe G. Disorders of gluconeogenesis. J Inherit Metab Dis 1996; 19:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/11\">",
"      Kalhan SC, D'Angelo LJ, Savin SM, Adam PA. Glucose production in pregnant women at term gestation. Sources of glucose for human fetus. J Clin Invest 1979; 63:388.",
"     </a>",
"    </li>",
"    <li>",
"     Gitzelmann R, Steinmann B, Van der Berghe G. Disorders of fructose metabolism. In: The Metabolic and Molecular Bases of Inherited Disease, 7th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 1995. Vol 1, p.905.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/13\">",
"      Ahmad A, Kahler SG, Kishnani PS, et al. Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. Am J Med Genet 1999; 87:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/14\">",
"      Nyhan WL, Khanna A, Barshop BA, et al. Pyruvate carboxylase deficiency--insights from liver transplantation. Mol Genet Metab 2002; 77:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/15\">",
"      Carbone MA, MacKay N, Ling M, et al. Amerindian pyruvate carboxylase deficiency is associated with two distinct missense mutations. Am J Hum Genet 1998; 62:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/16\">",
"      Hommes FA, Bendien K, Elema JD, et al. Two cases of phosphoenolpyruvate carboxykinase deficiency. Acta Paediatr Scand 1976; 65:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/17\">",
"      Verrotti A, Fusilli P, Pallotta R, et al. Hypoglycemia in childhood: a clinical approach. J Pediatr Endocrinol Metab 1998; 11 Suppl 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/18\">",
"      Baerlocher K, Gitzelmann R, Steinmann B, Gitzelmann-Cumarasamy N. Hereditary fructose intolerance in early childhood: a major diagnostic challenge. Survey of 20 symptomatic cases. Helv Paediatr Acta 1978; 33:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/19\">",
"      Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. J Med Genet 1998; 35:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/20\">",
"      Oberhaensli RD, Rajagopalan B, Taylor DJ, et al. Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. Lancet 1987; 2:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/21\">",
"      Cross NC, de Franchis R, Sebastio G, et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. Lancet 1990; 335:306.",
"     </a>",
"    </li>",
"    <li>",
"     Segal S, Berry GT. Disorders of galactose metabolism. In: The Metabolic and Molecular Bases of Inherited Disease, 7th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 1995. Vol 1, p.967.",
"    </li>",
"    <li>",
"     Cornblath M, Schwartz R. Disorders of Carbohydrate Metabolism in Infancy, Blackwell Publications, Cambridge 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/24\">",
"      Morris AA, Leonard JV. Early recognition of metabolic decompensation. Arch Dis Child 1997; 76:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/25\">",
"      Dixon MA, Leonard JV. Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child 1992; 67:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/26\">",
"      Stanley CA, Hale DE. Genetic disorders of mitochondrial fatty acid oxidation. Curr Opin Pediatr 1994; 6:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/27\">",
"      Bell AW, Thompson GE. Free fatty acid oxidation in bovine muscle in vivo: effects of cold exposure and feeding. Am J Physiol 1979; 237:E309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/28\">",
"      Taroni F, Uziel G. Fatty acid mitochondrial beta-oxidation and hypoglycaemia in children. Curr Opin Neurol 1996; 9:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/29\">",
"      Parini R, Garavaglia B, Saudubray JM, et al. Clinical diagnosis of long-chain acyl-coenzyme A-dehydrogenase deficiency: use of stress and fat-loading tests. J Pediatr 1991; 119:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/30\">",
"      Hale DE, Bennett MJ. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 1992; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/31\">",
"      Green RP, Hollander AS, Thevis M, et al. Detection of surreptitious administration of analog insulin to an 8-week-old infant. Pediatrics 2010; 125:e1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/32\">",
"      Ogilvy-Stuart AL, Soos MA, Hands SJ, et al. Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors. J Clin Endocrinol Metab 2001; 86:3319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/33\">",
"      Jeha GS, Karaviti LP, Anderson B, et al. Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. Diabetes Technol Ther 2005; 7:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/34\">",
"      Tubiana-Rufi N, Coutant R, Bloch J, et al. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. Horm Res 2004; 62:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/35\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/36\">",
"      Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001; 24:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/37\">",
"      Huidekoper HH, Duran M, Turkenburg M, et al. Fasting adaptation in idiopathic ketotic hypoglycemia: a mismatch between glucose production and demand. Eur J Pediatr 2008; 167:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/38\">",
"      Haymond MW, Howard C, Ben-Galim E, DeVivo DC. Effects of ketosis on glucose flux in children and adults. Am J Physiol 1983; 245:E373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/39\">",
"      Laron Z. Hypoglycemia due to hormone deficiencies. J Pediatr Endocrinol Metab 1998; 11 Suppl 1:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/40\">",
"      Aynsley-Green A, Moncrieff MW, Ratter S, et al. Isolated ACTH deficiency. Metabolic and endocrine studies in a 7-year-old boy. Arch Dis Child 1978; 53:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/41\">",
"      al Jurayyan NA. Isolated adrenocorticotropin deficiency as a rare cause of hypoglycaemia in children. Further studies and report of an additional case. Horm Res 1995; 44:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/42\">",
"      LaFranchi S. Hypoglycemia of infancy and childhood. Pediatr Clin North Am 1987; 34:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/43\">",
"      Hopwood NJ, Forsman PJ, Kenny FM, Drash AL. Hypoglycemia in hypopituitary children. Am J Dis Child 1975; 129:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/44\">",
"      Parks JS, Baker L, Vaidya V, et al. Hyperinsulinemia and hypoglycemia in hypopituitary children. Endocrinology 1973; 92:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/45\">",
"      Seltzer HS. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/46\">",
"      Tanaka K, Kean EA, Johnson B. Jamaican vomiting sickness. Biochemical investigation of two cases. N Engl J Med 1976; 295:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/47\">",
"      Chalmers RA, Lawson AM. Identification of 5-hydroxyhexanoic acid in the urine of twin siblings with a Reye's-like syndrome associated with dicarboxylic aciduria and hypoglycaemia and with similarities to Jamaican vomiting sickness. Biomed Mass Spectrom 1979; 6:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/48\">",
"      Vogel C, Caraccio T, Mofenson H, Hart S. Alcohol intoxication in young children. J Toxicol Clin Toxicol 1995; 33:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/49\">",
"      Hornfeldt CS. A report of acute ethanol poisoning in a child: mouthwash versus cologne, perfume and after-shave. J Toxicol Clin Toxicol 1992; 30:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/50\">",
"      Arky RA. Hypoglycemia associated with liver disease and ethanol. Endocrinol Metab Clin North Am 1989; 18:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/51\">",
"      Marks V. Alcohol and carbohydrate metabolism. Clin Endocrinol Metab 1978; 7:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/52\">",
"      Madison LL. Ethanol-induced hypoglycemia. Adv Metab Disord 1968; 3:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/53\">",
"      Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996; 15:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/54\">",
"      Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 1995; 18:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/55\">",
"      Benzing G 3rd, Schubert W, Sug G, Kaplan S. Simultaneous hypoglycemia and acute congestive heart failure. Circulation 1969; 40:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/40/16010/abstract/56\">",
"      Coen R, McAdams AJ. Visceral manifestation of shock in congenital heart disease. Am J Dis Child 1970; 119:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5801 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-217.117.136.88-07197F826D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16010=[""].join("\n");
var outline_f15_40_16010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13486427\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DISORDERS OF CARBOHYDRATE METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Disorders of glycogenolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Glycogen synthetase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Glucose-6-phosphatase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Debrancher deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hepatic phosphorylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hepatic phosphorylase b kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Disorders of gluconeogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fructose 1,6, bisphosphatase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pyruvate carboxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - PEPCK deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Galactosemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hereditary fructose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DISORDERS OF AMINO ACID METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DISORDERS OF FATTY ACID METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INCREASED UTILIZATION OF GLUCOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hyperinsulinism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Oral hypoglycemics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MISCELLANEOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ketotic hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hormone deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ingestions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Ethanol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Salicylates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Pentamidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13486427\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5801|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/16/44301\" title=\"figure 2\">",
"      Galactose metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5801|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/46/43756\" title=\"table 1\">",
"      Enzymes hepatic GSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/38/35436\" title=\"table 2\">",
"      Enzymes gluconeogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/12/24780\" title=\"table 3\">",
"      Disorders of fatty acid oxidation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=related_link\">",
"      Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=related_link\">",
"      Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13861?source=related_link\">",
"      Glycogen debrancher deficiency (glycogen storage disease III)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=related_link\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6836?source=related_link\">",
"      Liver glycogen synthase deficiency (glycogen storage disease 0)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20916?source=related_link\">",
"      Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36950?source=related_link\">",
"      Management and outcome of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=related_link\">",
"      Overview of maple syrup urine disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25237?source=related_link\">",
"      Phosphorylase b kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36872?source=related_link\">",
"      Sudden unexpected infant death including SIDS: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13687?source=related_link\">",
"      Sulfonylurea agent poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_40_16011="Elbow ligaments";
var content_f15_40_16011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ligaments of the elbow",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Ligament",
"       </td>",
"       <td class=\"subtitle1\">",
"        Origin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Insertion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulnar collateral",
"       </td>",
"       <td>",
"        Medial epicondyle",
"       </td>",
"       <td>",
"        Coronoid process",
"       </td>",
"       <td>",
"        Medial stability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annular",
"       </td>",
"       <td>",
"        Ulnar notch",
"       </td>",
"       <td>",
"        Ulnar notch",
"       </td>",
"       <td>",
"        Maintains contact between proximal radius and ulna",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radial collateral",
"       </td>",
"       <td>",
"        Lateral epicondyle",
"       </td>",
"       <td>",
"        Annular ligament",
"       </td>",
"       <td>",
"        Maintains radio-capitellar alignment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral ulnar collateral",
"       </td>",
"       <td>",
"        Lateral epicondyle (distal to radial collateral)",
"       </td>",
"       <td>",
"        Supinator tubercle of ulna",
"       </td>",
"       <td>",
"        Lateral elbow of elbow",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16011=[""].join("\n");
var outline_f15_40_16011=null;
var title_f15_40_16012="Glycemic index of foods";
var content_f15_40_16012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glycemic index of foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glycemic index",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baked russet potato",
"       </td>",
"       <td class=\"centered\">",
"        135",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cornflakes",
"       </td>",
"       <td class=\"centered\">",
"        119",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         White bread",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         100",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whole meal bread",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brown rice",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raisins",
"       </td>",
"       <td class=\"centered\">",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White rice",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Banana (raw)",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All-Bran",
"       </td>",
"       <td class=\"centered\">",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweet potato",
"       </td>",
"       <td class=\"centered\">",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spaghetti (white)",
"       </td>",
"       <td class=\"centered\">",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spaghetti (whole wheat)",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baked beans (tinned)",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ice cream, yogurt, whole milk, apple (raw)",
"       </td>",
"       <td class=\"centered\">",
"        49 to 53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red lentils",
"       </td>",
"       <td class=\"centered\">",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soya beans (tinned)",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Glycemic content of an assortment of foods, with white bread representing the standard value of 100. Values below 100 will produce a lesser rise in the blood glucose (for the same level of carbohydrate intake) than white bread.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jenkins DJ, Wolever TM, Jenkins AL, et al. The glycaemic response to carbohydrate foods. Lancet 1984; 2:388.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16012=[""].join("\n");
var outline_f15_40_16012=null;
var title_f15_40_16013="Mortality after thrombolysis based on TIMI flow";
var content_f15_40_16013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    TIMI grade 3 coronary flow is associated with improved survival after thrombolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the GUSTO-I trial, the 30-day mortality rate after thrombolysis for acute ST elevation myocardial infarction varied with the degree of vessel patency achieved. The mortality was lowest (4.3 percent) in patients with TIMI grade 3 (normal) flow in the infarct-related artery at 90 minutes. Partial restoration of flow (TIMI grade 2) did not improve outcomes compared to no or or faint flow (TIMI grade 0 or 1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The GUSTO Investigators. N Engl J Med 1993; 329:673.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16013=[""].join("\n");
var outline_f15_40_16013=null;
var title_f15_40_16014="Lipids and premature CHD";
var content_f15_40_16014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lipoproteins and and premature coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of different lipid abnormalities in men with premature coronary disease (&lt;60 years of age). Patients with more than one disturbance (eg, low HDL plus hypertriglyceridemia) are noted in the combined group. Only 12.5 percent of subjects were normal in this study versus 58.5 percent of age-matched controls without coronary disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Genest JJ, McNamara JR, Ordovas JM, et al. J Am Coll Cardiol 1992; 19:792.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16014=[""].join("\n");
var outline_f15_40_16014=null;
var title_f15_40_16015="Seborrheic keratosis";
var content_f15_40_16015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several scaly, well-circumscribed lesions that have a \"stuck on\" appearance are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_40_16015=[""].join("\n");
var outline_f15_40_16015=null;
